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Abstract 
 
Regulation of hair growth: prostaglandins and prostamides 
 
 
Keywords: Alopecia, balding, bimatoprost, hair follicle, human, organ culture, 
prostaglandin F2α, treatment. 
  
Hair growth disorders cause significant psychological distress, but are poorly 
controlled. Since prostaglandin F2α (PGF2α) and prostamide F2α analogue glaucoma 
treatments cause eyelash growth as side-effects, they may be useful for alopecia. 
How they function is unknown; possibilities include direct action on hair follicles 
or stimulating follicular blood flow. It is important to clarify whether scalp follicles 
can also respond as human follicle response to androgens differ with body site. 
Therefore, human scalp follicles were grown in vitro in organ culture with PGF2α, 
latanoprost, a PGF2α analogue, and bimatoprost, a prostamide F2α analogue, with, 
or without, appropriate antagonists, and the presence of PGF2α (FP) and 
prostamide F2α receptors were investigated using molecular biological and 
immunohiostochemical methods.  
Each treatment significantly stimulated follicle growth rate, the percentage of 
growing follicles, and the amount of hair produced in a dose-responsive manner 
(10nM-1µM); the receptor antagonists blocked these effects. ………………………... 
Immunohistochemistry of frozen scalp sections demonstrated FP protein only in 
dermal papillae and connective tissue sheaths. RT-PCR identified FP and various 
prostamide F2α receptors in anagen follicles and isolated dermal papillae and 
bulbar connective tissue sheath, but not in bulb matrix or other epithelial tissues. 
Therefore, isolated human scalp hair follicles can respond biologically to PGF2α and 
related pharmaceuticals in organ culture via follicular receptors and express the 
genes and protein for FP and prostamide F2α receptors. PGF2α-related drugs appear 
to act directly on follicles via receptors in the regulatory dermal papilla. They offer 
an exciting, novel approach for treating alopecia and merit clinical investigation. 
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1.1  The importance of hair  
The skin is the largest organ in the human body comprising about one sixth of the 
total body weight and it covers about 1.5 - 2 m2 (Chuong et al., 2002).  It contains a 
number of specialized appendages, developed not only to protect and reinforce the 
skin but also for social signalling. The most prominent of these appendages is the 
hair follicle, a special organ found only in mammals which produce the hair fibre.  
Hair follicles are found all over the body except in the glabrous skin of the lips, 
palms and soles.  
Hair has other many important roles in other mammals, one of the most important 
role is thermal insulation (Vaughan, 1986). It is an essential mammalian 
characteristic for warm bloodedness and crucial for their evolutionary success 
(Young, 1957).  In Man the thermoregulatory function is minor because of the 
reduction in large terminal hairs, probably to enable body cooling by evaporating 
eccrine sweat (Ebling, 1985), despite the residual display of hair erection in 
response to cold and seasonal variations in the rate of hair growth (Orentreich, 
1969; Randall and Ebling, 1991b; Courtois et al., 1996).  Hairs are also involved in 
camouflage (Cott, 1940), which protects mammals from predation.  They are often 
also specialised as neuroreceptors or sense organs for touch in certain mammals 
e.g. whiskers (Oliver and Jahoda, 1989b) or for sexual communication e.g. the lion’s 
mane (West and Packer, 2002a).   
The hair follicle is also of great interest to scientists; this miniorgan represents an 
attractive experimental system because of its accessibility, dispensability, and self-
renewal capacity. Its complex, but highly organised, structure make it an excellent 
model for investigating aspects of stem cell biology, cell lineage specification, 
patterning processes, cell differentiation and cell–cell interactions (Schlake, 
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2007a). It has the ability to regenerate itself (Dry, 1926b; Kligman, 1959a), 
recapitulating many steps of embryogenesis, which is of particular interest to cell 
and developmental biologists (Dry, 1926a; Kligman, 1959c). The human hair 
follicle is also a paradoxical tissue, where the same hormones, the androgens, can 
cause stimulation of hair growth in many areas e.g. beard, while inhibiting hair 
growth on the scalp of genetically predisposed people, causing baldness (Randall, 
1994, 2007). This characteristic of the hair follicle is of great interest to 
endocrinologists.  
The reduced hair in human beings has rather different roles to those of many other 
mammals. The hairs that are obvious in children are mainly protective, the 
eyelashes and eyebrows stop foreign bodies entering the eyes and scalp hair 
protects the head and back of the neck from sunlight, physical damage and even 
from cold since scalp has very little adipose tissue (Goodhart, 1960; Ebling, 1985). 
The lower incidence of balding among African men (Setty, 1970) suggests the 
greater importance of scalp hair for the protection of scalp from the hot tropical 
sun.  Abundance of strong, good quality hair signals good health, in contrast to the 
brittle hair seen during starvation or disease (Bradfield, 1971a). Human hair is 
also a signalling characteristic in sexual communication; the development of 
axillary and pubic hair in males and females is an indicator of the onset of puberty 
and their associated apocrine glands produce secretions yielding odours involved 
in sexual communication (Ebling, 1976). Growth of greater terminal hair on the 
face and chest, limbs and upper pubic triangle all indicate sexual maturity in men 
(Reynolds, 1951; Marshall and Tanner, 1969; Marshall and Tanner, 1970a).  Scalp 
hair also plays important role in many cultures throughout history.  Hair removal 
has strong depersonalising roles e.g. prisoners and ritual shaving of Christian or 
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Buddhist monks, while long uncut hair has positive connotation such as strength 
for Samson in the Bible and religion in Sikhs (Randall, 2007). Human hair plays an 
important role in a person's appearance and in social and sexual communication 
with other people throughout life (Jansen and van Baalen, 2006). This provides 
insight into why hair disorders such as alopecia areata, hirsutism and androgenetic 
alopecia have serious psychological effects on the quality of life, although hair 
disorders are not life threatening in human beings (Girman et al., 1998; Gulec et al., 
2004). Androgenetic alopecia, or male pattern hair loss or common balding 
(Randall, 2005b), results in anxiety and loss of confidence in affected men even 
whom never sought any medical help (Girman et al., 1998).   
Therefore, understandings of the mechanisms controlling hair growth are of great 
interest worldwide with the hope that they may lead to the development of new, 
better treatments for hair disorders. 
1.2  The structure and function of the hair follicle 
1.2.1  Structure of the hair follicle 
The hair follicle has a complex structure which results from epithelial-
mesenchymal interactions initiated around the 3rd month of embryonic 
development (Sengel, 1983; Hardy, 1992; Gorpinich and Nozdrin, 2007).  Hair 
follicles are continuous with the epidermis extending down through the dermis 
and often project into the subcutaneous adipose layer (Montagna and Van Scott, 
1958a); they give rise to the hair, a flexible tube of fully keratinised epithelial cells.  
At the base, the growing hair follicle enlarges into the hair bulb surrounding the 
mesenchyme-derived dermal papilla (Auber, 1952; Montagna and Van Scott, 
1958c; Oliver and Jahoda, 1989c) (Figure 1).  Each anagen hair follicle can be 
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divided into 3 distinct regions, the infundibulum, isthmus and bulbar regions.  The 
infundibulum includes the area joining the hair follicle to the surface epithelium 
down to where the sebaceous duct joins the hair follicle. The isthmus starts from 
below the sebaceous duct down to the bulbar region and contains the bulge area 
where the arrector pili muscle attaches to the hair follicle and connects it to the 
dermis. The bulbar region includes the hair bulb and the bulb neck (Montagna and 
Van Scott, 1958a; Sperling, 1991) (Figure 1). 
Figure 1 Illustrative representation of an anagen hair follicle showing the 
different component parts 
Reproduced from Randall (2000), with the author’s permission. 
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The hair follicle consists of several layers which hold and frame the emerging hair, 
the inner root sheath, the outer root sheath, the vitreous membrane and the 
connective tissue sheath (Forslind, 2000).  The inner root sheath which surrounds 
the hair fibre is composed of three distinct cell layers, the outer Henle’s layer, the 
Huxley layers and the inner cuticle; the latter is in direct contact with the cuticle of 
the hair fibre.  The inner root sheath surrounds the hair fibre from the bulb up to 
the level of the sebaceous gland (Forslind, 2000).  The cuticle cells of the hair fibre 
interconnect/interdigitate with the cuticle cells of the inner root sheath like a zip, 
consequently fastening the hair fibre to the follicle. The inner sheath is surrounded 
by the outer root sheath, which is continuous with the epidermis. The vitreous 
membrane and the connective tissue sheath lie outside the outer root sheath and 
they surround the whole follicle (Figure 2). 
The hair fibre consists of three distinct layers, the outer cuticle, the cortex, and the 
inner medulla. The cortex is composed of bundles of keratin filaments; the 
medulla, which is only present in terminal hairs, can be either continuous or 
discontinuous.  Hair fibres with a continuous medulla are stiff in character such as 
eyelashes (Forslind, 2000). 
The types of hair produced are greatly variable in colour, length, diameter and 
cross-sectional shape (Schlake, 2007b).  They can be classified into two main types, 
vellus hairs and terminal hairs. Vellus hairs are small, fine, unpigmented hairs 
located in regions of the body described as “hairless”, e.g. the cheek, while terminal 
hairs are longer, thicker, and deeply pigmented hairs located in regions such as the 
scalp, eyebrows and eyelashes (Blume et al., 1991; Vogt et al., 2007). 
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Figure 2  The structure of the hair follicle 
An isometric view of the lower part of a human hair follicle cut away to show 
component parts (drawn by Richard J. Dew).  Reproduced from Randall (1994), 
with the author’s permission. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The dermal papilla in the hair bulb has a well developed nerve and blood supply. It 
contains a relatively small number of specialised fibroblast cells called dermal 
papilla cells and a large amount of extracellular matrix containing 
mucopolysaccharides (Montagna et al., 1952) and basement membrane proteins 
(Messenger et al., 1991; Couchman, 1993).  Dermal papilla cells regulate and 
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control hair follicle growth through the expression and secretion of paracrine 
factors such as growth factors and cytokines. The dermal papilla plays an 
important role throughout hair follicle development and its life cycle.  The size of 
dermal papilla is proportional to the size of the hair follicle and therefore the hair 
fibre produced (Van Scott and Ekel, 1958; Ibrahim and Wright, 1982; Elliott et al., 
1999).  The hair matrix almost completely encloses the dermal papilla, with the 
exception of a gap at the base of the follicle bulb, which allows the entrance of 
blood vessels and nerves into the papilla. The dermal papilla is separated from the 
epithelial hair matrix by a trilaminar basement membrane (Nutbrown and Randall, 
1995).  The hair matrix gives rise to all epithelial compartments except the outer 
root sheath (Schlake, 2007b).  
A theoretical line drawn through the widest part of the follicular bulb is called the 
“critical level”; this separates the undifferentiated, mitotically active lower matrix 
from the differentiating, less mitotically active upper matrix (Auber, 1952) where 
cells differentiate into either the inner root sheath or hair fibre cells.  Hair 
production involves rapid cell division of the epithelial keratinocytes in the hair 
matrix.  As the cells move from the bulb into the narrower part of the follicle, the 
cells become elongated, and keratinisation takes place.  The keratinisation process 
continues as the cells migrate through the follicle, finally becoming fully 
keratinised when they reach the skin surface.  In pigmented hairs, melanocytes 
situated around the upper part of the dermal papilla incorporate melanin granules 
into the adjacent keratinocytes in the bulb; melanin is synthesised in a small 
melanocyte-specific organelle known as a melanosome (Chase, 1958; Castanet and 
Ortonne, 2000; Slominski et al., 2004; Lin and Fisher, 2007).  The amount and type 
of pigment, melanin, made by the bulb melanocytes and the balance of 
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brown/black eumelanin and red/yellow phaeomelanin in the hair shaft 
determines the hair colour (Slominski et al., 2004; Rousseau et al., 2007).  In most 
people, hair colour varies according to body site (Wasserman, 1974; Mc Donald, 
1991).  Eyelashes are usually the darkest and scalp hair is generally lighter than 
genital hair, which may be due to bleaching of the hair on the scalp as it is exposed 
to UV light (Rook and Dawber, 1991).  
The hair follicle is often referred to as the pilosebaceous unit, due to its association 
with the sebaceous gland (Wosicka and Cal, 2010).  Sebaceous glands secrete a 
waxy secretion into the follicle through the sebaceous duct, forming a waterproof 
coating over the hair fibre. Apocrine sweat glands are also present above the 
sebaceous ducts of follicles in some areas, such as those found in axillae and genital 
regions (Hurley, 2001).  They develop in the embryo, but normally become active 
at puberty (Cohn, 1994). The apocrine glands release an oily secretion into the 
superior portion of the hair follicle which is involved in human olfactory 
communication and is a possible origin of pheromones (Spielman et al., 1995).  The 
arrector pili muscle, a smooth muscle bundle, is also associated with the hair 
follicle, and attaches to the hair follicle below the bulge region.  This muscle allows 
adjustment of the hair for thermoregulation; for example erection of hairs in 
response to cold temperatures to trap a layer of air close to the skin to help in 
insulation.  The bulge is a region of outer root sheath below the attachment of the 
sebaceous gland and is the site of epithelial stem cells (Cotsarelis et al., 1990; Tiede 
et al., 2007; Yang and Xia, 2007).   
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1.2.2  The hair follicle growth cycle 
The hair follicle has a very important and unique mechanism of cyclic regeneration 
in mammals, including human beings, in which hairs are shed and re-grown. The 
hair follicle growth cycle originally described fully for mouse by Dry (1926) and 
later for human beings by Kligman (1959).  The hair follicle growth cycle includes 
the destruction of the original lower follicle and its regeneration to form a new 
follicle which can produce different hairs from the pre-existing one.  The role of 
hairs is different in many mammals through the year and at different stages of 
their lives.  They need a thick winter coat (Young, 1957) and seasonal colour 
variation for camouflage like the white winter, and brown summer coat of the 
arctic hare (Cott, 1940).  Hair follicle melanin synthesis is cyclical (unlike 
epidermal melanin synthesis) and confined to the anagen growth phase of the hair 
cycle (Burnett et al., 1969; Commo and Bernard, 2000; Slominski et al., 2004; 
Sharov et al., 2005).  The mane of the male red deer is also developed only in the 
breeding season for sexual attraction (Lincoln and Kay, 1971).  Therefore the hair 
produced by a follicle often needs to be changed and the changes happen during 
the hair growth cycle.  During androgenetic alopecia and puberty, the hair growth 
cycle enables gradual changes to occur in the type of hair produced by various 
follicles.   
The hair growth cycle includes four main stages, the growth phase, anagen, the 
regression phase, catagen, the resting phase, telogen and the shedding phase, 
exogen.  The hair growth cycle is summarized in figure 3. 
How different in size a hair can be to the pre-existing hair is unclear because many 
changes take place over several years.  For example, full beard production takes  
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Figure 3  The hair growth cycle 
Stages of hair growth cycle. Reproduced with the author’s permission, from 
Randall (2008).  
 
until over 30 years of age (Hamilton, 1958), while ear canal hair continues to 
develop until the 50`s (Hamilton, 1946). The duration of each phase varies 
between species and varies significantly from site to site on the human body 
(Trotter, 1924; Saitoh et al., 1970; Messenger, 1993).     
The matrix keratinocytes in the hair follicle bulb proliferate rapidly during the 
anagen phase adding cells to the growing hair fibre; in contrast at the end of 
anagen, matrix keratinocytes gradually cease proliferating and the follicular 
melanocytes cease melanin synthesis as the anagen follicle starts the transition 
into the catagen phase (Kligman, 1959a).  During the catagen phase, the follicular 
melanocytes resorb their dendrites and cease melanin synthesis.  Mitosis in the 
bulb matrix cells also stops; therefore no more cells are added to the hair fibre.  
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The catagen phase duration is short, lasting for about 2 weeks in human scalp 
follicles (Kligman, 1959a).  The base of the fully keratinised hair become expanded 
(club hair) and moves toward the skin surface till it reach the level of the 
sebaceous gland.  Condensation of the dermal papilla takes place and become a ball 
of cells.  The involution of the club hair results from apoptosis of the epithelial cells 
of the hair follicle (Weedon and Strutton, 1981; Lindner et al., 1997; Matsuo et al., 
1998; Botchkareva et al., 2006).  At the end of catagen, the ball of dermal papilla 
cells moves with the epithelial cells up in the same direction as the club hair and 
stops under the bulge; if the dermal papilla fails to reach the bulge level during 
catagen, the cycle stops and the hair is lost (Paus and Cotsarelis, 1999).  The 
lowermost portion of the bulge collapses around the hair and forms the secondary 
hair germ at the end of catagen (Ito et al., 2004). 
The catagen phase is followed by the telogen phase, the resting phase of the hair 
cycle. A telogen hair is distinguished by its fully keratinized club hair which is 
surrounded by a thick epithelial sac.  Below this lies the condensed dermal papilla, 
waiting for the signal to start a new hair growth cycle (Sperling, 1991). The telogen 
phase lasts around two to three months on the human scalp before the follicle re-
enters the anagen phase (Kligman, 1959c; Price and Griffiths, 1985). Plucking of a 
telogen club hair initiates a premature anagen phase (Ebling, 1976). 
The growth phase, anagen, is a period of high proliferation as the lower part of the 
follicle regenerates and forms a new hair.  Anagen has been sub-divided into six 
stages (Chase et al., 1951; Chase, 1954). Most of the hair growth takes place in 
anagen stage VI, while stages I–V of anagen are the developmental stages at which 
point the follicle regenerates.  The length of the anagen sub-phases I-V does not 
differ substantially between follicles from different regions, with the exception of 
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the last sub-phase, anagen VI, the duration of which dictates the shaft length 
(Trotter, 1924; Saitoh et al., 1970). 
The keratinocytes beneath the bulge region known as the hair germ which play a 
pivotal role in anagen induction (Cotsarelis et al., 1990; Paus et al., 1999). During 
anagen I, which is an early anagen stage, the hair germ become active mitotically. 
This is followed by anagen II, in which the germ starts to grow downward 
enveloping the ball of dermal papilla cells.  The matrix epithelial cells around the 
dermal papilla form an inverted cone and on top of it a layer of keratinised cells 
appear which give rise to the inner root sheath.  In anagen III, upward growth of 
the inner root sheath continues, the matrix cells are formed and the hair bulb 
develops a more characteristic appearance.  The matrix melanocytes are activated 
and start melanin synthesis; the matrix cells divide and generate the hair fibre and 
the layers of the hair follicle.  During anagen IV, the hair fibre reaches the level of 
the sebaceous gland, but it is still enveloped by an upwardly growing cone of inner 
root sheath.  An inverted cone of pigmented matrix and a narrow and long dermal 
papilla can be seen in the bulb area.  In anagen V, the new shaft breaks through the 
internal sheath and grows up to the skin surface alongside the telogen hair.  The 
hair fibre also reaches its maximum diameter in this stage.  During anagen VI the 
new hair shaft emerges from the skin surface and proceeds to grow until the 
follicle re-enters catagen and the cycle starts again.  In this stage the follicle is at its 
greatest depth within the skin.  The length of anagen VI determines the length of a 
hair produced by a follicle which varies with follicle location.  For example, 
eyebrow hair follicles are in anagen for about two to three weeks producing short 
hairs, while scalp hair follicles are in anagen for two to six years resulting in long 
hairs (Kligman, 1959c, 1961; Saitoh et al., 1970; Paus and Cotsarelis, 1999).   
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The last phase within the hair growth cycle is exogen, an active shedding phase, in 
which specific signals controlling the breakdown of cellular adhesion between the 
club hair and its surrounding epithelial sac, leading to the release of the old club 
hair rather than simply being pushed out of the skin (Stenn et al., 1998; Stenn and 
Paus, 2001; Stenn, 2005; Higgins et al., 2009b).   
1.2.3 Embryogenesis of the hair follicle 
The embryonic development of human hair follicles occurs first in areas of the 
developing upper lip, chin and eyebrow in the second pregnancy trimester and 
their development is completed by fetal month 6 (Pinkus, 1958).  The developing 
embryonic epidermis consists of the basal layer, intermediate layer and the 
periderm.  Hair follicle embryonic development is a result of interaction between 
epithelial and mesenchymal tissues and can be divided into three morphologically 
distinguishable stages: induction, organogenesis and cytodifferentiation.  The 
spacing, polarity and differentiation patterns of hair follicles are controlled by 
interactions of inhibitors and activators, which are established jointly by the skin 
epithelium and mesenchyme (Schmidt-Ullrich and Paus, 2005). Once a 
mesenchymal condensate of inductive fibroblasts has formed, it takes over control 
of most subsequent steps of hair follicle organogenesis and of epithelial stem cell 
differentiation into distinct lineages (Schmidt-Ullrich and Paus, 2005).  The hair 
follicle development initiates with the formation of the pre-germ, which begins as a 
result of localised thickening of the basal layer of the epidermis and an aggregation 
of mesenchymal cells at the junction of epidermis and dermis, and these 
mesenchymal and epidermal cells then continue to grow downward forming the 
hair germ (Pinkus, 1958; Holbrook and Minami, 1991) (Figure 4).  The hair germ 
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then elongates and grows deeper into the dermis to form a cone of epithelial cells 
with the cluster of mesenchymal cells at the base forming the hair peg.  
Figure 4  The hair follicle embryology 
The different stages of hair follicle embryogenesis. Reproduced from Randall 
(1994), with the author’s permission. 
 
The deepest end of the hair peg flattens, forming a concave-shaped bulbous 
structure called the bulbous hair peg which finally encloses the mesenchymal cells 
to form the dermal papilla.  The epidermal cells above the primitive dermal papilla 
become the matrix, which differentiates to form the inner root sheath and hair 
fibre.  The outer root sheath is formed from the epithelial cells connecting the 
matrix cells to the interfollicular epidermis; the connective tissue sheath is formed  
from the mesenchymal cells surrounding the epithelial down-growth. On the 
posterior side of the follicle, two epithelial protrusions develop at about 12-15 
weeks estimated gestational age; the uppermost epithelial swelling will develop to 
form the sebaceous gland and the lower one forms the bulge (the site at which the 
arrector pili muscle attaches to the follicle).  A third protrusion can develop above 
the sebaceous gland at some regions of the body such as the axilla and groin to 
form apocrine glands. 
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At about 15 weeks the middle cells of the bulbous hair peg degenerate to form the 
hair canal and keratinisation of the canal and the hair fibre begins.  At this stage 
the first sebocytes are seen and the dermal papilla is completely surrounded by 
epithelial cells.  The hair follicle components will continue to differentiate and the 
hair fibre continue to grow.  The follicle will maintain its downward growth into 
the dermis until it reaches its full depth within the skin.  The hair fibre continues 
growing and at about 19 weeks gestational age; the first lanugo hair emerges from 
the skin surface.  Most of the stages identified above are repeated during the hair 
growth cycle (Hardy, 1992; Wu-Kuo and Chuong, 2000).  
1.2.4 Mesenchymal and epithelial interactions in the hair follicle 
The hair follicle is composed of structures that are derived from both the 
mesenchyme and the ectoderm as described in section 1.2.3.  There is a series of 
signals between the dermal and epithelial cells of the hair germ during early stages 
of hair follicle development and these early signals have been shown by several 
tissue recombination experiments on embryonic skin from several species (Sengel, 
1983; Hardy, 1992; Ferraris et al., 2000).  The early signal from aggregated dermal 
cells is transmitted to the overlying epithelial cells to start thickening and form an 
appendage. The type of the appendage formed depends on the origin of the 
epidermis.   
The epidermis initiates the next signal to instruct the cluster of dermal cells to 
form a dermal papilla. A second message from the dermal papilla eventually 
transmits to adjacent epithelial cells and stimulates them to divide rapidly and 
form a specific appendage. Therefore the embryogenesis of the hair follicle 
depends on a series of signals between the mesenchyme and epithelia (Mikkola 
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and Millar, 2006; Fuchs, 2007).  The Wnt/beta-catenin activity in the dermal 
papilla regulates signaling pathways, including IGF and FGF that can mediate the 
dermal papilla's inductive effects. The inactivation of the Wnt/beta-catenin gene 
within the dermal papilla of fully developed hair follicles results in dramatically 
reduced proliferation of the progenitors and their progeny that generate the hair 
shaft, and then premature induction of the catagen phase of the hair cycle (Enshell-
Seijffers et al., 2010). 
The dermal papilla is a permanent structure which stays throughout the hair cycle, 
and controls post-embryonic mesenchymal-epithelial interactions. The important 
role of the dermal papilla is shown by its removal from anagen vibrissae follicles 
which results in stopping hair growth (Oliver, 1966; Link et al., 1990).  The dermal 
papilla cells are in direct contact with epithelial cells; the cells of the outer root 
sheath organise around the dermal papilla to form an epithelial matrix and reform 
the bulb (Oliver, 1967; Jahoda et al., 1984).   
A series of experiments using mainly rat vibrissae follicles has highlighted some of 
the epithelial-mesenchymal interactions in the adult hair follicle (Oliver and 
Jahoda, 1989a). When cultured dermal papilla cells from rat vibrissae were 
implanted in rat ear skin superficially, they induced the formation of new follicles 
as a result of contact with the epidermis (Jahoda and Oliver, 1984).  Vibrissae 
dermal papilla cells also induced vibrissae follicle formation in rat ear wounds 
(Jahoda, 1992).  So the follicle and the type of hair produced are determined by the 
origin of the dermal papilla and not by the transplantation site (Reynolds and 
Jahoda, 1992; Jahoda et al., 1993).  This feature of hair growth is a big advantage in 
hair follicle transplantation surgery, in which hair follicles are relocated from non-
balding occipital and parietal sites to cover the balding areas (Orentreich and Durr, 
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1982; Epstein, 2007).  Cultured dermal papilla cells from rat pelage can induce 
follicle growth when implanted between the dermis and epidermis of afollicular 
foot-pad skin, which suggests that the dermal papilla has the ability of changing the 
gene expression of the tissue around it (Reynolds and Jahoda, 1991, 1992).  In a 
recent experiment, the vibrissae dermal papilla of adult rat and mouse revealed 
the ability to induce new hair follicle structures in rabbit corneal epithelium 
(Waters et al., 2007).  There is evidence that the germinative epithelium and the 
dermal sheath can also play a role in follicle induction. When germinative 
epithelium from the hair bulb matrix was cultured alone or with 3T3 feeder cell 
layers, no growth was observed, but when co-cultured with dermal papilla cells, 
growth occurred and organoid structures were formed with the dermal papilla 
cells (Reynolds et al., 1991).  When dermal sheath or germinative epithelium cells 
were implanted into ear skin, they failed to induce follicle formation, but when 
both were implanted together into the ear wound they induced follicle formation 
(Reynolds and Jahoda, 1996). This suggests that the dermal sheath cells require 
signals from the germinative epithelial cells to alter their differentiation state to 
function as dermal papilla cells and induce follicle formation.  In a recent study it 
was demonstrated that labelled dermal papilla cells made new dermal sheath in 
induced follicles, suggesting that transformation of dermal sheath cells into dermal 
papilla cells is not unidirectional (Inamatsu et al., 2006). 
Another study demonstrated that cells from dermal sheath cup surrounding the 
hair bulb had a similar role as dermal papilla cells in inducing hair follicles 
(McElwee et al., 2003). In this experiment donor mice were used with green 
fluorescent protein.  The cells of the dermal sheath cup were able to form dermal 
papilla, whilst implantation of non-bulbar dermal sheath cells to induce hair 
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follicle development was unsuccessful.  This suggests that dermal sheath cup cells 
may be functionally similar to the dermal papilla cells. This was confirmed in 
another study where dermal sheath cells from scalp hair follicles of a male donor 
were implanted superficially in the forearm of a female recipient (Reynolds et al., 
1999).  At the site of implantation new hair follicle was formed producing large 
and thick hairs; DNA extracted from the dermal papilla cells was found to be of 
male origin. 
These results all suggest that mesenchymal-epithelial interactions are important 
for both hair follicle development and hair cycling.  
1.3 Regulation of hair growth 
1.3.1 Hormonal regulation of hair growth 
The hair follicle growth cycle allows the hair produced from the follicle to change 
during sexual development or to change and be replaced by one more suitable to 
seasonal variations in climate.  In mammals this can be detected in the changing of 
coat thickness and colour induced by several factors such as temperature, day 
length (photoperiod) and availability of nutrients (Chase, 1954; Galbraith, 1998). 
These environmental changes are translated to follicles through the endocrine 
system, via the pineal and the hypothalamus-pituitary route (Ebling et al., 1991; 
Randall, 2007). The hormones involved differ according to the species, but 
generally include gonadal hormones, corticosteroids, thyroid hormones, prolactin 
and melanocyte stimulating hormone (MSH). 
In human beings, a wave of hair shedding occurs a few weeks after birth (Pecoraro, 
1968), after this the hair cycle is asynchronous except for the local groups of three 
follicles called DeMeijère trios (Saitoh and Sakamoto, 1970).  The human hair 
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follicle is also influenced by circulating hormones and by nutrient levels (Bradfield, 
1971b; Rushton, 2003; Randall, 2007).  Circannual changes in the rate of human 
hair growth have been reported on the scalp, beard and thigh (Orentreich, 1969; 
Randall and Ebling, 1991b; Courtois et al., 1996).   
Androgens are the major regulating hormones of human hair growth (Randall, 
1994, 2008).  They have paradoxical effects, stimulating hair growth in many areas 
such as the face in males after puberty causing transition of vellus follicles into 
terminal follicles (Hamilton, 1958; Marshall and Tanner, 1969; Marshall and 
Tanner, 1970b), whilst transforming terminal hair follicles into vellus one on the 
scalp in genetically predisposed individuals in androgenetic alopecia (Hamilton, 
1942, 1960).  However, androgens have no effects in other body areas such as the 
eyelashes, so the response of a hair follicle to androgens depends on the body site; 
this suggests that the responses of the hair follicles to androgen is intrinsic to the 
hair follicles itself. This is further illustrated by hair transplantation, where the 
follicle retains the characteristics of the donor site (Orentreich and Durr, 1982; 
Orentreich and Orentreich, 1985; Bernstein and Rassman, 1999).  These changes 
are a gradual process, in which several hair growth cycles take place before the 
type of hair produced is changed (Randall, 1994).  The maximal amount of beard 
growth is achieved around the mid-thirties (Hamilton, 1958) and androgenetic 
alopecia develops over several years (Kligman, 1959b).  
Testosterone is the major circulating androgen; it is derived from cholesterol like 
all other steroids.  In human males, more than 95% of testosterone is produced 
and secreted by the Leydig cells of the testes and the remaining testosterone is 
produced by the adrenal cortex.  Testosterone also plays a role in hair 
pigmentation, it had been shown to increase pigmentation in Mallard feathers 
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(Haase et al., 1995) and deer hair (Bubenik and Bubenik, 1985); high testosterone 
levels also make lion manes darker (West and Packer, 2002b). 
Androgens circulate in the blood either free or bound to proteins such as the sex-
hormone-binding globulin (SHBG) and albumin (Rommerts, 2004).  Androgens can 
enter the hair follicle through its blood capillaries into the dermal papilla and the 
dermal sheath. Androgens diffuse through the cell membrane, passing the 
cytoplasm and enter the nucleus as androgens are lipophilic molecules; they bind 
to the androgen receptor leading to the removal of inhibitory proteins such as heat 
shock protein 90. This induces a conformational change in the receptor exposing 
the DNA binding domain followed by dimerisation of the androgen-receptor 
complex; this then binds to a regulatory DNA sequence in or near to the target 
gene which is known as a hormone response element  (Handelsman, 2005).  This 
leads to activation of appropriate genes and transcription of DNA. 
The enzyme 5α-reductase can metabolise testosterone intracellularly to 5α-
dihydrotestosterone (DHT). The 5α-dihydrotestosterone is a more potent 
androgen and binds preferentially and more strongly to the androgen receptor to 
induce gene expression  (Randall, 1994). Testosterone metabolism to 5α-
dihydrotestosterone occurs in many tissues including the androgen target organ, 
prostate.  However, testosterone is the active hormone in skeletal muscle (Randall, 
2007). The general mechanism of action for both testosterone and 5α- 
dihydrotestosterone is shown in figure 5. 
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Figure 5  Mechanism of action of androgens 
This model demonstrates the mechanism of action of testosterone and 5α-
dihydrotestosterone. Obtained from Randall (2000), with permission by the 
author.  
 
 
Two forms of 5α-reductase have been identified, type 1 and type 2 (Blanchard et 
al., 2007).  The type 1 is mostly found in the liver, but its role is not obvious, whilst 
lack of 5α-reductase type 2 leads to the syndrome of 5α-reductase deficiency, a 
rare form of male pseudohermaphroditism, in which they are unable to convert 
testosterone to 5α-dihydrotestosterone (Andersson et al., 1991). Men with 5α-
reductase deficiency demonstrate female patterns of axillary and pubic hair; 
although they have high levels of circulating androgens, they grow little or no 
beard, suggesting that pubic and axillary follicles respond to testosterone, but the 
male secondary sexual hair growth requires 5α-dihydrotestosterone (Imperato-
McGinley et al., 1974; Wilson et al., 1993; Randall, 2007). 
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The various forms of androgen insensitivity syndrome explain the mechanism of 
action of androgens in hair follicles. Individuals with androgen insensitivity 
syndrome have an XY genotype but without functional androgen receptors, they 
develop a female phenotype despite normal, or high, circulating androgen levels.  
However, they do not develop female patterns of pubic or axillary hair and they do 
not undergo androgen-dependent scalp hair thinning (McPhaul, 2004; Randall, 
2007).  This suggests that terminal hair growth in these areas is androgen 
dependant, but growth of follicles located on the scalp, eyelashes and eyebrows are 
androgen independent.       
The current hypothesis of androgen action in hair follicles is that androgens act on 
the other hair follicle components through the dermal papilla (Randall and Ebling, 
1991a; Randall, 2007).  Circulating androgens enter the dermal papilla through its 
blood supply, bind to androgen receptors within dermal papilla cells and then alter 
the gene expression of the dermal papilla cells in production of regulatory factors, 
which influence other target cells in a paracrine fashion (Figure 6). These 
paracrine factors could be soluble mitogenic factors such as growth factors and/or 
extracellular matrix components. They target the follicular melanocytes, which 
alter the amount of pigment produced, the keratinocytes, which proliferate to form 
the hair fibre, various sheaths and the follicle endothelial cells to allow the blood 
supply (Randall, 2000).  The dermal papilla itself is a target of such factors, as a 
change in hair size can occur through a change in dermal papilla size (Van Scott EJ, 
1958; Elliott et al., 1999).  The processes involved in embryonic development in 
other steroid hormone regulated tissues, the prostate and the mammary gland are 
also in support of this hypothesis (Oka and Yoshimura, 1986; Cunha et al., 1987). 
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Recent observations suggest minor modifications to the hypothesis.  The dermal 
sheath and medulla cells are also affected directly by androgen action (Randall, 
2007).  The dermal sheath cells have the ability to form a new dermal papilla and 
stimulate new hair follicle development (Reynolds et al., 1999).  Expression of the  
Figure 6  Mode of androgens action on the human hair follicle  
Diagrammatic representation of the current model of androgen action in the hair 
follicle.  In this model androgens enter the follicle via the blood supply in to the 
dermal papilla where they bind to androgen receptors in the dermal papilla cells, 
causing changes in their production of regulatory paracrine factors.  This would 
alter the activity of other follicular components.  T: testosterone; ?: unknown 
paracrine factor.  Reproduced from Randall (2007), with permission by the author.  
 
 
 
genes for 5α-reductase type 2 was reported in the dermal papilla and dermal 
sheath of follicles from both balding and non-balding scalp (Asada et al., 2001).  
The dermal sheath cells may act as a reserve source to replace dermal papilla cells 
in case of dermal papilla loss (Randall, 2007).  Pregnancy hormones also affect hair 
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growth causing diffuse hair loss shortly after birth. They maintain scalp hair 
follicles in the anagen phase, 95% anagen during the second and third trimesters 
of pregnancy and for about a week after birth.  Many follicles enter catagen and 
telogen phases post-partum, this decreasing to about 76% in anagen and remained 
low for three months (Lynfield, 1960), causing simultaneous partial shedding 
(Lynfield, 1960). The possible hormones involved in altering hair growth are 
oestrogen and prolactin, however, the precise hormone involved is not clear.  
Human hair follicles possess prolactin and 17β-oestradiol receptors (Thornton et 
al., 2003; Foitzik et al., 2006; Thornton et al., 2006) and prolactin decreses human 
hair growth in vitro, supporting its role in hair shedding after birth (Foitzik et al., 
2006).  
As androgens affect the dermal papilla production of regulatory paracrine factors 
and they also influence follicular melanocytes resulting in hair colour alterations.  
One pituitary hormone in particular, α-melanocyte stimulating hormone (α-MSH), 
can affect follicular melanogenesis (Logan and Weatherhead, 1981; Burchill and 
Thody, 1986; Slominski et al., 2004).  Melanocyte-stimulating hormone (MSH) is an 
important hormone involved in enhancing pigmentation (Lerner and Case, 1959; 
Lerner, 1960; Lerner and McGuire, 1961).  There are three identified types of MSH, 
α, β and γ (Lerner and Case, 1959). These three types of MSH alongside with 
adrenocorticotrophic hormone (ACTH) are called melanocortins and all derive 
from a common precursor, pro-opiomelanocortin (POMC), which is secreted from 
the intermediate lobe of the pituitary gland. These factors, especially the 
melanocortins and ACTH, can effect epidermal melanocytes through melacortin-1 
receptor (MC-1R) (Rousseau et al., 2007). The human MC-1R gene has been shown 
to play a crucial role in pigmentation features of eye, hair and skin colour 
 
 
40 
 
(Ibarrola-Villava et al., 2010).  The level of plasma MSH was found to vary in 
pathological conditions and in different circumstances depending on the 
environmental factors such as the amount of UV light exposure.  The skin also 
produces MSH and other POMC-derived peptides (Thody et al., 1983); both 
melanocytes and keratinocytes were involved in this local production (Slominski 
et al., 1995; Chakraborty et al., 1996).   
Some other local factors such as β-endorphin, endothelin and catecholamines also 
have an effect on epidermal melanocytes (Slominski et al., 2004; Lin and Fisher, 
2007).  Factors like POMC, ACTH and α-MSH, have roles in balancing eumelanin 
and phaeomelanin proportions (Slominski et al., 2004; Tobin and Kauser, 2005; 
Rousseau et al., 2007). The α-MSH acts on follicular melanocytes and causes 
darkening of hair colour (Bolognia and Pawelek, 1988).  Quantitative electron 
microscopy has shown that α-MSH and its artificial analogue; NDP-MSH stimulate 
eumelanogenesis rather than phaeomelanogenesis in hair bulb melanocytes of 
C57BL/6J mice (Granholm and van amerongen 1991) using the stage and shape of 
melanosomes as a guide to the type of melanin produced.  The α-MSH and ACTH 
were increased melanogenesis in cultured human melanocytes (Hunt et al., 1994a; 
Hunt et al., 1994b).  Systemic administration of α-MSH, β-MSH, or ACTH in human 
beings stimulates skin pigmentation, particularly in the sun-exposed areas.  
Injection of oestrogen or testosterone to menopausal women or women who had 
undergone ovariectomy, was increased skin pigmentation (Snell and Bischitz, 
1960); increasing pigmentation level occur in the nipples, areola and face of 
pregnant women (Snell, 1964).  In murine, estrogen is an important factor in 
determining the content of eumelanin and pheomelanin in female hair (Hirobe et 
al., 2010). 
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1.3.2 Potential paracrine factors produced by hair follicles 
Paracrine factors produced by dermal papilla cells in androgen-regulated follicles 
have been the focus of much research as they are believed to play an important 
role in the regulation of the hair follicle (Blume-Peytavi and Mandt, 2000; Paus, 
2000; Philpott, 2000; Randall et al., 2000; Hamada and Randall, 2006).  A number 
of growth factors and cytokines have been recognised in androgen action, mainly 
by investigating cultured dermal papilla cells.  
Insulin like growth factor-I (IGF-I) is a potent mitogen which maintains cultured 
human scalp hair follicles in anagen at physiological concentration (Philpott et al., 
1994).  Androgens increased gene expression of IGF-I in beard dermal papilla cells 
in vitro (Itami et al., 1995) and androgens also stimulated the proliferation of outer 
root sheath cells when co-cultured with dermal papilla cells; the stimulatory effect 
of androgens on the growth of outer root sheath cells was stopped when IGF-I was 
blocked with antibodies.  Abnormal hair growth and differentiation occurred in 
hair follicles when the action of IGF-I is blocked in the IGF-I receptor deficient 
mouse (Liu et al., 1993).  These results implicate IGF-I involvement in hair growth, 
including androgen-stimulation 
Stem cell factor (SCF), also known as mast cell growth factor, c-kit ligand or steel 
factor, plays a role in the development of epidermal (Williams et al., 1992; Grichnik 
et al., 1998) and hair pigmentation (Geissler et al., 1988; Fleischman et al., 1991).  
Beard dermal papilla cells secrete more SCF than non-balding scalp cells (Hibberts 
et al., 1996) while cells derived from pale balding scalp follicles secreted less 
(Randall et al., 2008).  Dermal papilla cells secrete SCF and adult scalp hair follicle 
melanocytes express the receptor for SCF, c-kit, (Randall et al., 2008) suggesting 
that SCF secreted by the dermal papilla could alter pigmentation by acting on the 
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hair follicle melanocytes.  Interestingly, androgens in vivo may alter SCF 
production by facial or scalp dermal papilla cells resulting in darker facial hair 
when boys vellus hairs transform to adult beard and paler hairs during the 
miniaturisation of scalp hair follicles.  
Hepatocyte growth factor (HGF) also known as scatter factor, was shown to be a 
mitogen and morphogen of epithelial cells (Sonnenberg et al., 1993).  HGF had a 
stimulatory effect on follicle length and 3H-thymidine uptake in both mouse 
vibrissae (Jindo et al., 1994) and human scalp hair follicles in organ culture (Jindo 
et al., 1995; Shimaoka et al., 1995).  HGF was detected in dermal papilla cells, while 
the HGF receptor, c-Met, was localised in the hair bulb keratinocytes in anagen 
mouse follicles using immunohistochemistry (Lindner et al., 2000).  HGF mRNA is 
expressed by cultured human hair follicle dermal papilla cells (Shimaoka et al., 
1994; Merrick, 2000).  HGF stimulated DNA synthesis in keratinocytes derived 
from the human hair bulb in vitro (Shimaoka et al., 1995) suggesting an active role.  
Cultured beard dermal papilla cells showed a greater HGF expression than non-
balding scalp dermal papilla cells, but balding scalp dermal papilla cells showed 
very low HGF expression (Merrick, 2000 b).  These results suggest that HGF may 
play a role in maintaining large follicles and androgens may control the level of 
HGF in androgen-dependent follicles in vivo (Randall et al., 2001b). 
Another possible paracrine factor is vascular endothelial growth factor (VEGF), a 
modulator of angiogenesis and vascular permeability. Terminal follicles have a 
good blood supply, suggesting that microvascular angiogenesis occurs at an early 
anagen phase (Montagna and Van Scott, 1958b).  Cultured dermal papilla cells 
have been shown to express VEGF (Hibberts, 1996; Lachgar et al., 1996b; Merrick, 
1999).  Catagen and telogen phase human scalp dermal papilla cells were found to 
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express decreased levels of VEGF mRNA (Lachgar et al., 1996a).  Minoxidil, a 
treatment for androgenetic alopecia, has been shown to stimulate VEGF mRNA 
expression in cultured human dermal papilla cells (Lachgar et al., 1998).  VEGF 
expression in a number of cell types is influenced by steroid hormones, such as 
oestrogen which up-regulates the expression of VEGF in rat ovary (Shweiki et al., 
1993) and uterus (Cullinan-Bove and Koos, 1993); and in the human endometrium 
(Shifren et al., 1996).  In a different study, it was reported that patients receiving 
androgen deprivation therapy for prostate cancer showed decreased levels of 
VEGF compared to the levels measured before the treatment (Aslan et al., 2005).  
Therefore, VEGF appears to respond to steroid hormones including androgens 
making it a likely factor involved in androgen-regulation of hair growth.   
 Transforming growth factor-β1 (TGF-β1) is another paracrine factor which 
inhibits hair growth in vitro and may be a negative regulator of hair follicle growth 
(Philpott, 2000). TGF-β1 inhibits human hair growth during organ culture 
(Philpott et al., 1990).  When TGF-β1 was investigated in a co-culture system of 
balding dermal papilla cells with transfected androgen receptors and keratinocytes 
(Inui et al., 2002, 2003), there was a significant suppression in keratinocytes 
growth with the addition of a synthetic androgen to the culture.  Androgens also 
stimulated the expression of TGF-β1 in the cultured balding dermal papilla cells.  
In addition an antibody against TGF-β1 reversed growth inhibition of the 
keratinocytes, which suggests that androgens induce the expression of TGF-β1 
from balding dermal papilla cells which leads to the suppression of epithelial cell 
growth.  TGF-β1 has also been reported to involve in controlling catagen, in which 
a suppressor of TGF-β1 delayed progression of catagen in mice in vivo (Tsuji et al., 
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2003).  The injection of TGF-β1 into the back skin of mice induced premature 
catagen (Foitzik et al., 2000).   
In order to reveal further the effect of androgen on the dermal papilla production 
of paracrine factors, Rutberg et al (2006) compared gene expression patterns in 
cultured human dermal papilla cells isolated from beard (androgen-sensitive) and 
occipital scalp (androgen-insensitive) hair follicles using DNA microarray methods. 
Three genes, sfrp-2, mn1 and atp1β1, were expressed at significantly higher levels 
in the beard dermal papilla cells than non-balding scalp cells (Rutberg et al., 2006) 
but their significance is not clear.  
1.4 Hair disorders 
Hair disorders are not life threatening, however the important role of hair in 
human social and sexual communication through life, makes any pathological 
abnormalities in hair growth psychologically distressing in both men (Cash, 1992; 
Gulec et al., 2004) and women (Cash et al., 1993) (Figure 7).  The most common 
hair disorders are: androgenetic alopecia, hirsutism and alopecia areata.     
Androgenetic alopecia  
Androgenetic alopecia, also known as common baldness or male pattern baldness, 
is the most common type of hair loss disorder in men (Rathnayake and Sinclair, 
2010).  It occurs on the scalp of both men (Hamilton, 1951) and women (Ludwig, 
1977), but more frequently in men.  In androgenetic alopecia, thin, short and non-
pigmented vellus hairs replace the thick, pigmented terminal hairs on the scalp in 
slow progression (Figure 7 and 8).  The hair loss follows a distinctive pattern of 
progression, which was first described in men by Hamilton (1951).  The degree of 
hair loss severity was classified to include seven types, with type I being the 
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normal pre-pubertal scalp hair pattern.  The hair loss normally occurs through 
gradual recession of the bitemporal hairline and thinning of the vertex to type VII 
in which hair only remains around the back and sides of the head (Norwood, 1975) 
(Figure 8).  Although male pattern balding can occur in women, a different pattern 
of hair loss is more common, where there is generally a progressive hair loss in the 
crown, with preservation of the frontal hair line (Ludwig, 1977; Price, 2003). 
In androgenetic alopecia, the anagen phase of the hair growth cycle starts to 
become shorter while the telogen phase remains constant, meaning that the 
proportion of the telogen follicles increases  (Hamilton, 1951; Norwood, 1975; 
Randall, 2005a). Two main factors play a role in the pathogenesis of androgenetic 
alopecia: the genetic predisposition and androgen involvement.  Androgens are 
necessary for the progression of the disorder and several studies provided 
evidence to support this, for example, androgenetic alopecia does not occur in 
males castrated prior to puberty and progression is stopped if postpubertal males 
are castrated (Hamilton, 1960); testosterone replacement therapy can also induce 
hair loss in castrated males (Hamilton, 1958). The role of androgen in 
androgenetic alopecia is also confirmed by the absence of androgenetic alopecia in 
people with complete androgen insensitivity syndrome (lack of functional 
androgen receptors) (McPhaul, 2004).  For the onset of alopecia, a genetic 
predisposition is required alongside androgens (Birch and Messenger, 2001; Ellis 
and Harrap, 2001).   
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Figure 7  Patterns of human hair growth   
Modified from Randall (2000), with the author’s permission. 
 
 
Figure 8  The patterns of hair loss in androgenetic alopecia in men 
Classification of the common types of baldness in men. Hamilton scale (modified 
by Norwood).  Reproduced from Randall (2000), with the author’s permission. 
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Treatments for androgenetic alopecia include surgery, wigs, hairpieces, hormonal 
and non-hormonal therapy. The surgical treatment relies on the intrinsic 
responses of hair follicles to androgens, in which hair follicles from the non-
balding areas such as occipital and parietal sites can be relocated on to the bald 
area to cover it (Orentreich and Durr, 1982).  The surgical treatment lasts for a 
long time, but it also has some disadvantages as it is expensive, painful and may 
require more surgery as the hair loss develops around the transplanted region.   
Hormonal treatments include 5α-reductase inhibitors and anti-androgens.  Anti-
androgen treatments act by blocking the androgen binding to the androgen 
receptor, however, this is not a desirable treatment for men as they also affect 
male masculinity.  The 5α-reductase inhibitors such as finasteride, a 5α-reductase 
type 2 inhibitor, block the conversion of testosterone to its more active metabolite, 
5α-dihydrotestosterone (DHT).  Finasteride slows down hair loss progression and 
also promotes hair growth in men under 42 with stage II to V hair loss (Kaufman et 
al., 1998).  Dutasteride, which is a both type 1 and type 2 5α-reductase inhibitor, 
has been shown to have a more rapid effect on scalp hair growth in men with 
androgenetic alopecia than the finasteride (Olsen et al., 2006).  Currently 5α-
reductase inhibitors are the best treatment for androgenetic alopecia in men, but 
like all other hormonal treatments, must be taken continuously and side-effects are 
reported (Kaufman et al., 1998; Libecco and Bergfeld, 2004; Finn et al., 2006; 
Naslund and Miner, 2007; Erdemir et al., 2008).    
Minoxidil is the most commonly used non-hormonal treatment for androgenetic 
alopecia (Lachgar et al., 1998; Li et al., 2001; Messenger and Rundegren, 2004).  It 
is a widely used topical treatment for hair loss in men and women. It was initially 
developed for the oral treatment of hypertension, but hypertrichosis happened as 
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a common side effect (Dawber, 2000).  Unfortunately hair loss progresses once 
treatment is stopped (Shapiro and Price, 1998; Dawber, 2000) like all medical 
approaches as the hormone trigger is being continually produced.  It was originally 
believed to act on the vasculature, increasing the blood supply to the follicle, but a 
recent study showed its mechanism of action is through the opening of ATP-
sensitive potassium K(ATP) channels in the dermal papilla cell membrane (Shorter et 
al., 2008). 
Hirsutism 
Hirsutism is the excessive hair growth on the body of women in the same pattern 
as a post-pubertal normal male (Brodell and Mercurio, 2010).  These areas in 
normal women are typically covered with fine hair or no hair at all, for example 
areas on the face like above the upper lip and on the chin, and on other areas of the 
body like the chest, forearms, back and abdomen (Figure 7).  This excessive hair 
growth can be triggered by excess androgen production above the normal female 
level which triggers transformation of small, fine vellus hairs to thick, pigmented 
hairs. This is a paradoxically different effect of androgens compared to their 
involvement in androgenetic alopecia. There are a number of conditions which can 
lead to hirsutism; the most common condition is polycystic ovary syndrome 
(PCOS) which is characterised by over production of androgens (Franks, 1989; 
Liepa et al., 2008).  However a small portion of cases have idiopathic hirsutism, 
with no hormonal abnormality.  
 Treatment of hirsutism includes both cosmetic and pharmacological approaches. 
The cosmetic approach employs various methods which physically remove or 
lighten the excess hairs, and such treatments include bleaching, shaving, waxing, 
depilatory creams, electrolysis and laser hair removal.  Pharmacological methods 
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include treatment with anti-androgen drugs, as hirsutism is mediated by 
androgens.  The most commonly used anti-androgen drugs are cyproterone 
acetate (CPA) and spironolactone (Hammerstein, 1987; Shapiro and Lui, 2005).  
Anti-androgen drugs also have some disadvantages as the treatment takes a long 
time before detecting any effect on the hair growth, there may only be partial 
improvement and there is risk of feminisation of a male foetus (Hughes and 
Cunliffe, 1988).     
Alopecia areata 
Alopecia areata is an autoimmune disorder resulting in hair loss, causing patches 
of baldness particularly on the scalp, but with no scarring of the affected area 
(Delamere et al., 2008; Alkhalifah et al., 2010); it also occurs in the eyebrows, 
beard, or other hair-bearing areas of the body (Epstein, 2001).  It happens in both 
male and female adults, children and in all ethnic groups (Muller and Winkelmann, 
1963; Sharma et al., 1996). Alopecia areata has two major forms, alopecia 
universalis which is a more generalised pattern of total body and scalp hair loss, 
and alopecia totalis, which is less common, and confined to the entire scalp 
(Delamere et al., 2008) 
Although it is believed to be an autoimmune disease the exact cause of alopecia 
areata is still unknown (Randall, 2001a).  The presence of a lymphocytic infiltrate 
in and around the hair follicles supports the idea that alopecia areata is an 
autoimmune disease (Wasserman et al., 2007).  Several factors have been 
associated with its pathogenesis, e.g., genetic, neurological factors, possible 
emotional stress, vaccines, exposure to chemicals and infectious agents (Madani 
and Shapiro, 2000).  It appears to be inherited as an autosomal dominant trait with 
variable penetrance (Sinclair et al., 1999).   
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There is no definitive treatment available for alopecia areata yet although, there 
are some ways to help patients like using wigs and hairpieces (Epstein, 2001).  The 
available treatments include a range of therapies like immune inhibitors, contact 
sensitizers, immunomodulators, biologic response modifiers, cortico-steroids, 
minoxidil and non-specific irritants (Gilhar et al., 1998; Wasserman et al., 2007; 
Delamere et al., 2008).  These treatments have varying success rates, but they also 
have negative side effects and therefore there is no fully satisfactory treatment 
available for alopecia areata.  
Overall, there is a major need for novel approaches to regulate hair growth without 
androgen-based side effects and preferably useful in both men and women. 
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1.5  Prostanoids and hair growth 
1.5.1 Glaucoma treatments stimulate eyelash growth 
A prostaglandin F2α analogue, latanoprost (Xalatan®), is a common medication in 
the treatment of open-angle glaucoma, ocular hypertension (Camras, 1996). It 
lowers intraocular pressure by increasing the natural outflow of fluid from inside 
the eye into the blood stream (Watson, 1999) and is administered as a single eye-
drop once a day into the affected eye or eyes. After its introduction, latanoprost 
was reported to have a side effect which stimulated the growth of eyelashes and 
eyebrow hairs (Johnstone, 1997).  When 43 patients were unilaterally treated with 
latanoprost, the eyelashes of the treated eyes showed hypertrichosis.  Latanoprost 
treatment increased the numbers of terminal follicles compared to vellus and 
intermediate follicles and the pigmentation of the eyelashes was also increased. 
Curling of the lashes also occurred in several patients.  Therefore, increased length, 
number, thickness, pigmentation and curvature of eyelashes was reported as side 
effects of latanoprost treatment (Johnstone, 1997).   
In Europe and the U.S., latanoprost was first made available in 1996; it is 
considered to have long term local and systemic safety (Alm et al., 2004).  
In another study, hypertrichosis of eyelashes was reported after unilateral topical 
latanoprost treatment of 89 glaucoma patients; changes to eyelashes including 
increased number, thickness, length and pigmentation had occurred in 5 of the 
patients in less than 3 weeks, similar to those patients who had received long term 
treatment (Johnstone, 1998), suggesting effects on follicles already in anagen.  
Several other studies have also reported hypertrichosis and darkening of eyelashes 
in patients following latanoprost treatment (Wand, 1997; Reynolds et al., 1998; 
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Strober et al., 2001; Sugimoto et al., 2002; Elgin et al., 2006). For example 
seventeen patients with glaucoma, treated unilaterally with latanoprost, showed a 
significant increase in eyelash length after 2, 6, and 8 weeks (Sugimoto et al., 
2002), with no difference in eyelash measurement in the untreated eyes.   
However, in another study, when 7 patients were treated with latanoprost for 5 
months eyelash length increased only in one patient (Noecker et al., 1999), though 
thicker lashes were noticed in 10 of the 14 eyes examined. In a different study, 
timolol, a beta-receptor antagonist, used for treatment of high intraocular pressure 
was also examined.  Patients (44) were divided into two groups, one treated with 
timolol and the other with latanoprost. There was an increase in eyelash length in 
7% of the patients treated with latanoprost (Stecchi et al., 2002), but no 
hypertrichosis occurred in any of the patients treated with timolol.   
Travoprost (TravatanTM), another PGF2α analogue, which is structurally similar to 
latanoprost (Hellberg et al., 2002), was also studied for its effect on eyelash 
growth; greater increases in eyelash length occurred after treatment with 
travoprost than latanoprost (Netland et al., 2001; Li et al., 2006).  Latanoprost has 
also been reported to cause re-growth of eyelashes in alopecia areata (Mansberger 
and Cioffi, 2000; Mehta et al., 2003).  In a recent clinical study when they tested the 
efficacy of latanoprost in eyelash alopecia areata, latanoprost induced acceptable, 
total and moderate responses in 45% of the patients (Coronel-Perez et al., 2010).  
In another study, a murine model (C57BL/6 mice) was used to investigate the 
effects of prostaglandin F2α, and its analogues, latanoprost and isopropyl 
unoprostone, on hair follicles (Sasaki et al., 2005).  In this model system, active 
melanocytes are confined to the hair follicle, therefore the skin is only pigmented 
when the follicles are in anagen and during telogen the skin appears pink/white 
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(Chase et al., 1951; Paus et al., 1994).  This model allows observation of the hair 
cycle stages (section 1.2.2). Mice with dorsal skin in the telogen phase were 
topically treated with prostaglandin F2α, latanoprost, isopropyl unoprostone or 
vehicle control.  After 12 days of treatment prostaglandin F2α and its analogues all 
caused the development of a grey skin colour indicating the onset of the anagen 
phase.  Overall, these studies showed that PGF2α and its analogues stimulated 
anagen hair follicle elongation and caused conversion of the telogen to anagen 
phase in mice (Sasaki et al., 2005). 
1.5.2 The Prostanoids 
The prostanoids, which include prostaglandins (PGs), thromboxanes (TXs) and 
prostacyclins (PGI2) are members of the eicosanoids, a family of oxygenated 
metabolites of arachidonic acid which includes the prostaglandins, leukotrienes, 
thromboxanes, lipoxins and other oxygenated derivatives (Haeggstrom et al., 
2010).  These are potent lipid mediators which are derived from 20 carbon 
polyunsaturated fatty acids (PUFA). They show a vast number of physiological 
effects in a wide range of biological systems, such as the brain, eye, cardiovascular 
system, kidney, skin and lung and are also involved in inflammation (Samad et al., 
2002; Wise et al., 2002).  Prostanoids act in a paracrine manner, they are produced 
and inactivated within the same or neighbouring cells before their release as 
inactive metabolites (15-keto- and 13,14-dihydroketo metabolites) into the 
circulation (Schuster, 1998; Nomura et al., 2004). The prostanoid signal is ended 
locally to avoid undesired action at a distance; this metabolic clearance is 
suggested to happen by two steps, selective uptake across the plasma membrane 
and oxidation inside the cells (Nomura et al., 2004). 
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1.5.2.1 Prostanoid biosynthesis 
Prostanoid biosynthesis involves 3 main steps (Figure 9). Firstly, membrane 
glycerophospholipids are hydrolysed by phospholipases A2 (PLA2) to generate free 
fatty acids.  The cyclooxygenases, COX-1 and COX-2, catalyse the second step in 
prostanoid biosynthesis mainly catalysing arachidonic acid (AA) oxidation but also 
that of docosahexaenoic (DHA) and eicosapentaenoic acid (EPA) (Smith and Song, 
2002).  COX-1 and COX-2 both have similar active site structures, but the active site 
of COX-2 is larger than that of COX-1, and COX-2 catalyses more prostanoid 
synthesis than COX-1 (Smith and Song, 2002). Arachidonic acid is converted by 
cyclooxygenase to prostaglandin G2 (PGG2) (Figure 9) and PGG2 is reduced to 
prostaglandin H2 (PGH2) by a peroxidase reaction; the highly reactive PGH2 is 
processed further to individual prostanoids by the action of a series of prostanoid 
synthases (Smith et al., 2000).    
The prostanoid synthases are localised in either the cytoplasm or the microsomes 
(Ruzicka and Aubock, 1987).  Prostaglandin E synthase (PGES), which has different 
forms with individual enzymatic properties, catalyses the isomerisation of PGH2 to 
PGE2.  The cytosolic PGES is expressed constitutively in a wide range of cells and 
tissues, whilst the membrane-associated PGES isozyme is inducible and reacts to a 
variety of pro-inflammatory stimuli (Jakobsson et al., 1999). The prostaglandin D 
synthase (PGDS) catalyses the isomerisation of PGH2 to PGD2.  There are two types 
of PGDS: the haematopoietic PGDS (H-PGDS) and the lipocaline PGDS (L-PGDS) 
(Urade and Eguchi, 2002; Kohno et al., 2006). The synthesis of prostaglandin F2 
occurs through three pathways from PGH2, PGE2 and PGD2.  PGH2 is catalysed to
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PGF2α by the enzyme PGH 9,11-endoperoxide reductase (PGH9,11-ER), PGE2 to 
PGF2α by PGE 9-ketoreductase (PGE9-KR) and PGD2 to PGF9α & 11β- PGF2α by PGD 
11-ketoreductase (PGD11-KR) (Suzuki-Yamamoto et al., 1999; Komoto et al., 
2006). PGH2 is catalysed to prostacyclin PGI2 by the enzyme prostacyclin synthase 
(PGIS) and this unstable PGI2 is instantly hydrolysed to the inactive 6-keto-F1α 
metabolite. The dehydration within the cyclopentane ring of PGE1, PGE2 and PGD2 
produces the cyclopentanone prostaglandins, PGA1, PGA2 and PGJ2 respectively 
(Straus and Glass, 2001).  PGH2 is catalysed to thromboxane A2 (TXA2) by the 
enzyme thromboxane A synthase (TXAS), and the unstable TXA2 breaks down to 
the inactive, but stable TXB2 (Miyata et al., 1994). 
The isoprostanes are prostaglandin-like molecules formed by free radical 
oxidation of arachidonic acid and other polysaturated fatty acids non-
enzymatically (Morrow et al., 1990).  The side chains in isoprostanes are cis to the 
cyclopentane ring which are different from that of prostaglandins which are in 
trans orientation. The F-ring compounds (diol substitution on the cyclopentane 
ring) are isomeric to PGF2α and they are known as F2-isoprostanes. The 15-series 
F2-isoprostanes are usually referred to as 8-iso-PGF2.  The isoprostanes have been 
recognised as a marker for lipid peroxidation and oxidative stress in vivo 
(Montuschi et al., 1998; Mehlhorn et al., 2003). 
1.5.2.2  The roles of prostanoids 
Prostanoids have a wide range of biological effects such as an involvement in 
inflammation in which they mediate fever, pain, swelling and erythema; they can 
act as both proinflammatory and anti-inflammatory mediators depending on the 
receptors and signalling pathways that they are coupled to (Tilley et al., 2001).    
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In the vascular system prostanoids are involved in platelet aggregation, 
haemostasis and thrombosis. Both TXA2 (mainly synthesised in platelets) and 
prostacyclin (PGI2; mainly produced by endothelial cells) play a vital role in the 
preservation of vascular homeostasis and control of the blood flow (McAdam et al., 
1999). COX-2 is present constitutively in the brain, primarily in neurons and has 
been shown to play a key role in neuroinflammation and associated disorders such 
as Alzheimer’s disease (Bazan and Flower, 2002).  Prostanoids have been reported 
to be produced in human skin and are involved in the regulation of growth and 
differentiation of the epidermis (Ikai, 1999); human epidermis expresses both 
COX-1 and 2 (Goldyne, 2000).  Prostanoids also show immunoregulatory and 
proinflammatory actions in human skin through their effects on blood vessels and 
inflammatory cells (Ikai, 1999).  Both COX-1 and 2 play roles in keratinocyte 
differentiation and the absence of either isoform can lead to premature 
differentiation of initiated keratinocytes (Tiano et al., 2002). The main 
prostaglandins produced in cultured human skin keratinocytes are PGF2α, PGE2 
and a small amount of prostacyclin (PGI2) (Pentland and Mahoney, 1990).  PGD2 
was reported to bind to the DP receptor on Langerhans cells and inhibit their 
migration (Angeli et al., 2001), however, PGE2 binds to the EP4 receptor on 
Langerhans cells and promotes their maturation and migration; this assists in the  
initiation of the skin immune response (Kabashima et al., 2003).           
Prostanoids are involved in normal renal function by regulating normal blood flow 
and vascular tone (Agnoli et al., 1999). Prostaglandins are also involved in many 
reproductive processes from ovulation and fertilisation to parturition and labour.  
It has been reported that local control of prostaglandin synthesis and degradation 
occurs in the foetal membranes, myometrium and placenta (Sullivan et al., 1992; 
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Grigsby et al., 2006); nineteen prostanoids have been identified in human non-
labouring and labouring myometrium (Durn et al., 2010b).  In the gastrointestinal 
tract, COX-1 has been shown to be expressed constitutively and COX-1-derived 
prostanoids especially PGE2 and PGI2, have important cytoprotective effects on the 
gastrointestinal mucosa (Hansen et al., 1999; Haworth et al., 2005). The 
involvement of COX-1 in the early stages of tumorigenesis has been reported 
(Houchen et al., 2000) and an increase in the expression of COX-2 was noted in a 
wide range of cancers (Bishop-Bailey et al., 2002; Muller-Decker and 
Furstenberger, 2007).  However, some studies indicated that prolonged use of non-
steroidal anti-inflammatory drugs (NSAID), such as aspirin, reduced the risk of 
developing many types of cancer, such as lung, stomach and colon cancer (Anand 
and Graham, 1999; Khuder et al., 2005); these suggest that specific COX-2 
inhibitors may be useful as anticancer treatments.  Isoprostanes are indicators of 
oxidative stress status or free radical lipid peroxidation (Roberts et al., 1998; 
Cracowski et al., 2002). They have been linked to a number of disorders, such as 
diabetes, inflammation, cardiovascular disease, atherosclerosis, neurological 
disoreders, reproductive disorders and pulmonary disease (Li et al., 1999; Junger 
and Sorkin, 2000; Greco and Minghetti, 2004). Both 8-iso-PGF2α and 8-iso-PGE2 are 
biologically active in bronchoconstriction and vasoconstriction and these effects 
were believed to be mediated by isoprostanes through the activation of prostanoid 
receptors (Daray et al., 2004).   
1.5.3  Prostaglandins 
Prostaglandins are biologically active acidic lipids that are abundantly distributed 
in mammalian tissues (Piper, 1973). They were first noticed in 1930 by two 
American gynaecologists, Kurzork and Lieb, whilst working on female sterility. 
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Later, a Swedish physiologist, Ulf von Euler (Von Euler, 1935) isolated lipid soluble 
acid extracts from seminal fluid and named them prostaglandins (Curtis-Prior, 
1976), believing they were part of the prostatic secretions, but afterwards it 
became clear that many other tissues secrete prostaglandins for various functions. 
Prostaglandins are oxygenated polyunsaturated 20 carbon carboxylic acids that 
contain a five-member ring. Thromboxane A (TXA) has an unstable bicyclic oxane-
oxetane ring structure, thromboxane B (TXB) is a stable oxane and prostacyclin 
(PGI) contains an oxygen bridge between C6 and C9 (Slater and McDonald-Gibson, 
1987).  The number of double bonds in the prostanoid alkyl chain depends on the 
precursor fatty acid.  The prostaglandins of the 1-series with 1 double bond, are 
derived from dihomo-γ-linolenic acid (DHGLA; 20:3 n-6), the II-series, with 2 
double bonds, are derived from arachidonic acid (AA; 20:4 n-6) and the III-series, 
with 3 double bonds, are derived from eicosapentaenoic acid (EPA; 20:5 n-3). 
Figure 10 shows the structures of prostaglandin F and E of all 3 series and their 
precursor polyunsaturated fatty acids.   
Prostaglandins were originally believed to leave cells via passive diffusion because 
of their high lipophilicity. The discovery of the prostaglandin transporter (PGT, 
SLCO2A1) which mediates the cellular uptake of prostaglandins, suggests that 
prostaglandin penetration through the cellular membrane occurs via both simple 
diffusion and prostaglandin transporters (Chi and Schuster, 2010).  Prostaglandins 
act as autocrine/paracrine local hormones through specific G-protein coupled 
receptors (GPCRS) (Kobayashi and Narumiya, 2002).  The presence of a large 
number of prostaglandin receptors allows prostaglandins to act on a range of cells, 
and have a wide variety of actions.  The known functions are: constriction or  
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Figure 10  The structures of prostaglandins F and E 
The structures of series I, II and III prostaglandin F and E; their precursor 
polyunsaturated fatty acids (Nicolaou, 2005).  
 
 
   
dilatation of vascular smooth muscle cells, aggregation or disaggregation of 
platelets, sensitisation of spinal neurons to pain, constriction of smooth muscle, 
regulation of inflammatory mediation, regulation of calcium movement, control of 
hormone regulation and control of cell growth (Bikowski et al., 2010). 
Prostaglandins, in particular PGF2α, are also known to induce labour (Karim et al., 
1968). The common functions for each type of prostaglandin are summarised in 
Table 1.   
Prostaglandin receptors belong to the rhodopsin seven transmembrane domains 
superfamily of receptors, and the five types of prostanoids (PGE2, PGF2α, PGD2, PGI2 
and TXA2) bind to their specific receptors (EP1, EP2, EP3, EP4; FP; DP1, DP2; IP; TP  
dihomo-γ-linolenic acid 
   (all cis 8,11,14 C20:3) 
              
                (DHGLA) 
arachidonic acid
(all cis 5,8,11,14 C20:4) 
 
(AA) 
eicosapentaenoic acid
(all cis 5,8,11,14,17 C20:5) 
 
(EPA) 
PGE1 PGE2 PGE3 
PGF1α PGF2α PGF3α 
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Table 1 Different prostaglandin types, their receptors and their functions 
Type Receptor Function 
PGD2 
DP1  inhibits vascular permeability 
DP2  vasodilatation 
 Inhibition of platelet aggregation 
PGE2 
EP1  bronchoconstriction 
 GI tract smooth muscle contraction 
EP2 & EP4 
 bronchodilatation 
 GI tract smooth muscle relaxation 
 vasodilatation 
EP3 
 decrease gastric acid secretion 
 increase gastric mucus secretion 
 uterus contraction 
 GI tract smooth muscle contraction 
 lipolysis inhibition 
 increase autonomic      
neurotransmitters 
PGI2 IP 
nocioception 
antithrombosis 
vasodilator actions 
pulmonary hypotension 
PGF2α FP 
 uterus contraction 
 essential for normal birth 
 bronchoconstriction 
TXA2 TP 
 mediate platelet shape change and     
 aggregation 
 smooth muscle contraction and   
 proliferation 
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respectively).  Despite a high affinity of each prostaglandin binding with its specific 
receptor, there is significant ligand-binding cross reactivity within the 
prostaglandin family (Breyer, 2001).  
Prostanoid receptors have been classified into three subgroups based upon G 
protein activity.  The first subgroup, FP, EP1 and TP, trigger Gq protein-coupled 
activating Ca2+ signalling pathways, which lead to inositol 1,4,5-triphosphate 
turnover and activation of protein kinase C.  The second subgroup, IP, EP2, EP4 and 
DP1, trigger Gαs protein-coupled adenylate cyclase activation which results in 
protein kinase A activation and cAMP synthesis.  The last subgroup, EP3 and DP2, 
trigger Gi protein-coupled adenylate cyclase inhibition and decrease intracellular 
cAMP (Coleman et al., 1994; Breyer et al., 2001).  Therefore, prostaglandins act by 
causing rapid changes in the intracellular levels of secondary mediators cAMP or 
Ca2+ generating specific induction of cell regulatory mechanisms.   
1.5.4  Prostaglandins and hair growth 
Positive effects of prostaglandin F2α analogue, latanoprost, on human eyelash 
growth have been reported (Johnstone, 1997, 1998; Johnstone and Albert, 2002) 
(reviewed 1.5.1), but the underlying mechanism of prostaglandin-associated hair 
growth is poorly understood.  Interestingly, minoxidil, a current main treatment 
for alopecia, was reported to activate purified COX-1 and prostaglandin 
endoperoxide synthase-1 (PGHS-1) in human hair follicle dermal papilla cells by an 
oxygen consumption and prostaglandin production assay; this activation was also 
evidenced by cultured BALB/c3T3 fibroblasts (Michelet et al., 1997).   
Various studies have reported that various enzymes involved in prostaglandin 
synthesis are present in skin tissues.  In another study on mice, COX isozymes were 
shown to be spatiotemporally expressed during morphogenesis of dorsal skin 
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epithelium of NMRI mice. COX-1 and COX-2 mRNA and protein were detected in 
embryonic and postnatal epidermal tissue by RT-PCR, northern blot and 
immunoblot analysis indicating that both isoforms may contribute to 
prostaglandin production in skin (Muller-Decker et al., 2003).  In two different 
studies, it has also been indicated that the enzymes involved in PGF2α and PGE2 
metabolism were present in human scalp skin (Kabashima and Miyachi, 2004), and 
hair follicle dermal papilla cells (Colombe et al., 2007) using RT-PCR, Western blot 
and immunohistochemistry.  
In order to further investigate the hair growth effects of prostaglandins in vivo, 
several experiments have been performed on animal models. Prostaglandin 
receptors were investigated in the anagen hair follicle from mouse dorsal skin by 
RT-PCR and both EP3 and EP4 mRNA were shown to be expressed in dermal papilla 
cells and outer root sheath cells respectively.  After 8 weeks, further signals for EP3 
and EP4 mRNA disappeared when the follicles were in telogen phase.  This could 
suggest that prostaglandin receptors may play a role in mouse hair growth (Torii 
et al., 2002). 
Latanoprost had promoted hair growth in C57/B16 mice compared to control mice 
(Stjernschantz, 2001). In a further study on stump-tailed macaque (Macaca 
arctoides) (a primate model of androgenetic alopecia), eight monkeys were divided 
into 2 groups; one group received a daily topical application of 115 nM of 
latanoprost and the other group had a daily application of vehicle.  For an 
additional 3 months, 2 monkeys from each group were given 1.15 µM latanoprost, 
while the remaining monkeys continued with the previous treatment. The 
administration of 115 nM  latanoprost caused minimal hair growth, whilst 1.15 µM 
latanoprost increased hair density and converted vellus hairs to intermediate or 
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terminal hairs; the vehicle group showed no effect (Uno et al., 2002).  Some other 
drugs such as ibuprofen, aspirin and indometacin, the inhibitors of prostaglandin 
endoperoxide synthase, were also reported to block prostaglandin synthesis and 
inhibit hair growth in humans (Meyer, 1979; Pillans and Woods, 1995).  These 
studies all suggest that prostaglandins may be able to regulate hair growth. 
1.5.5  Prostamides and hair growth 
Bimatoprost, a prostamide F2α analogue, rather than prostaglandin F2α analogue 
like latanoprost is the most efficient ocular hypotensive agent currently available 
for the treatment of glaucoma (Woodward et al., 2008b; Centofanti et al., 2010; 
Law, 2010).  Recently, a paired-eye comparison of medical therapies for glaucoma 
study was carried out on patients with uncontrolled glaucoma (n = 55) (Solish et 
al., 2010).  The patients were treated with bimatoprost 0.03% once daily in one 
eye and travoprost 0.004% once daily in the fellow eye. Intra ocular pressure (IOP) 
was evaluated for 4-6 weeks. Bimatoprost significantly reduced mean IOP (from 
19.8 mmHg to 17.1 mmHg, P < 0.0001) and slightly more than travoprost (from 
19.4 mmHg at baseline to 17.7 mmHg at follow-up, P = 0.009) (Solish et al., 2010). 
Following treatment with the antiglaucoma drug, bimatoprost, increases in eyelash 
growth were also noted (Hart and Shafranov, 2004). Bimatoprost (Latisse®) was 
licensed for the treatment of hypotrichosis of the eyelashes by the FDA in 
December 2008 (NDA 022369); it stimulates eyelashes to lengthen, thicken and 
darken (Easthope and Perry, 2002; Law, 2007, 2010).  Latisse was also reported to 
induce periocular skin hyperpigmentation in some cases as a side-effect (Priluck 
and Fu, 2010).  No other drugs have caused such a dramatic stimulation of hair 
growth after a local application as these glaucoma treatments have on eyelashes; 
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minoxidil’s effect topically is much less than via the original oral ingestion 
(Messenger and Rundegren, 2004).   
1.5.5.1  Prostamides 
Prostamides (prostaglandin-ethanolamide) are a large series of neutral lipids; they 
are COX-2 derived oxidation products of the endocannabinoid/endovanniloid 
anandamide (Woodward et al., 2008b). They were first identified during studies on 
endocannabinoid oxygenation via COX-2, which resulted in the formation of 
pharmacologically unique prostamides and PG-glyceryl esters (Yu et al., 1997). 
Anandamide and 2-arachidonylglyceryol ester (2-AG) are converted to a range of 
products that are closely related to those formed by COX-1 and COX-2 from 
arachidonic acid (Kozak et al., 2002) and prostamides can be produced from 
anandamide in mice (Weber et al., 2004). The oxidation of anandamide by COX-2 
results in a loss of activity at cannabinoid-1 receptors and formation of the 
prostamides (De Petrocellis et al., 2004). The fatty acid amide hydrolase (FAAHs) 
hydrolyses anandamide to arachidonic acid, which may supply a substrate source 
for COX-1 and COX-2 or lipo-oxygenases (Figures 9, 11) (Wei et al., 2006).  
It has been reported that prostamide F2α and its analogue, bimatoprost, show 
effects independent of prostanoid FP receptor activation; studies involving feline 
iridial smooth muscle cells had shown that bimatoprost and FP receptor agonists 
stimulated different cells (Liang et al., 2008).  
1.5.5.2  Prostamide biosynthesis 
Anandamide is catabolised to arachidonic acid and ethanolamine by the fatty acid 
amide hydrolase (FAAHs) enzymes (Cravatt et al., 1996; Wei et al., 2006).  It is also 
oxidised by COX-2 and lipo-oxygenase pathways to the endoperoxide 
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intermediates, prostamide G2 and prostamide H2; they are then converted to the 
various prostamides by specific prostaglandin synthases (Kozak et al., 2002; Yang 
et al., 2005). The prostaglandin F synthase catalyses both prostamide H2 and 
prostamide D2 substrates to form prostamide F2α and 11β-prostamide F2α (Koda et 
al., 2004; Yang et al., 2005) (Figure 11).  The 2-AG is also a substrate for FAAH in 
addition to anandamide and other fatty acid amides (De Petrocellis et al., 2004). 
PGE2-ethanolamide was recognised as the major product when anandamide was 
incubated with COX-2 or human foreskin fibroblasts expressing COX-2 (Yu et al., 
1997); a later study on mouse leukaemic monocyte macrophage cell line, RAW 
264.7 also confirmed the production of prostamide E2 from anandamide (Burstein 
et al., 2000).  
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Figure 11 Anandamide conversion pathways 
The biosynthesis of prostamides from anandamide. Adapted from (Woodward et 
al., 2008b) 
 
 
 
1.5.5.3  Prostamide analogues and their therapeutic roles 
The most extensive pharmacological studies with prostanoids have been 
conducted for prostamide F2α and its analogue, bimatoprost; bimatoprost has been 
the focus of many studies due to its clinical importance as an intra-ocular pressure 
lowering agent (Law, 2010). The amide substituent compounds were the most 
acceptable both pharmacologically and ophthalmologically; the primary amide 
(CONH2) and N-monosubstituted analogues offered potent and selective 
prostamide agonists.  A number of prostamide analogues including bimatoprost 
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have been made based on the essential PGF2α 1-amide structure (Woodward et al., 
2004).  The unique pharmacology of PGF2α amides was originally shown through a 
FP receptor-mediated event by comparing responses in the isolated feline iris with 
Ca2+ signalling (Woodward and Lawrence, 1994).  It was shown that only certain 
isolated tissue preparations distinctively identified prostamide F2α receptor, such 
as feline lung parenchyma (Woodward et al., 2003), feline iris (Matias et al., 2004) 
and rabbit uterus (Chen et al., 2005). 
A number of tissues which were known to constitutively express FP receptors like 
gerbil colon, mouse uterus, intact rabbit jugular vein, rat uterus and human uterus, 
were found to be insensitive to prostamide F2α and bimatoprost (Woodward et al., 
2001; Woodward et al., 2003; Matias et al., 2004; Chen et al., 2005).  However, 
bimatoprost at certain micromolar concentrations acts as a FP receptor agonist 
(Sharif et al., 2001; Sharif et al., 2003).  
Initially it was believed that prostamide activity was species and tissue specific, 
but when further studies were carried out similar results were obtained when the 
responses of feline and human recombinant FP receptors were compared 
(Woodward et al., 2003; Matias et al., 2004).  In a different study, the rabbit uterus 
showed high sensitivity to bimatoprost, but no such activity was observed in the 
intact rabbit jugular vein (Chen et al., 2005). Further gene regulation studies 
confirmed that prostamide activity is cell type specific (Liang et al., 2003).  In a 
study when they compared the effects of PGF2α and bimatoprost on the 
expressions of connective tissue growth factor and cysteine-rich angiogenic 
protein 61 (Cyr 61) in human ciliary smooth muscle cells, PGF2α upregulated both 
connective tissue growth factor and Cyr 61, while bimatoprost only upregulated 
Cyr 61 (Liang et al., 2003). Similarity in responses of cells and tissues to 
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prostamide F2α and PGF2α and their alike FP receptor stimulation have made 
pharmacological analysis extremely difficult (Woodward et al., 2008b).  A further 
study was performed to verify whether the FP receptor subclass equally 
recognised both PGF2α and prostamide F2α.  When the effects of a series of agonists 
were investigated on isolated feline iris cells with Ca2+ signalling and monitored by 
fluorescence confocal microscopy, bimatoprost and the FP receptor agonists 
(PGF2α, 17-phenyl PGF2α) stimulated entirely different cells (Spada et al., 2005).  
Identification of prostamide receptor genes was reported in a study on human 
ocular tissue which recognised the expression of splicing variants of FP receptor 
genes; bimatoprost actively interacted with FP-altFP4 heterodimer receptor (Liang 
et al., 2008).  
Prostamides seem to be involved in disease processes as studies showed 
upregulation of COX-2 together with anandamide levels at inflammation and 
infection sites, which could result in the formation of prostamides as main 
products (Glass et al., 2005; Woodward et al., 2008a; Woodward et al., 2008b). 
Prostamides were suggested to work in a different fashion to prostaglandins; 
clinical studies had shown that glaucoma patients who did not react to latanoprost 
treatment were found to be susceptible to bimatoprost, which produced a marked 
lowering of intraocular pressure (Williams, 2002; Gandolfi and Cimino, 2003).  The 
high efficacy of bimatoprost was linked to the dual mechanism of action on 
aqueous humour outflow that involved both uveoscleral and trabecular 
meshwork/Schlemm's canal pathways, causing a controlled remodelling of the 
anterior third of the ciliary body and resulting in new and organized drainage 
channels that were partially lined with endothelial cells (Richter et al., 2003; Wan 
et al., 2007). Despite being considered a very safe drug, bimatoprost does have 
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some side effects, such as periorbital hyperpigmentation, ocular surface 
hyperaemia and eyelash hypertrichosis (Hollo, 2007; Woodward and Chen, 2007). 
Bimatoprost causes significantly less iridial hyperpigmentation compared to the 
latanoprost therapy (Sherwood and Brandt, 2001; Alm et al., 2004).  
1.6  Aims and experimental design 
Clinical observations of increased eyelash growth as a side-effect of glaucoma 
treatment by PGF2α and prostamide F2α analogues (1.5.1) and a range of studies in 
rodents (1.5.4) (Bikowski et al.; Johnstone and Albert, 2002; Namazi, 2003; Wolf et 
al., 2003; Hart and Shafranov, 2004; Faghihi et al., 2009) suggest that these drugs 
may be useful for stimulating hair growth in human hair disorders. However, the 
regulation of human hair growth and pigmentation is complex with their 
responses varyring in different parts of the body.  For example, androgens 
stimulate hair growth in many areas after puberty e.g. the beard and axillary 
regions, but have no effect on eyelashes. In contrast, the same levels of androgens 
cause gradual inhibition of hair growth and balding on the scalp in men with the 
correct genetic background (Randall, 2007). Similarly, loss of pigmentation, hair 
greying, does not occur in all follicles at the same time; it starts above the ears and 
progresses across the scalp (Keogh and Walsh, 1965). Eyelashes, while being 
produced by hair follicles on the eyelid and passing through continuous hair cycles 
similarly to scalp follicles, spend much less time in the growing phase, anagen (see 
1.2.2), than scalp follicles (Thibaut et al., 2009). Eyelashes are specialised hairs 
designed to protect the eyes and are much shorter, thicker and frequently darker 
than scalp hairs.  The melanocytes in human eyelashes also exhibit tyrosinase-
related protein 2 (TRP-2) (Thibaut et al., 2009), unlike human scalp follicles. 
Therefore, it is important to clarify whether human scalp follicles will also respond 
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to PGF2α and prostamide F2α analogues.  In addition, there is no understanding of 
how these drugs actually cause the eyelash stimulation.  It is unclear if this is due 
to direct effects on the eyelash follicles or indirectly via the vasculature by 
increasing the blood flow. The overall aim of this study was to investigate the 
hypothesis that PGF2α and prostamide F2α can affect human scalp hair follicle 
growth through PGF2α and/or prostamide F2α receptors located in the hair follicle 
itself. The initial objectives were to investigate the biological effects of PGF2α and a 
PGF2α analogue, latanoprost, on human scalp hair follicle growth in the absence of 
any blood supply in vitro using the hair follicle organ culture model.  Isolated scalp 
hair follicles were grown in organ culture for 9 days in serum-free medium using 
different concentrations of PGF2α and latanoprost (isopropyl-(Z)-
7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]-cyclopentyl]-5-
heptenoate). Initially experiments were carried out to determine which 
concentration would alter hair growth most significantly using PGF2α and 
latanoprost. 
This organ culture study of isolated human scalp hair follicles was carried out for 9 
days in serum-free medium with or without different concentrations of PGF2α and 
latanoprost using skin samples from 10 donors. Serum was excluded from the 
culture media, as it has an inhibitory effect on hair growth in vitro (Philpott et al., 
1996).  Daily observation of hair bulb morphology, measurement of length and 
photography were carried out, a modification of the original technique which 
enables much more detail to be assessed (Philpot 1990).   
Follicles were monitored for changes in morphology, as changes in hair follicle 
cycle stages are significant to hair growth in vivo, recorded as the number of 
follicles remaining in anagen.  The daily increase in hair follicle length and the 
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overall amount of hair actually produced by all the follicles was also calculated 
from the final increase in length of each follicle on the final day, day 9, or the last 
day the follicle maintained a normal anagen morphology.  At least 6 follicles were 
examined per person for each condition.   
The next objective of this study was to clarify whether the PGF2α and latanoprost-
stimulated growth was a receptor-mediated response after the most effective 
concentration for PGF2α and latanoprost was found. Therefore, the effect of two 
efficient FP antagonists, AS604872 (1 µM) and AL-8810 (10 µM) (Woodward et al., 
2007) on PGF2α and latanoprost-stimulated (100 nM) hair growth was investigated 
on follicles from 5 further individuals in the same manner. DMSO 0.01% was 
included in all media for these experiments since the FP antagonists had to be 
solubilised in DMSO.   
Having established that human scalp hair follicles could respond to PGF2α and 
latanoprost by increased growth by a receptor-mediated manner in organ culture, 
i.e. in the absence of the blood supply, so the next aim was to establish the 
presence of the receptors in human scalp hair follicles. This stage of the 
investigation required familiarisation with hair follicle structure and learning the 
techniques of cryosectioning and staining.  Deer skin was used first as it is easily 
obtainable and easier to work with than human skin due to the large size of the 
follicles. Later, human skin sections were prepared and stained with the 
histological stain, Sacpic.  
To confirm the presence of FP in scalp hair follicle, the expression of FP proteins 
were investigated in human scalp anagen hair follicles, using 
immunohistochemistry.   
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Initially, the location of cytokeratins 5 & 6, a highly expressed proteins in the hair 
follicle outer root sheath (Hans-Jürgen et al., 1987), in human skin and hair follicle 
were investigated by immunohistochemistry to learn the immunohistochemistry 
techniques with a highly expressed antigen.  
Since the glaucoma drugs also darkened eyelashes (Reynolds et al., 1998), the 
location of melanocytes was also determined in human scalp hair follicles by 
immunohistochemistry using a monoclonal primary antibody to NKI-beteb, 
melanoma associated antigen. The NKI-beteb antibody detects all melanocytes in 
the hair follicle (Staricco, 1963; Hayashibe et al., 1986; Randall et al., 2008).   
To investigate the location of FP protein within the hair follicle, 
immunohistochemistry was performed using two polyclonal primary antibodies 
for human FP.    
The next objective was to investigate the expression of genes for FP in human 
anagen scalp hair follicles using the molecular biological approach: reverse 
transcription-polymerase chain reaction (RT-PCR). This required designing 
specific forward and reverse primers for FP from the human FP gene sequence and 
synthesising cDNAs from 5 samples of microdissected anagen hair follicles; 
amplifying the gene for FP and confirming gene identity by the size of product 
bands on gel electrophoresis and gene product sequence analysis, using the NCBI 
BLAST programme to align the homology of the sequenced PCR products against 
the known human FP gene sequence.  Three samples were used for the hair follicle 
components to localise the FP gene expression in hair follicle components, the 
dermal papilla, connective tissue sheath around the bulb, epithelial matrix, hair 
follicle “bulge” area and the follicle area between the “bulge” and the bulb; these 
were microdissected individually for the RT-PCR analysis. To increase the yield 
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from the isolated components 3 further sets of isolated hair follicle component’s 
RNA was amplified prior to analysis.  
A third aim of this study was to investigate the in vivo relevance of these in vitro 
experiments, therefore, the presence of prostanoid lipid mediators in scalp anagen 
hair follicles from 3 individuals was analysed, using quantitative lipidomic 
approaches. Electrospray tandem mass spectrometry coupled to liquid 
chromatography (LC/ESI-MS/MS) was used to investigate the presence of 
prostaglandins, dihydroprostaglandins and isoprostanes.  These lipid mediators 
were selected as they had been reported previously expressed in other human 
tissues including myometrium (Masoodi and Nicolaou, 2006). A range of multiple 
reaction monitoring (MRM) transitions and optimum collision energies were used 
for each compound to detect and quantify the most abundant product ions from 
scalp anagen hair follicles.   
Since PGE2 was the most prevalent prostaglandin detected (with PGF2α next) and 
PGE2 has been reported to cause re-growth of hair in mice (Torii et al., 2002) and is 
produced by cultured rat vibrissae dermal papilla (Lachgar et al., 1996a) and 
human dermal papilla cells (Michelet et al., 1997); the presence of one of its 
receptors, EP2, was localised in the dermal papilla using immunohistochemistry. 
Therefore, to investigate the location of  PGE2 receptor (EP2) protein within the 
human hair follicles, immunohistochemistry was performed using a polyclonal 
primary antibody for human EP2.      
The final aim of this study was to investigate whether bimatoprost itself can effect 
scalp hair follicle growth in organ culture.  The bimatoprost (Z-7-[(1R,2R,3R,5S)-
3,5-dihydroxy-2-[1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5-N-
ethylheptenamide) was donated by Dr Woodward of Allergan, California as a 
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personal favour to Professor V A Randall.  The effects of this drug at different 
concentrations (10, 100, 1000 nM) on isolated hair follicles in organ culture was 
also investigated as described previously to determine which, if any, concentration 
would alter hair growth most significantly. These concentrations were selected to 
concur with the saturation of a receptor-mediated effect as reported in other 
tissues (Sharif et al., 1999; Liang et al., 2003; Woodward et al., 2003).  
To clarify whether the bimatoprost-stimulated growth was a receptor-mediated 
response after the most effective concentration for bimatoprost (100 nM) was 
found, the effect of a prostamide F2α receptor antagonist, AGN211336, and an FP 
antagonist, AS604872, on bimatoprost-stimulated hair growth in organ culture 
was also investigated on follicles from 5 further individuals.   
To confirm and localise the expression of prostamide F2α receptors in scalp hair 
follicles, the expression of prostamide F2α receptor genes in isolated scalp hair 
follicle and hair follicle components was investigated by molecular biological 
methods as described for FP.  Prostamide F2α receptor genes are alternative 
splicing variants of the FP gene such as FP variant 4 which appears to 
heterodimerise with FP to create a bimatoprost-sensitive receptor (Liang et al., 
2008). The detection of prostamide F2α receptor genes was carried out using 
specific primers for FP splice variants including one which detected FP, all 5 
known splice variants and 5 pairs for the 5 different FP splice variants.  Primers for 
FP variant4 (altFP4) and FP variant1 (altFP1) were newly designed from human 
gene sequence; the others were from Liang et al (2008).  
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2  Materials and Methods 
2.1  Histological and immunohistological staining of human and red deer hair 
follicles  
2.1.1  Tissue samples 
2.1.1.1  Deer skin 
Red deer skin samples were collected as waste products from healthy animals 
routinely bred and harvested for food in Yorkshire.  They were collected during 
October when the hair follicles were in anagen from the neck/mane region of 
young male adults, ranging from 12 to 18 months old.  Collection medium was 
prepared prior to the abattoir visit. It consisted of RPMI 1640 supplemented with: 
10% fetal calf serum, 10 units/ml penicillin, 100µg/ml streptomycin, 100 ng/ml 
fungizone (amphotericin B), and 2mM L-glutamate (Gibco, Paisley, UK); the 
collection medium was aliquoted into 50ml Falcon tubes (Greiner Bio-One Ltd, 
Gloucestershire, UK) and pre-cooled on ice (4oC).  
Skin samples were collected shortly after death, dissected into strips, cleaned of 
extra fat tissue and the long hairs trimmed using a sterile blade before transfer to 
labelled tubes of collection medium.  The tubes were stored on ice for the duration 
of transportation, and once at the university the samples were washed thoroughly 
in sterile PBS to remove all traces of cell debris and blood.  Samples for histology 
were dissected into 1cm2 pieces (Figure 12), washed thoroughly in sterile 
phosphate buffered saline (PBS; appendix 6.2) and placed individually into 1.5 ml 
sterile plastic vials (Sarstedt, Nűmbrecht, Germany) containing the cryoprotectant 
Sakura Tissue-Tek O.C.TTM (Raymond A Lamb Ltd, Sussex, UK) and stored at -80oC 
until used.    
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Figure 12 Deer skin sample 
A piece of deer neck skin sample of approximately  1cm2, showing the hair fibre, 
dermis and hair follicle inside dermis. Photographed on a dissecting microscope 
(Leica MZ8, Leica, Germany) using a Nikon Coolpix4500 (Nikon E4500) digital 
camera (Scale bar=1mm).  
 
    
 
2.1.1.2 Human skin 
Human scalp skin samples were obtained from non-balding areas (occipital and 
temporal regions) of healthy donors (26-48 years) undergoing elective cosmetic 
surgery with ethical approval and written donor consent. Samples were placed in 
collection medium RPMI as described earlier (2.1.1.1) and kept on ice until return 
to the university and then dissected into 1cm2 pieces (Figure 13), washed 
thoroughly in sterile PBS and stored in O.C.TTM at -80°C until further use.  
   
 
 
 
 
Deer hair fibre 
Deer hair follicle 
within dermis 
Dermis 
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Figure 13  Human skin sample 
A human temporal region skin piece of approximately 1cm2 photographed on light 
dissecting microscope (Leica MZ8, Leica, Germany) using a Nikon Coolpix4500 
(Nikon E4500) digital camera (Scale bar=0.5mm).  
 
 
  
2.1.2  Preparation of poly-l-lysine coated slides  
To help sections to adhere to twin-frost glass slides (76 x 26 x 1 mm; BDH, 
Lutterworth, UK), the slides were cleaned and coated in poly-l-lysine (Sigma-
Aldrich Ltd, Dorset, UK).  The slides were placed individually into a plastic slide 
carrier, before cleaning in pyrogen detergent (Diversey Lever Ltd, Northampton, 
UK) and distilled water for 20 minutes. To wash out traces of detergent the slides 
were rinsed thoroughly in distilled water then immersed in absolute ethanol 
(Sigma-Aldrich Ltd, Dorset, UK) for 5 minutes.  The slides were allowed to dry in 
the drying cabinet at 60 oC, before being immersed in 10% (v/v) poly-l-lysine in 
distilled water for 5 minutes.  Once dry, the slides were stored in the original box 
and kept at room temperature until required.   
Epidermis 
Dermis 
Sub-cutaneous 
fat 
Hair follicle 
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2.1.3  Tissue sectioning 
The skin samples were removed from -80oC and sections were prepared using the 
Leica CM 1800 Cryostat (Leica, Germany).  O.C.T™ was applied to the small, round, 
specimen disc to form an even disc, ensuring all bubbles were removed and placed 
in the cryostat set at -27oC to freeze solid.  The frozen O.C.T™ disc was then placed 
into the sample holder of the cryostat and sliced until level.  A small cubic piece of 
the skin sample (~0.5cm2) was placed onto the O.C.T™ disc on its side to ensure 
the blade cut through the dermis and fat simultaneously and therefore cut 
smoothly; it was orientated so that longitudinal hair follicle sections could be 
obtained (Figure 14). Then O.C.T™ was gradually applied all around the sample 
until it was no longer visible, and allowed to freeze solid.  Sections (5µm) were cut 
at -23 oC and mounted on to labelled poly-l-lysine coated slides at room 
temperature, then checked under the light microscope, placed into labelled slide 
carrier wrapped with foil and kept at -20°C until use for histological or 
immunohistological analysis. 
2.1.4 Histological study of skin and hair follicle structure using Sacpic 
staining 
Frozen deer and human skin sections were stained with the Sacpic staining 
technique, which is a histochemical staining procedure employing different dyes to 
distinguish the different components of the hair follicle and skin. The method used 
was adapted from Nutbrown and Randall (1996) and Nixon (1993). The 
preparation of the stains is given in appendix 6.1.  Frozen skin sections were left at 
room temperature for about 30 minutes to defrost gradually to prevent the tissue 
getting temperature shock, before being placed into ice cold acetone (Fisher 
Scientific, Loughborough, UK) for 15 minutes to fix the proteins; this was followed 
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Figure 14 Mounted skin sample on the cryostat machine  
Mounted skin sample on the Leica CM 1800 cryostat (Leica) photographed using a 
Nikon Coolpix4500 (Nikon E4500) digital camera. 
 
 
 
by two rinses in distilled water. The sections were immersed in celestine blue 
staining solution for 5 minutes then rinsed in tap water before placing in Gill’s 
haematoxylin for 5 minutes and a further rinse in tap water. The sections were 
blued in Scott’s tap water for 2 minutes and rinsed in tap water before staining in 
2% safranin for 5 minutes.  The sections were then immersed for 1 minute in each 
of the following: tap water, 70% ethanol and 95% ethanol to become dehydrated. 
The slides were differentiated in absolute picric acid/ethanol for 3 minutes before 
placing in 95% ethanol, 70% ethanol and tap water for 1 minute each, to rehydrate 
the sections.  After staining in picro-indigo carmine for 1 minute and rinsing in tap 
water, the sections were dehydrated in ascending ethanol solutions 70%, 95% and 
absolute ethanol for 5 minutes each.  The sections were cleared by placing in 
histoclear:ethanol (50:50 v/v), and absolute histoclear (National Diagnostices, 
Hull, UK) for 4 minutes at a time before mounting using coverslips (VWR 
International, Leicester, UK) and histomount (VWR International).   
Specimen disc 
Skin sample 
Frozen O.C.T™ 
Anti-roll glass 
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2.1.5  Immunohistochemical studies 
Immunohistochemistry was carried out to study expression and localisation of 
protein to a number of markers of skin and hair follicles. The technique was 
carried out several times to establish the optimum concentrations of the primary 
antibodies which needed to be high enough to produce sufficient staining, and low 
enough to reduce background staining and cost.  The concentration of the blocking 
and diluting solutions of mouse and goat serum (Sigma-Aldrich Ltd) were also 
optimised. All the incubations were carried out in a histology wet box to prevent 
evaporation, at room temperature (25oC) apart from the primary antibodies which 
were incubated at 4oC for 18 hours. 
2.1.5.1  Immunohistochemical localisation of cytokeratins 5 & 6  
Human skin sections were immunostained with cytokeratins 5 & 6 which is a 
marker for the outer root sheath of the hair follicle.  Longitudinal (5µm) sections of 
human hair follicle (as described in section 2.1.3) which were mounted to poly-l-
lysine coated slides (as described in section 2.1.2) were air dried at room 
temperature for 30 min. The sections were then fixed in ice cold (4oC) acetone for 
10 minutes to fix the proteins, followed by 3 washes in sterile PBS. The sections 
were circled with a Vector ImmEdge Pen (Vector Laboratories, Peterborough, UK) 
to produce a hydrophobic ring around the sections and therefore reduce the 
volume of antibody needing to be applied.  The sections were incubated with 0.3% 
(v/v) hydrogen peroxide (Sigma-Aldrich Ltd, Dorset, UK) in methanol (Fisher 
Scientific, Loughborough, UK) for 30 minutes to block endogenous peroxidase 
activity and rinsed in PBS for 5 minutes.  Incubation with normal mouse serum 
(5% v/v) (Sigma-Aldridge Ltd) in PBS for 20 minutes blocked potential non-
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speciﬁc binding (Serum must be from the host of the secondary antibody) (Ramos-
Vara, 2005); excess serum was blotted away from the sections and followed by 2 
washes in sterile PBS.  The sections were incubated with the primary antibody, 
goat polyclonal anti-cytokeratins 5 & 6 antibody (SantaCruz Biotechnology, INC, 
California, USA) for 18 hours at 4oC. The antibody was diluted 1:50 with 1.5% 
(v/v) mouse serum in PBS (Sigma-Aldrich Ltd).  The sections were washed in PBS 
twice for 10 minutes to remove excess primary antibody. Goat ExtrAvidin® 
Peroxidase Staining Kit (Sigma-Aldrich Ltd) was used to detect the primary 
antibody. The sections were incubated with mouse monoclonal anti-goat IgG biotin 
conjugate secondary antibody (from Goat ExtrAvidin® Peroxidase Staining Kit-
Product code EXTRA-1, Sigma-Aldrich Ltd) to detect the goat antigens, for 30 
minutes then washed in PBS twice for 10 minutes. The sections were incubated 
with ExtrAvidin-Peroxidase (from kit) for 30 minutes, followed by two 10 minute 
washes in PBS.  
The peroxidise substrate 3-amino-9-ethylcarbazole (AEC; Vector Laboratories, 
Peterborough, UK) visualised antibody binding. The reaction of AEC substrate with 
the peroxidase enzyme produces a red-brown chromogen; this reaction was 
monitored under the light microscope and when sufficient colour had developed 
the reaction was halted by placing the slides in distilled water. To enable the clear 
definition of tissue structure, the sections were counter stained with Harris’s 
haematoxylin for 30 seconds and rinsed in tap water for 3 minutes.  The sections 
were then blued in Scott’s tap water for 5 minutes and finally rinsed in tap water 
for 3 minutes before being mounted with aqueous mountant, Aquamount (VWR 
International, Leicester, UK); they were left to dry overnight before clear nail 
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varnish (Laval, UK) was applied around the edges of the coverslips to prevent 
evaporation of the aquamount.  
To ensure no non-specific binding was occurring, each time the procedure was 
carried out negative controls were also conducted.  The negative controls were: 
1. 1.5% NMS + secondary antibody + Chromogen system 
Initially, the primary antibody was excluded and replaced with 1.5% normal 
mouse serum to check that the secondary antibody was not binding non-
specifically to the tissue without the presence of the primary antibody. The AEC 
solution was added to detect any non-specifically bound secondary antibody. 
2. Primary antibody + PBS + Chromogen system 
In this control the secondary antibody was excluded and replaced with PBS; this 
checked that the primary antibody was not activating the AEC solution without the 
existence of the secondary antibody. 
3. 1.5% NMS + PBS + Chromogen system 
In the third control, both the primary and secondary antibodies were also replaced 
with 1.5% normal mouse serum and PBS respectively.  This checked that the 
blocking procedure had been successful and there was no endogenous peroxidase 
activity left in the tissue which could activate the AEC. 
2.1.5.2  Localisation of melanoma-associated antigen, NKI-beteb, in human 
hair follicles  
Melanocytes were localised in the human hair follicle bulb by 
immunohistochemistry using an antibody to human melanoma associated antigen, 
NKI-beteb.  Immunostaining of human hair follicles with NKI-beteb was carried out 
using the procedure described in section 2.1.5.1.  However, a mouse monoclonal 
anti-human NKI-beteb primary antibody (Hycult biotechnology, Uden, Netherland) 
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was incubated with sections at a dilution of 1:10 and 1:30 with 1% (v/v) normal 
goat serum in PBS at 4oC for 18 hours.  To block non-specific binding the sections 
were incubated with 10% goat serum for 1 hour at room temperature prior to 
antibody application and a goat anti-mouse IgG secondary antibody kit was used to 
detect the primary antibody (Dako LSAB2® system kit, Dako, Cambridge, UK). 
2.1.5.3 Localisation of PGF2α receptor (FP) in human hair follicles by 
immunohistochemistry 
In order to investigate whether FP protein was present in human hair follicles, 
immunostaining of scalp hair follicle sections from five individuals (3 men and 2 
women aged between 38-55) was performed using two polyclonal primary 
antibodies to the FP; these were called PGF2αR (N-18; sc-33363) and (T-15; sc-
46449) (Santa Cruz Biotechnology, INC). The immunohistochemistry technique 
used to detect the FP was other wise as described in section 2.1.5.1.  These 
polyclonal antibodies against the FP were the only types commercially available 
and had not previously been used for immunostaining of human tissues and 
therefore had to be optimised.  The goat polyclonal anti-human FP antibodies were 
incubated with human hair follicle sections at a dilution of 1:75 with 1.5% (v/v) 
normal mouse serum which considered optimal; at 4oC for 18 hours.  
2.1.5.4  Localisation of PGE2 receptor (EP2) expression in human hair follicles  
To investigate the expression of EP2 protein in human hair follicles 
immunohistochemistry carried out on scalp hair follicle sections from five 
individuals (same samples used in section 2.1.5.3). Immunostaining was 
performed using a polyclonal primary antibody to the EP2 (Santa Cruz 
Biotechnology, INC); the technique was other wise the same as that for 
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cytokeratins 5 & 6 as described in section 2.1.5.1.  The antibody for the EP2 was 
also optimised as it had not previously been used for immunostaining human 
tissues. The goat polyclonal anti-human EP2 antibody was incubated with human 
hair follicle sections at a dilution of 1:100 with 1.5% (v/v) normal mouse serum 
which considered optimal; at 4oC for 18 hours.   
2.1.6  Visualising the staining  
The immunohistochemistry stained sections were examined and photographs 
were captured using an Nikon Eclipse 80i microscope with a Nikon ACT-2U 
photographic system (Nikon, Surrey, UK).  The Sacpic stained sections were 
photographed using a Nikon Coolpix4500 (Nikon E4500) digital camera fixed on 
an Ortholux II light microscope (Leitz, Germany) and the images were downloaded 
using Nikon View 5 software. The pictures were measured and measurements 
were converted to mm using a stage micrometer (Figure 15). 
2.2 Detection of gene expression in human hair follicles by reverse 
transcription - polymerase chain reaction (RT-PCR)   
Amplification of a specific region of template DNA can be achieved by PCR. The 
template can include genomic, plasmid and phage DNA or RNA converted to 
complementary DNA (cDNA) (Cha and Thilly, 1995). Investigating mRNA 
expression has great advantage as it indicates the genes expressed in the cell or 
tissue from which RNA was extracted. cDNA can be synthesised from mRNA by the 
enzyme reverse transcriptase which is used alongside oligo (dT) primers that bind 
to the poly (A) tail of mRNA.  To identify specific DNA sequences, the cDNA is then 
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Figure 15  Stage micrometer 
A stage micrometer, photographed on the Orthodox II light microscope (Leitz, 
Germany) using a Nikon Coolpix4500 (Nikon E4500) digital camera. 
                  
                    
                    
 
applied in the PCR reaction, indicating whether genes are actively expressed in the 
cell or tissue at the time of RNA extraction (Kawasaki, 1990). 
Amplification of a target DNA sequence by PCR requires specific forward and 
reverse primers which should be carefully designed to be complementary to the 
regions bordering the target DNA sequence. The specific forward and reverse 
primers anneal to either end of the target DNA sequence and they run in opposite 
directions to each other, spanning the entire target DNA region for amplification. 
Thermostable Taq DNA polymerase, buffers and a mixture of deoxynucleotide 
triphosphates (dNTPs), which contain the four bases, are required for synthesis of 
100 µm 
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new DNA strands in a PCR reaction alongside with the template DNA and specific 
forward and reverse primers. 
To allow DNA amplification to occur, the PCR reaction mixture is exposed to cycles 
of specific set temperatures using PCR thermocycler.  Firstly, a high temperature is 
used to denature the DNA template, and if double stranded, separates them. In 
order to allow the oligonucleotide primers to anneal to the complementary single-
stranded target DNA sequence after denaturation, the temperature is then lowered 
and this annealing temperature is critical and depends on the primer set used. 
Generally it is a few degrees below the average melting temperature of the 
primers, determined from the base composition of the oligonucleotides.  The 
annealing temperature must be perfectly adjusted and must not be too high to 
allow efficient annealing of the primer, or too low to minimise non-specific 
binding.  Eventually the temperature is raised to allow Taq DNA polymerase to 
extend the annealed oligonucleotide primers at 72-74°C, which is the optimal 
temperature for the enzyme.  As a result of the PCR cycles a new strand of DNA will 
be produced, if cDNA is used as a template, or it will produce two new strands of 
DNA when double stranded DNA is used as a template.  This cycle of temperatures 
is repeated between 25-40 times and the amplified products from each PCR cycle 
act as a template for the next cycle, so that there is a significant rise in the number 
of target DNA sequences (McPherson and Moller, 2000).  
The concentration of MgCl2 salt is critical in the PCR reaction mix and can affect the 
activity of DNA polymerase, which in turn can affect yield and primer annealing, 
which can affect specificity (Cha and Thilly, 1995).  Mismatches in primer 
hybridisation may occur resulting in undesired amplicons when the MgCl2 
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concentration is too high, however, if it is too low a lower yield of amplification 
occurs. 
2.2.1  Investigations into whether human hair follicles express the genes for 
prostaglandin and prostamide F2α receptors using RT-PCR  
In order to investigate the expression of PGF2α receptor (FP) and prostamide F2α 
receptor (FP-variant complexes (altFPs)) genes in human hair follicles, RT-PCR 
was performed. The gene expression for specific molecules can be identified using 
PCR, which amplifies a specific region of template DNA that can include genomic, 
plasmid and phage DNA or can be from RNA transformed to complementary DNA 
(cDNA) using reverse transcriptase (RT).  Investigating mRNA expression reveals 
the genes expressed in the cell or tissue from which the RNA was extracted (Cha 
and Thilly, 1995).   
Specific forward and reverse primers for the PGF2α receptor (FP) and prostamide 
F2α receptors, altFP1 and altFP4, were carefully designed from the human FP gene 
sequence (Section 2.2.1.6); all other primers used were obtained from published 
sources (Liang et al 2008, Shorter et al 2008). Taq DNA polymerase, buffers, MgCl2 
and a mixture of deoxynucleotide triphosphates (dNTPs) containing the four bases 
as well as the template DNA and specific forward and reverse primers were 
required for synthesis of new DNA strands in a PCR reaction.  The PCR 
thermocycler was used to amplify the DNA sequence.  A control gene, β-actin, was 
first used to check the quality of the cDNA samples and the PCR system.  The gene 
expression of the FP and FP splice variants (altFPs) was investigated in samples of 
isolated hair follicles from 10 men (33-46 years).  To localise the gene expression 
in the scalp hair follicle, the process was repeated using cDNA from isolated hair 
follicle components: the dermal papilla, the dermal sheath around the bulb, the 
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bulb matrix, the follicle at the level of the bulge area and the lower follicle between 
the bulb and the bulge. These were isolated separately from follicles from 2 men 
aged 39, 42 and a woman aged 48.  For detection of gene expression in amplified 
RNA from scalp hair follicle components due to the limited sample size, the same 
components were microdissected from scalp hair follicles from a further 3 men, 
aged 30, 41 and 45, and their mRNAs were amplified before cDNA synthesis.  
To prevent genomic contamination, all work areas were cleaned thoroughly with 
70% ethanol and RNAse Zap solution (Sigma-Aldrich Ltd) prior to undertaking any 
procedure, and gloves were worn and changed frequently.    
2.2.1.1  Tissue collection  
Human skin samples from occipital regions of scalp (non-balding) were gathered 
as described in section 2.1.1.2, with the exception that the skin samples were 
placed into 50ml falcon tubes that contained 30ml RNA stabilisation solution, 
RNAlaterTM, to preserve the tissue by inhibiting RNases (Sigma-Aldrich Ltd). The 
tubes were labelled with the patient’s age and gender and accompanied by an 
information sheet including the date of sample collection, sample site, gender and 
age of donor.  The tubes were kept on ice until brought to the university and then 
transferred to the fridge (4oC) overnight to allow the RNAlaterTM to penetrate the 
tissue.  After 24 hours the tubes were stored in the freezer (-80oC) until needed.    
2.2.1.2  Hair follicle microdissection  
A Leica MZ8 (Leica, Germany) dissecting microscope was used at x20-30 
magnification to dissect individual hair follicles from the skin samples using 
autoclaved dissection tools and sterile plastic-ware. Initially the frozen skin 
samples in RNAlaterTM were defrosted on ice then transferred to a petri dish 
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(35x10mm) containing cold (4oC) RNAlaterTM to ensure the skin remained at a low 
temperature.  Then the skin sample inside the petri dish was placed under the 
dissecting microscope and the skin was cut at the junction of dermis and 
subcutaneous fat (Figure 16a) using a sterile scalpel blade.  Fine forceps (size 5 
and 7) were used to pluck the follicles out from the skin by gently grasping the 
outer root sheath and then the dissected follicle was transferred to a fresh dish of 
RNAlaterTM on ice.   Under a higher magnification (x50) the freshly isolated follicles 
were cleaned of any dermis or fat debris (Figure 16b) using syringe needles 
(27G1/2 tuberculin syringe; Sigma) before transfer to a 1.5ml Eppendorf 
containing 150 µl RNAlaterTM placed on ice.  A total of 65 hair follicles were 
isolated from each donor for hair follicle total RNA isolation.  
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Figure 16  Isolation of hair follicles from human scalp skin 
The skin samples which were collected in RNAlater and kept at 4oC overnight were 
cut into small sections (a) to promote conspicuousness of hair follicles and 
individual lower follicles were microdissected (b), which were then cleaned to 
remove any dermis and subcutaneous fat using syringe needles.  Photographed on 
a dissecting microscope (Leica MZ8, Leica, Germany) using a Nikon Coolpix4500 
(Nikon E4500) digital camera.  
(a) Human scalp skin showing hair follicle and skin layers, epidermis, dermis and 
subcutaneous fat.  Scale bar = 400 µm  
(b) Isolated hair follicle, demonstrating lower follicle parts including hair fibre, 
hair matrix, dermal papilla and connective tissue sheath.  Scale bar = 200 µm  
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2.2.1.3  Microdissection of human hair follicle components 
To localise the FP and FP-variant complexes (altFPs) gene expression in the scalp 
hair follicle, hair follicle components: the dermal papilla, the dermal sheath around 
the bulb, the bulb matrix, the follicle at the level of the bulge area and the lower 
follicle between the bulb and the bulge, were microdissected from isolated whole 
follicles under the Leica MZ8 (Leica) dissecting microscope (x40-60 
magnification). The follicles were harder to dissect than fresh tissue because they 
had been kept in the preservative solution, RNAlaterTM.   
2.2.1.3.1 Experiment to determine follicle area including the bulge 
The sebaceous gland cannot be seen in tissues which had been kept in RNAlaterTM, 
therefore, a small experiment was carried out to detect the sebaceous gland and 
then the area including the follicle bulge.  The distance of the top of sebaceous 
gland from the skin surface and the bottom of sebaceous gland from the bottom of 
the follicle bulb were measured in 10 follicles from a fresh human scalp skin 
sample using a dissecting microscope (Leica MZ8) fitted with an eyepiece graticule.  
The measurement values were converted to mm using a stage micrometer and the 
average measurements worked out.  
The skin samples which were in RNAlater (Figure 16a) were first measured under 
the dissecting microscope using the data obtained from the experiment mentioned 
earlier.  The hair follicle was cut at both the upper and lower level of sebaceous 
gland and this follicle area was microdissected out from the skin using fine 
tweezers (size 5) and collected in an Eppendorf tube containing cold RNAlaterTM.  
This was then used as the hair follicle bulge area, as the bulge area is located in the 
follicle outer root sheath below the sebaceous gland level (Ohyama, 2007; Waters 
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et al., 2007). The remaining hair follicle was microdissected further to isolate the 
other hair follicle components.  
2.2.1.3.2  Microdissection procedure to isolate human follicle components 
The skin piece which contained follicles below the sebaceous gland level was cut at 
the junction of the dermis and the subcutaneous fat to get the hair follicle bulb and 
the lower follicle area (Figure 17a).  The follicles were plucked out from the skin by 
gently grasping the outer root sheath using fine forceps (size 5 and 7) and the 
isolated follicles were transferred to a fresh dish of RNAlaterTM for further 
microdissections. Under a higher magnification (X50) the isolated hair follicles 
were dissected to separate the individual follicle’s “bulge” region and lower follicle 
part (Figure 17b, c) from the bulb (Figure 17d); the isolated follicle bulbs were 
transferred to a fresh dish of RNAlaterTM for further microdissections of follicle 
bulb components using sterile syringe needles (27G1/2 tuberculin syringe).  The 
side of the connective tissue sheath was cut to avoid damaging the dermal papilla, 
and then the connective tissue sheath inverted to expose the matrix with dermal 
papilla. The matrix was gently pushed out (Figure 17e) and separated from the 
dermal papilla and the connective tissue sheath (Figure 17f) before collecting in an 
Eppendorf tube containing 150µl RNAlaterTM left on ice.  The dermal papillae were 
separated from the connective tissue sheath (Figure 17g) by cutting through the 
dermal papilla stalk and they were cleaned from any remains of connective tissue 
sheath then both dermal papilla (Figure 17h) and connective tissue sheath were 
collected in different Eppendorf tubes containing 150µl RNAlaterTM.  The micro-
dissection continued until a total of 125 of each hair follicle component was 
obtained. 
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Figure 17 Micro-dissection of hair follicle components: the dermal papilla, 
the dermal sheath around the bulb, the bulb matrix, the follicle at the level of 
the bulge area and the lower follicle between the bulb and the bulge 
(a) Human scalp skin showing hair follicle and skin layers, epidermis, dermis and    
       subcutaneous fat.  Scale bar = 400µm   
(b) The hair follicle part including the bulge.   
       Scale bar = 100µm   
(c) Lower hair follicle part between sebaceous gland and hair bulb.   
       Scale bar = 500µm   
(d) Isolated hair follicle bulb, demonstrating hair follicle matrix, dermal papilla   
       and connective tissue sheath.  Scale bar = 200µm     
(e) Isolated hair matrix.  Scale bar = 200µm     
(f) Connective tissue sheath of hair bulb and dermal papilla is still inside the  
       sheath. Scale bar = 200µm     
(g)  The dermal papilla and the connective tissue sheath were separated.  A small      
        part of connective tissue sheath was left over on the dermal papilla which had       
       to be removed.  Scale bar = 200µm     
(h) Isolated and cleaned dermal papilla.  Scale bar = 100µm 
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2.2.1.4  RNA isolation, DNase treatment and cDNA synthesis   
When dissection of the required number of hair follicles was completed, total RNA 
was isolated, checked for quality, purity and concentration using agarose gel-
electrophoresis and spectrophotometry respectively. Further purification was 
carried out to isolate poly(A)+RNA followed by DNase treatment to remove any 
contaminating DNA from isolated poly(A)+RNA samples; then they were converted 
to single stranded cDNA using the Avian Myeloblastosis Virus (AMV) reverse 
transcription system ready for PCR amplification.  
2.2.1.4.1  Total RNA extraction 
Total RNA was extracted using a GenElute Mammalian Total RNA kit (Sigma-
Aldrich Ltd) in accordance with the manufacturer’s instructions provided with the 
kit.  The microdissected hair follicles and hair follicle components from each 
individual were transferred separately into glass homogenisers with 500µl lysis 
Dermal papilla 
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solution and 5µl 2-mercaptoethanol solution.  Each sample was homogenised for 
about 10 minutes until no visible pieces remained and the homogenate was then 
transferred to a GenElute filtration column and centrifuged (Eppendorf 5415 R) at 
13000x g for 2 minutes to remove all cellular debris and to shear the DNA.  After 
centrifugation, the filtration column was discarded, and an equal volume of 70% 
ethanol (made using 0.05% (v/v) DEPC treated water) was added to the filtered 
lysate and mixed thoroughly by vortexing. 
The lysate/ethanol mixture (700 µl) was then transferred to a clear GenElute 
binding column and centrifuged for 15 seconds at 13000x g to bind RNA to the 
column.  The flow through was then discarded, and the binding column with the 
bound total RNA moved back to the collection tube.  The remaining sample was 
added to the binding column, and the same procedure repeated.  The binding 
column was then transferred to a new collection tube.   
To wash the binding column, 500 µl of wash solution 1 was added to the binding 
column and centrifuged for 15 seconds.  The column was transferred to a new 
collection tube and a second wash carried out by adding 500 µl of wash solution 2 
to the binding column and centrifuging for 15 seconds, the flow-through was 
discarded.  The binding column was placed back into the collection tube.  To 
remove ethanol and dry the column, a third wash was carried out by the addition 
of a second 500 µl of wash solution 2, centrifuged for 2 minutes and the column 
was transfered to a new collection tube. To elute the RNA from the binding column, 
50 µl of Elution Solution was added to the centre of the binding column and 
centrifuged for 1 minute.  To elute all RNA bound to the column, a second 50 µl of 
Elution Solution was added to the centre of the column and centrifuged for 1 
minute.  The flow through containing the purified total RNA was collected, and 
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could be used immediately for quality, purity and concentration checking and then 
poly(A)+RNA extraction, or stored at -80°C until used. 
2.2.1.4.2  Agarose gel electrophoresis  
To check the quality of the extracted total RNA samples, agarose gel 
electrophoresis were carried out using 1.5% (w/v) agarose gel. Agarose (1.5 g; 
Invitrogen Ltd) was dissolved in 100 ml of 1X tris-acetate-EDTA (TAE) buffer by 
using a 950 W microwave (Proline Microchef ST44) with sporadic swirling of the 
mixture until the boiling point (~135 sec). The molten agarose was left at room 
temperature to cool down to approximately 50-55°C before the addition of 25µl 
ethidium bromide (1 mg/ml; Sigma-Aldrich Ltd).  The gel was immediately poured 
into plastic gel trays containing gel combs to form wells, and left for approximately 
45 minutes to set.  After the gel set, the gel combs were removed gently and the gel, 
which was still in the tray, was placed in the electrophoresis tank containing 300 µl 
1X TAE buffer with 75 µl 0.5 µg/ml ethidium bromide.  A 10 µl aliquot from the 
total RNA was mixed with 2 µl of blue/orange 6X loading dye in a ratio of 5:1 
(Promega, Southampton, UK) to assist loading and monitor the progression of the 
total RNA through the gel during electrophoresis; then carefully loaded into the 
gel.  The tank was set to run at 100 volts for approximately 30 minutes.  The UVitec 
gel documentation system (UVItec Limited, Cambridge, UK) was used to visualise 
total RNA at 312nm wavelength and the images were captured and stored on the 
computer.    
2.2.1.4.3  Spectrophotometric analysis  
The concentrations of the total RNA samples were checked 
spectrophotometrically. The spectrophotometer (Ultrospec II,Cambridge, UK) was 
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calibrated first using 400µl nuclease free water in a quartz cuvette.  The RNA 
sample, 20µl was mixed with 380µl of nuclease free water in another quartz 
cuvette by pipetting up and down, placed in the spectrophotometer and the 
absorbence reading recorded both at 260 nm and 280 nm wavelengths.  The blank 
cuvette was used to calibrate the spectrophotometer to zero between the readings.   
The concentration of RNA in µg/ml was calculated as follows: 
Concentration of RNA = X × Y × 40 µg/ml (X: absorbance value at 260 or 280 nm 
and Y: dilution factor).  The ratio of absorbance at 260 to 280 nm values for total 
RNA should fall between 1.8 to 2.2 and any total RNA sample quantity with less 
than 1.8 value indicates that the RNA quality is not good enough and will result in 
poor cDNA (Farrell, 1998).  
2.2.1.4.4  Poly (A)+RNA isolation 
Poly (A)+RNA was isolated from the total RNA samples using a GenElute mRNA 
Miniprep kit (Sigma-Aldrich Ltd) in accordance with the manufacturer’s 
instructions provided. The volume of each total RNA samples was brought up to 
250µl using RNase-free water, then mixed with 250µl of 2X Binding solution and 
15µl of oligo (dT) beads, and vortexed thoroughly.  The samples were incubated at 
70°C for 3 minutes to denature RNA and were then left at room temperature for 10 
minutes.  The samples were then centrifuged for 2 minutes at 13000 g to pellet the 
beads: poly(A)+RNA complexes. The supernatants were discarded and the pellets 
resuspended in 500 µl of wash solution by vortexing.  Each sample suspension was 
then transferred to a spin filter/collection tube and centrifuged for 2 minutes at 
13000 g, before the flow through was discarded and the column containing the 
beads: poly(A)+RNA complex was washed again with a second 500 µl of wash 
solution followed by centrifugation for 2 minutes. The column was transferred into 
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a fresh collection tube and 50 µl Elution solution (preheated to 70°C) was added to 
the centre of the filter and incubated for 5 minutes at 70°C, before centrifuging for 
1 minute.  This elution procedure was repeated with an additional 50 µl elution 
solution.  The isolated poly(A)+RNA was then stored at -80°C until further use or 
kept on ice for immediate DNase treatment and cDNA synthesis.  
2.2.1.4.5  Amplification of mRNA samples 
Due to the limited amounts of tissue after microdissection into components (the 
dermal papilla, connective tissue sheath around the bulb, hair bulb matrix, follicle 
bulge region and the lower follicle area between the bulge and the bulb), the 
components mRNA was amplified before cDNA synthesis using the SMARTTM 
mRNA Amplification Kit (Clontech Laboratories, Inc. CA, USA) according to the 
manufacturer’s instructions.  Initially first-strand cDNA was synthesised by adding 
1 µl of CDS primer II A (12 µM; 5’-AAGCAGTGGTATCAACGCAGAGTACTVN-3’) 
(Figure 18) and 1.25 µl deionised water to 3 µl of mRNA sample (0.1-5 µg) in a 0.5 
ml eppendorf tube (Alpha Laboratories); this was mixed thoroughly and incubated 
for 3 minutes at 70°C, followed by 42°C for 2 minutes in a PCR Sprint thermal 
cycler (Thermo Hybaid, Ashford, UK). A master mix was prepared for each reaction 
tube in a 0.5 ml eppendorf tube containing 2 µl 5X first-strand buffer, 0.5 µl DTT 
(100 mM), 0.25 µl RNase inhibitor, 1 µl SMARTTM T7 oligonucleotide (10 µM; 5’-
ACTCTAATA CGACTCACTATAGGGAGAGGGCGGG-3’), 1 µl 50X dNTP mix (10 nM 
each dATP, dGTP, dCTP and dTTP) and 1 µl MMLV reverse transcriptase; this was 
mixed well by vortexing and spinning briefly in a microcentrifuge. The master mix 
(5.75 µl) was added to the mRNA (4.25 µl) tube and mixed thoroughly before 
incubating at 42°C for 1.5 hour. The reaction was terminated by heating at 68°C for 
10 minutes. 
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Second-strand cDNA was synthesised by preparing a master mix for each reaction 
containing 73 µl deionised water, 10 µl 10X advantage® 2 PCR buffer, 2 µl 50X 
dNTP mix (10 nM each), 2 µl T7 extension primer (10 µM; 5’-GCTCTAATACG 
ACTCACTATAGG-3’), 1 µl RNase H (10U/µl) and 2 µl 50X advantage® 2 polymerase 
mix. The master mix was mixed well by vortexing and spinning briefly in a 
microcentrifuge, then added to the first-strand cDNA tube, mixed well and placed 
in the PCR Sprint thermal cycler (Thermo Hybaid); the thermocycling programme 
ran was: 37°C for 15 minutes, 95°C for 2 minutes, 60°C for 1 minutes and 68°C for 
10 minutes. The double-stranded cDNA was purified prior to performing in vitro  
Figure 18  mRNA Amplification  
A diagram shows SMARTTM mRNA Amplification protocol (Chenchik and al, 1998). 
 
 
 
transcription using the Atlas Nucleospin® Extract II kit following the 
manufacturer’s instructions. Buffer NT (2 volumes) was added to 1 volume of 
sample (200 µl buffer NT and 100 µl double-stranded cDNA), then loaded in to a 
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Nucleospin® Extract II column in a 2 ml collection tube and centrifuged for 1 
minute at 11000g. The flow-through was discarded and the column with the bound 
double-stranded cDNA moved back to the collection tube. Buffer NT3 (600 µl) was 
added to the column and centrifuged for 1 minute at 11000g; the flow-through was 
discarded and the column placed back in to the collection tube. The column was 
centrifuged for an additional 2 minutes at 11000g to remove any residual buffer 
NT3 and the column transferred to a new 1.5 ml microcentrifuge tube. To elute the 
cDNA, 50 µl buffer NE was added to the column, incubated at room temperature 
for 1 min and centrifuged at 13000 g for 1 minute. To ensure complete elution, this 
process was repeated. The eluted cDNA was centrifuged at 13000 g for 3 minutes 
and the supernatant transferred to a new collection tube. Linear acrylamide (3 µl), 
10 µl sodium acetate (3 M) and 250 µl 100% ethanol were added to the 
supernatant and mixed thoroughly. The tube was placed on dry ice for 15 minutes 
to precipitate the cDNA, centrifuged for 20 minutes at 13000 g and the supernatant 
carefully removed. The pellet was washed in 100 µl of 70% ethanol for 10 minutes 
and then dissolved in 9 µl deionised water.            
Finally T7 transcription was carried out by preparing a master mix of 10X T7 
transcription buffer (2 µl), 3X rNTP mix (7 µl), RNase inhibitor (1 µl) and T7 RNA 
polymerase (1 µl) (1000U/ µl), mixed well and added in to the tube containing the 
resuspended cDNA. The reaction mix was mixed well and incubated at 37°C for 12 
hours.  After sense RNA was transcribed, reinitiated and elongated, this resulted in 
a successful linear amplification of mRNA in vitro; cDNA was synthesised from the 
amplified mRNA samples of scalp hair follicle components after they were DNase 
treated. 
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2.2.1.4.6  DNase treatment  
The mRNA samples were treated with the enzyme dideoxynuclease I (DNase I) to 
remove any contaminating genomic DNA prior to cDNA synthesis by reverse 
transcription.  A 0.5 ml eppendorf tube (Alpha Laboratories, Ltd, Eastleigh, UK) 
was used to make each reaction mix. This consisted of 8µl of poly (A)+RNA, 1µl 
DNase I amplification grade and 1µl 10X reaction buffer (Invitrogen Ltd); mixed 
thoroughly before incubating for 15 minutes at room temperature. To inactivate 
the DNase enzyme, 1µl EDTA (25mM; Invitrogen Ltd) was added and incubated at 
65°C for 10 minutes. The DNase treated poly (A)+RNA samples were either placed 
on ice to be used immediately for cDNA synthesis or stored at -80°C until further 
use. 
2.2.1.4.7  Synthesis of cDNA by reverse transcription  
The DNase treated poly (A)+RNA samples were converted to cDNA using the Avian 
Myeloblastosis Virus (AMV) reverse transcription system (Promega).  All reaction 
mixes were prepared in 0.5 ml eppendorf tubes (Alpha Laboratories) on ice, 
containing 1µl oligo (dT)15 primer (0.5 µg/µl; Promega), 2µl dNTP mix (10mM; 
Promega), 2µl 10X reaction buffer (Promega), 0.5µl recombinant RNasin® 
ribonuclease inhibitor (40 units/µl; Promega) and 0.75µl AMV reverse 
transcriptase (high concentration: 25 units/µl, Promega). The reaction mix was 
brought to a final volume of 10µl by the addition of 3.75µl nuclease free water and 
mixed thoroughly. This reaction mix was added to a 0.5 ml eppendorf tube 
containing 10µl of DNase treated poly (A)+RNA, and mixed using a vortex mixer.  
The eppendorf tubes were then placed in the PCR Sprint thermal cycler (Thermo 
Hybaid) and set to run the reverse transcription programme which was: 
incubation for 1 hour at 42°C to allow cDNA synthesis from mRNA by reverse 
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transcription, followed by 5 minutes incubation at 99°C to inhibit the reverse 
transcriptase and finally 5 minutes at 4°C to let the tubes cool down.  To ensure 
that all cDNA was collected at the base of the eppendorf tubes, the tubes were 
centrifuged at 13000 g for 10 seconds, and then the cDNA was aliquoted into 10µl 
sample per tube, labelled and kept at -20°C until required. 
2.2.1.5  Polymerase Chain Reaction    
All PCR reaction mixes were prepared on ice in 0.5 ml eppendorf tubes (Alpha 
Laboratories) containing 2.5µl of forward and reverse positive control primers 
(10µM) or 3µl of forward and reverse FP and FP-variant complexes (altFP) primers 
(5µM); 5µl of 10X reaction buffer (Invitrogen Ltd); 1µl of nucleotide mix containing 
equal volumes of ATP, CTP, GTP and TTP (10 mM each; Promega); 1.5–2.5 µl MgCl2 
(50 mM; Invitrogen Ltd) and 3–10 µl cDNA depending on the target primer set; 
0.5µl recombinant Taq DNA polymerase (5 units/µl; Invitrogen Ltd).  Nuclease free 
water was used to bring up the final volume of the mixture to 50µl, and then mixed 
thoroughly.  By replacing the cDNA with nuclease free water, a negative control 
was prepared for every PCR reaction.  To prevent evaporation of reaction 
components during PCR thermocycling, one drop of mineral oil (Sigma-Aldrich 
Ltd) was added on to the top of each reaction mixture, except when the PCR was 
done to prepare the DNA product to be sent for sequencing.   
In order to get the best amplification during PCR, each target primer set required 
optimisation of primer concentrations, annealing temperatures and MgCl2 
concentrations.  Details for each target primer set optimisation are shown in table 
2. For the β-actin primer set, the PCR thermocycling programme was: initial 
denaturation at 94°C for 5 minutes followed by 35 cycles of: PCR amplification at 
94°C, optimum annealing temperature at 56°C for 1 minute, extension at 72°C for 1 
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minute, followed by a final extension of 11 minutes at 72°C. After the 
thermocycling finished the tubes were cooled at 4°C.  The PCR products were 
placed on ice to be analysed immediately by agarose gel electrophoresis or could 
be stored at -20°C for later analysis. 
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2.2.1.6  PCR primer design  
The β-actin primer set, which was used for positive control gene expression, has 
been used previously for human hair follicle cDNA (Shorter et al., 2008); this was 
slightly modified from an existing established primer set (Merrick, 2000).  
Although there are few published primer sets for prostaglandin F2α receptor (FP) 
used for mouse, when they were checked on the human prostanoid receptor gene 
sequence using NCBI BLAST, none of them matched.  Therefore, the primer sets 
used for detection of prostaglandin F2α receptor (FP) and FP splice variants 1 & 4 
(altFP1 & altFP4) gene expression were newly designed from the human FP gene 
sequence. The ensemble genome browser was used to find the human prostanoid 
receptor genomic sequence, and the exon information was used for primer design.  
Primers were selected from exon numbers three and four: forward primers from 
exon 3 and reverse from exon 4.  This primer combination using two different 
exons, crossing an intron, was selected to ensure that the correct sized product 
would only be obtained from cDNA and not from any contaminating genomic DNA 
sequence which might be present in the PCR mixture and to pick up any splice 
variants expressed in areas between these two functional exons. The designed 
primer sets were then checked with the human gene sequence using the NCBI 
BLAST programme (http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi) to 
confirm that they were appropriate for use in human samples. Ensemble blast was 
also used to check the chromosomal location of each primer, the length of 
matching area on the chromosome and the length of the gap between the end of 
forward primer matching area and the start of reverse primer matching area, all 
done against the human genome.  The primers were synthesised by Sigma Genosys 
Biotechnologies Ltd (Pampisford, UK).  The designed FP primer set was first 
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checked on a positive control tissue, rat liver, cDNA which is known to express FP 
gene (Arend et al., 2005; Koukoui et al., 2006), it was available and easy to prepare 
compared to human hair follicle cDNA which is very valuable due to the limited 
sample availability and the time consuming process involved in isolating hair 
follicles.  
2.2.1.7 Agarose gel electrophoresis of PCR products  
RT-PCR products were analysed using agarose gel electrophoresis by separating 
the products on a 1.5% (w/v) agarose gel prepared as in section 2.2.1.4.2.  Aliquots 
from all PCR products were mixed with agarose blue/orange 6X loading dye 
(Promega) in a ratio of 5:1 to assist loading and monitor the progression of the 
product through the gel during electrophoresis.  The mixture and the negative 
controls were loaded into the wells, and their positions noted.  In order to estimate 
the product size, 10 µl of standard DNA fragments was mixed with 2 µl of loading 
dye, and then loaded onto the gel to provide a DNA ladder (The ladder consisted of 
eleven fragments that ranged in size from 100–1,500 bp; Promega). The tank was 
set to run at 100 volts for approximately 40 minutes until the orange dye reached 
the other side of the gel.  The Uvitec gel documentation system (UVItec Limited) 
was used to visualise the PCR products at a wavelength of 312nm and the image 
captured and recorded on a computer.  In order to get rid of any white shadows on 
the pictures which were due to ethidium bromide over staining, some of the PCR 
products were analysed on 1.5% (w/v) agarose gel made without ethidium 
bromide and the electrophoresis tank contained only 1 X TAE buffer.   Ethidium 
bromide staining was carried out after electrophoresis by placing the gel in a light 
protected container with ethidium bromide solution (100µl ethidium bromide in 1 
L distilled water) for 20 minutes.  To wash out extra ethidium bromide on the gel, 
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the gel was placed in distilled water for 20 minutes, then visualised by Uvitec gel 
documentation system (UVItec Limited).   
2.2.1.8  Sequencing of PCR products 
The identities of PCR products were verified by sending the expected amplicon size 
products to a commercial company (Geneblitz, Sunderland, UK) for sequencing.  
The PCR products were prepared for this as described in section 2.2.1.5 except that 
small, thin walled PCR tubes (VWR International Ltd, Poole, UK) and the hot lid 
were used in the thermocycler instead of adding mineral oil, as the oil may 
interfere with the sequencing.  Low-melting point agarose gel (Invitrogen Ltd) was 
used to separate the PCR products in order to allow using a lower temperature to 
dissolve the gel during the purification of the PCR products to prevent the DNA 
from degradation.  Approximately 50 ng/µl of DNA was required by the 
commercial sequencing service, therefore 30µl of weaker PCR products were 
loaded onto the gel to allow sufficient product for sequencing.  The MinElute Gel 
Extraction kit (Qiagen, Crawley, UK) was used, according to manufacturer’s 
instructions to purify the PCR products prior to sending them for sequencing.  
Using a UV-light source (UVitec) to visualise the separated product bands inside 
the gel, the target DNA fragment was excised from the gel using a scalpel blade, and 
transferred to an empty pre-weighted 1.5ml Eppendorf tube.  The tube with the gel 
containing the DNA fragment was weighed to obtain the net weight of the gel.  To 
dissolve the gel slice, buffer QC was added in the proportion of 3 volumes of buffer 
to 1 mg of gel (e.g. 300 µl of Buffer QC to 100 mg of gel) and the tube was incubated 
at 50°C for 10 minutes and vortex mixed every 3 minutes during this incubation.  
After the gel was fully dissolved, one volume of isopropanol (Sigma-Aldrich Ltd) 
was added, and mixed by inversion.  The sample was added to a MinElute column 
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and centrifuged (13000 g) for 1 minute to bind the DNA to the column, then the 
flow-through from the column was discarded.  Further buffer QC 500µl was added 
to the column and the process repeated as mentioned earlier.  The column was 
placed back in the collection tube, and washed by adding 750µl of buffer PE to the 
column and incubated for 5 minutes at room temperature before centrifuging for 1 
minute at 13000 g and discarding the flow-through.  The column was centrifuged 
(13000 g) for another minute and the flow-through discarded to remove any 
residual ethanol from buffer PE.  The MinElute column was placed into a clean 1.5 
ml Eppendorf tube, followed by addition of 10 µl of buffer EB to the centre of the 
column and incubated at room temperature for 1 minute before centrifuging at 
13000 g for 1 minute to elute the purified DNA from the column.  The purified PCR 
product was sent with 20 µl of appropriate forward and reverse primers (10 µM) 
for sequencing at Geneblitz (Sunderland, UK). 
To compare the homology of the sequencing result to the known published 
sequences, the NCBI BLAST programme (http://www.ncbi.nlm.nih.gov/ 
blast/bl2seq/wblast2.cgi) was used.  The chromatogram of the sequencing data 
was produced using the Chromas Lite software (version 2.0) available from 
http://www.technelysium.com.au/.  The chromatogram was used to analyse any 
non-matching nucleotides between the sequenced and known data.  In the 
chromatogram, each base is allocated a different colour, and the sequence 
determined by the highest peak.  If more than one peak is of a similar height, 
without significant distance, then the base was recorded as ‘n’ in the sequence. 
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2.3  Human hair follicle organ culture                     
2.3.1  Skin samples 
Human scalp skin samples were obtained from healthy donors, 1 woman and 14 
men aged between 22-48 years undergoing elective cosmetic surgery; donors 
provided written consent, and appropriate ethical committee approval was 
obtained. The samples were collected as whole skin specimens or as individual 
follicles into 50 ml falcon tubes containing 30 ml transport medium: William’s E 
medium (Sigma-Aldrich Ltd) supplemented with 100ng/ml hydrocortisone 
(Sigma-Aldrich Ltd), 10µg/ml insulin (Sigma-Aldrich Ltd), 10 units/ml penicillin 
(Sigma-Aldrich Ltd) and 2mM L-glutamine (Gibco, Paisley, UK). The tubes were 
labelled with the patient’s age, gender, date of sample collection and sample site. 
Throughout the transportation, the samples were kept on ice and when arrived at 
the University they were stored at 4oC until micro-dissection, which was 
performed within 10 hours of removal.   
2.3.2 Hair follicle isolation  
A Leica MZ8 dissecting microscope was used to dissect anagen hair follicles from 
the scalp skin samples in a sterile condition; all plasticware used was sterile and 
sterile cold PBS was used as a dissecting medium.  Special care was taken 
throughout the dissection process to ensure the follicles were intact as undamaged 
follicles are essential for successful culture (Philpott et al., 1990).  A scalpel blade 
was used to cut the skin (Figure 16a) at the level of the dermal-subcutaneous fat 
interface and then intact anagen hair follicles were pulled out from the 
subcutaneous fat gently with fine forceps (sizes 5 and 7).  The isolated undamaged 
follicles were transferred into fresh cold PBS and gently cleaned of any attached 
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subcutaneous fat or dermis by using 271/2 gauge sterile syringe needles (Tyco 
health care Ltd, Gosport, UK).  The isolated clean and undamaged follicles were 
transferred to the culture medium immediately after isolation was completed 
(Figure 16b).  
2.3.3  Hair growth culture conditions 
William’s E medium (containing 10µg/ml phenol red) (sigma) was prepared 
supplemented with 2mM L-glutamine (Gilbco), 10 µg/ml insulin, 10units/ml 
penicillin (Sigma) and 100ng/ml hydrocortisone (Sigma).  This culture medium 
was further supplemented depending on which experiment was being conducted, 
with one of the following: PGF2α (10, 100 & 1000 nM; dissolved in a stock solution 
of William’s E medium; Sigma), latanoprost (10, 100 & 1000 nM; dissolved in a 
stock solution of William’s E medium), bimatoprost (10, 100 & 1000 nM;  dissolved  
in  a  stock  solution  of  dimethyl  sulfoxide (DMSO); Sigma), prostaglandin F2α 
receptor (FP) antagonist AS604872 (1 µM; dissolved in a stock solution of DMSO), 
FP antagonist AL-8810 (10 µM; dissolved in a stock solution of DMSO), prostamide 
F2α receptor antagonist AGN211336 (1µM; dissolved in a stock solution of DMSO), 
both PGF2α (100 nM) and AS604872 (1 µM), both PGF2α (100 nM) and AL-8810 (10 
µM), both latanoprost (100 nM) and AS604872 (1µM), both latanoprost (100 nM) 
and AL-8810 (10 µM), both bimatoprost (100 nM) and AS604872 (1 µM), both 
bimatoprost (100 nM) and AGN211336 (1 µM).  Stock solutions of all compounds 
were dissolved using a sonicating water bath (Dawe Instruments Ltd., Middlesex, 
UK). Control medium was prepared without supplements, but for bimatoprost and 
antagonists experiments contained the vehicle (0.001% DMSO). The media were 
prepared in advance and were sterile-filtered using a 0.2 µm pore filter (Sarstedt, 
Nümbrecht, Germany).   
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Each isolated and cleaned human anagen hair follicle was transferred carefully to 
an individual well of a 24-well plate (Corning Glassworks, Corning, NY, USA) 
containing 1 ml of William’s E medium supplemented as described above. Follicles 
were incubated and maintained free-floating at 37˚C in an atmosphere of 5% CO2 
and 95% air in a humidified incubator over a period of nine days. To feed the 
cultured follicles, fresh & pre-warmed media was introduced at three day intervals, 
taking care not to damage or lose the follicles. 
2.3.4  Measurement of cultured hair follicles 
Hair follicles were assessed for morphology of the follicle bulb, photographed using 
a Nikon Coolpix 4500 digital camera (Nikon, Tokyo, Japan) and measured every 24 
hours for 9 days, using a Leitz Labovert inverted microscope (Leitz Labovert FS, 
Wetzlar, Germany) fitted with an eyepiece graticule.  All measurements were taken 
at X 50 magnification (eyepiece 12.5 × objective lens 4X) and then converted to 
mm by comparison with a stage micrometer.  To work out variation in growth rate 
of the follicles, the initial length of each follicle was deducted from the 
measurement obtained at each time point, so results were recorded as increase in 
hair follicle length over time.  Hair follicles that had not grown after 3 days in 
culture were classed as nonviable and excluded from further study. Any changes in 
follicle morphology were also recorded within these nine days.  
2.3.5 Statistical analysis 
The mean value per person for each parameter for each treatment was determined 
before calculation of the sample mean. The elongation of hair follicles in each 
individual treatment group was expressed as the mean increase in length (mm) ± 
SEM of the number of individuals used.  Data from each experimental group were 
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analyzed for normal distribution using the Kolmogorov-Smirnof test. The effect of 
the different treatments with time on the daily rate of growth, percentage of 
follicles remaining in anagen and total amount of hair follicle produced in culture 
was analyzed by a two-factor, within-subjects analysis of variance using the SPSS 
statistical analysis program (SPSS Inc., Chicago, IL, USA).  If the sample means of 
the different experimental groups differed significantly (P<0.05), selected 
experimental group means were compared using a Student’s paired t test with 
Sidak’s correction for multiple comparisons.  
2.4  Analysis of prostanoid lipid mediators 
Prostanoid profiles are tissue- and stimuli-dependent and their metabolites have 
low concentrations, short half-lives and structural similarities, therefore, all 
quantitative methodologies require high selectivity and sensitivity (Yue et al., 
2007). A variety of methodologies for the analysis of prostanoids have been 
developed such as gas chromatography/mass spectrometry (GC/MS), high 
pressure liquid chromatography (HPLC) with fluorescence or UV detection, 
chromatography/tandem mass spectrometry (GC/MS/MS), enzyme immunoassays 
and radioimmunoassay (Hoch et al., 2000; Waddington et al., 2001; Wiswedel et 
al., 2002; Yue et al., 2007). Immunoassays are very common even though they do 
not allow simultaneous analysis of more than one metabolite. GC/MS offers more 
sensitivity compared to immunoassays, but requires extensive sample preparation. 
Most prostanoids do not absorb UV except at low wavelengths, therefore, using 
radiolabelled fatty acid precursors is essential in HPLC-based methods (Terragno 
et al., 1981). Electrospray ionisation (ESI) is a very suitable ionisation method for 
the analysis of eicosanoids (Murphy et al., 2005). ESI is commonly used in the 
negative ionisation mode as prostanoid and other fatty acid derivatives are readily 
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ionised to form carboxylate anions (Yue et al., 2007). The liquid chromatography 
electrospray tandem mass spectrometry (LC/ESI-MS/MS) method allows the 
analysis of wide range of lipids from biological samples quickly and with high 
sensitivity.  Mass spectrometry identifies the chemical composition of compounds 
on the basis of the mass/charge (m/z) ratio of ions and their relative abundances 
(Bruins, 1991). The mass spectrometers comprise three main parts, the ionisation 
source, the analyser and the detector. The first step involves using electron 
ionisation to generate gas-phase ions of the compound of interest (Hoffmann and 
Stroobant, 1999). The common ionisation methods are ESI, Fast Atom 
Bombardment (FAB), Matrix-Assisted Laser Desorption Ionisation (MALDI) and 
Atmospheric Pressure Chemical Ionisation (APCI). After ionisation of the 
compound of interest, the ions pass through a mass analyser and they are 
separated according to their m/z ratio. The analyser’s main characteristics are the 
transmission, the upper mass limit and the resolution. The transmission is the 
ratio between the number of ions reaching the detector and the number of ions 
produced by the source, and  mass limit determines the highest value of m/z ratio 
that could be measured; resolution is the ability of the instrument to yield different 
signals for two ions with small mass difference (Hoffmann and Stroobant, 1999). 
The common types of mass analysers are: Quadrupoles, Time of Flight (ToF), Ion 
Traps and magnetic & electromagnetic analysers with Fourier transform. The main 
types of detectors are the photographic plate and the Faraday cage that permit 
direct measurement of the charge that reaches the detector and the electron or 
photon multiplier detectors and array detectors that allow enhancement of the 
intensity of the signal (Hoffmann and Stroobant, 1999).  
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In the electrospray ionisation method, the samples are dissolved in a volatile 
solvent, ionised at atmospheric pressure and passed through a high voltage (2000-
5000 v) capillary tube to create an electric field gradient; the solvent evaporates 
rapidly as the charged droplets travel through the electric field. The large droplets 
then divide into smaller droplets and eventually into individual charged molecules 
which enter the mass spectrometer (Watson, 2006).  
Tandem mass spectrometry (MS/MS) involves two stages of analysis, the first 
analyser isolates the precursor ion followed by fragmentation to yield product 
ions; the second stage involves fragmentation of the precursor ions selected by 
first analyser to allow the second analyser to analyse the product ions by the 
spectrophotometer. A collision cell is placed between the two mass analysers in 
the MS/MS instrument in order to obtain optimal collision activation (Hoffmann 
and Stroobant, 1999).       
2.4.1  Lipidomic analysis 
Lipid mediator extraction from isolated scalp anagen hair follicles from 3 men 
(aged 34-42) was undertaken using the method adapted from Masoodi and 
Nicolaou (2006) and the lipid extracts were investigated using a targeted approach 
for identification and quantification of prostanoids, dihydroprostaglandins and 
isoprostanes using electrospray tandem mass spectrometry coupled to liquid 
chromatography (LC/ESI-MS/MS).  A range of multiple reaction monitoring (MRM) 
transitions and optimum collision energy for each compound were used to 
generate the most abundant product ions (Kempen et al., 2001; Yang et al., 2002; 
Masoodi and Nicolaou, 2006; Taylor et al., 2006) (see Table 8).  
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2.4.2  Skin samples  
Occipital scalp skin samples were obtained from 3 healthy male donors (aged 34, 
39, 42) with written consent. The samples were immediately placed in to 50ml 
falcon tubes that contained either 30ml RNAlaterTM (Sigma-Aldrich Ltd) or normal 
saline solution; the tubes were kept on ice until brought to the University, cut into 
small pieces (approximately 1 cm2) and then stored at -80oC until analysed.    
2.4.3  Sample preparation 
The prostanoids, dihydroprostaglandins and isoprostane were from Cayman 
Chemicals (Michigan, USA). HPLC-grade ethanol, methanol, hexane, hydrochloric 
acid and acetonitrile were from Fisher Chemicals, UK. HPLC-grade glacial-acetic 
acid and methyl formate were from Sigma-Aldrich). 
Anagen lower hair follicles (60) were microdissected from each individual’s scalp 
skin sample as described in section 2.2.1.2.  Isolated hair follicles were disrupted in 
3 ml ice-cold Milli-Q water using a sonicator (Dawe Instruments Ltd., Middlesex, 
UK) at 60 Hz for 3 two minute intervals with 1 minute cooling down on ice in 
between. The homogenate was then transferred to a glass tube with glass Pasteur 
pipette and methanol (HPLC grade) was added to adjust the solution to 15% 
methanol (v/v), followed by 40 µl of internal standard (IS) (PGB2-d4) (Cayman 
Chemical); the resulting solutions were vortexed and centrifuged at 3000 rpm 
(849 g) for 5 min at 4 °C to remove any precipitating proteins. The clear 
supernatant was collected, acidified to pH 3.0 using 0.1 M hydrochloric acid (5-10 
drops); a pH indicator paper (pH range 2.5-4.5) was used to test the pH of the 
solutions. To extract the lipid mediators, the acidified samples were immediately 
applied to solid phase extraction (SPE) cartridges (C18-E, 500 mg, 6 ml, 
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Phenomenex, Macclesfield, UK). The SPE cartridges were attached to a vacuum 
manifold (Phenomenex) and they were pre-conditioned with methanol (20 ml) 
followed by water (20 ml) and then washed with 15% (v/v) methanol (20 ml), 
water (20 ml), and hexane (10 ml) in series. The vacuum pressure of the manifold 
used was adjusted to ~5 mmHg so that individual drops could be eluted from each 
cartridge. The lipid mediators were then eluted in 15 ml methyl formate and 
gathered in clean glass tubes. The organic solvent, methyl formate, was evaporated 
under a fine stream of nitrogen and the residue was re-constituted in 100 µl 
ethanol (HPLC grade), transferred to a small glass vial using a glass syringe, which 
was sealed with a screw cap and Teflon septa and then stored at -20°C for up to 1 
week until further analysed on LC/MS/MS.  
2.4.4  Preparation of standards and calibration lines 
For all prostanoids, dihydroprostaglandins and isoprostane, stock standard 
solutions were prepared in ethanol (400 pg/µl) and stored at -20°C under 
nitrogen. Suitable stock solution dilutions of 100, 50, 20, 10 and 1 pg/µl were 
prepared to be used as composite standard solutions. The internal standard, PGB2-
d4, was prepared in ethanol (1 ng/µl) and added to all composite standards at a 
final concentration of 400 pg/µl. Peak-area ratios of every compound to PGB2-d4 
were calculated and plotted against the concentration of the calibration standards; 
calibration lines were calculated by the least-squares linear regression method. To 
calculate the concentration of any given analyte the peak-area ratio to PGB2-d4 was 
calculated and read off the corresponding calibration line. Peak integrations and 
signal-to-noise (S/N) ratio calculations were performed using the MassLynxTM V4.0 
software (Waters, Elstree, UK). 
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2.4.5  LC/ESI-MS/MS analysis 
The LC/MS/MS analysis was carried out using a Waters Alliance 2695 HPLC pump 
coupled to an electrospray ionisation (ESI) triple quadrupole Quattro Ultima mass 
spectrometer (Waters, Elstree, Hertsfordshire, UK). Instrument control and data 
acquisition were performed using the MassLynxTM V4.0 software. The instrument 
was operated in the negative ion mode. For optimisation of MS and MS/MS 
conditions, standards at a concentration of 10 ng/µl were individually introduced 
into the spectrometer by direct infusion through a syringe pump (flow rate of 10 
µl/min) into the HPLC solvent flow (flow rate 0.2 ml/min). Sample injections were 
performed with a Waters 2690 autosampler and the sample chamber temperature 
was set at 8°C. The sample injection volume was 10 µl and the flow rate 0.2 
ml/min. The column was maintained at ambient temperature. The capillary 
voltage was set at 3.00 KV, source temperature 120°C, desolvation temperature 
360°C, and cone voltage 35 eV.  The optimum collision energy was applied for each 
compound and argon was used as the collision gas; the reside times were 0.2 
second.  
Chromatographic analysis was carried out using a gradient system comprising 
(45:55:0.02) (v/v/v) and (90:10:0.02) (v/v/v) of acetonitrile: water: glacial acetic 
acid at a flow rate of 0.2 ml/min as described previously (Masoodi and Nicolaou, 
2006).   
The identified prostanoids were quantified using calibration lines of commercially 
available standards (Cayman Chemicals). The amount of protein in each sample 
was estimated with a BioRad protein assay kit using the Lowry method (appendix 
6.3) (BioRad laboratories, Herts, UK); BSA at a range of 0-1.5 dilutions in NaOH 
(0.5M) was used as standard. Results are expressed as pg/mg protein. 
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3 Results 
3.1  Human hair follicle growth in organ culture 
3.1.1  Effects of PGF2α and its analogue, latanoprost, on human hair follicles in 
organ culture 
3.1.1.1  Scalp hair follicle growth in control conditions 
To investigate the effects of PGF2α on scalp hair follicle growth in the absence of 
any blood supply in vitro, isolated hair follicles (Figure 19a) were grown in organ 
culture for 9 days. Carefully micro-dissected hair follicles were maintained in 
serum-free culture medium with daily observation of their morphology, 
measurement and photography as detailed in section 2.3.4, a modification of the 
original technique (Philpott et al., 1990) which enables much more detail to be 
assessed. Follicles which showed no increase over 3 days were assumed to be 
damaged and removed from the experiment. Most of the hair follicles in normal 
culture medium (approximately 70%) increased in length regularly during the 
nine day culture period (Figures 19a, 20, 21).  Sequential photographs taken every 
24 hours showed that this hair follicle elongation was due to the production of a 
new hair fibre with associated inner and outer root sheath, but the connective 
tissue sheath did not grow and remained at the initial length over the culture 
period (Figure 19a).  Daily observation of the hair follicle bulb morphology was 
carried out to monitor if the follicle remained in anagen.  Some hair follicles 
developed catagen-like changes in their bulb morphology, but most follicles 
maintained their anagen bulb morphology during the nine days of culture (Figure 
19c, 21). Those follicles which were designated as undergoing catagen-like 
changes in their hair bulb morphology showed that pigmentation had ceased and 
the base of the hair fibre moved upward, losing contact with the regulatory 
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mesenchyme-derived dermal papilla, which became rounded up into a ball of cells 
(Figure 19c, d).  After 2 days there was a gradual increase in the number of follicles 
showing catagen-like changes in the hair bulb region (Figure 21).  The overall 
amount of hair actually produced by all the follicles in the organ culture was also 
calculated from the final increase in length of each follicle on the final day, day 9, or 
the last day the follicle maintained a normal anagen morphology (Figure 22). 
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Figure 19  Sequential photomicrographs of a human hair follicle growing in 
vitro in control medium 
(a) Photographs taken every 24 h for 9 days of a typical scalp anagen hair follicle 
in organ culture under control conditions using an inverted microscope (Leica 
MZ8, Leica) with a Nikon Coolpix4500 (Nikon E4500) digital camera, show growth 
of hair fibre and the inner and outer root sheaths, but not the connective tissue 
sheath (CTS).  Hair follicles synthesised new hair fibre increasing in length over 9 
days, and most maintained the follicle bulb anagen morphology.  
Scale bar = 0.5 mm  
(b) Enlarged photomicrographs of the hair follicle bulb (pictured in a), showing 
anagen morphology during 9 days in culture. Scale bar = 0.2 mm 
(c) Sequential photomicrographs of a hair follicle entering a catagen-like state, 
showing catagen-like changes in hair bulb morphology.  By day 5, pigmentation 
had ceased; the base of the hair fibre appeared to be retracting up the follicle, 
leaving behind a ball of dermal papilla (DP) cells. Scale bar = 0.5 mm 
(d) Enlarged photomicrographs of the hair follicle bulb in (c), Initial changes in 
hair bulb morphology were clearly visible by day 4. Scale bar = 0.2 mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
 
             
 
 (b) 
 
           
 
 
          
 
 
 
                Day 0                    Day 1              Day 2                       Day 3                     Day 4 
               Day 5                   Day 6                   Day 7                  Day 8                       Day 9 
               
0.2 mm 
(a) 
Hair 
 bulb 
0.5 mm 
CTS 
Hair 
 fibre 
Emerging 
hair & sheath  
  0               1            2           3                4              5             6            7             8            9
                                                                    Day 
Dermal 
papilla 
Pigmented matrix with active melanocytes 
 
 
127 
 
 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
    0         1           2         3          4            5             Rounded 
                                 Day                                      dermal papilla 
0.5 mm 
Catagen-like 
hair bulb 
Anagen  
hair bulb 
Hair fibre 
CTS 
0.2 mm 
(d) 
Day 0            Day 1             Day 2            Day 3              Day 4              Day 5 
                
0.2 mm 
Rounded 
dermal 
papilla 
The base of the hair fibre moving 
up the follicle leaving behind a dermal papilla 
 
 
128 
 
Figure 20  Scalp hair follicle growth in organ culture under control 
conditions  
Anagen follicles were assessed daily for changes in morphology and measured 
while cultured in basic culture medium using an inverted microscope fitted with 
an eyepiece graticule. The increase in follicle length occurred regularly throughout 
the culture period at a rate of approximately 100 µm/day. Values are the mean ± 
SEM of 5 individuals; at least 6 follicles were examined per person.  
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Figure 21  Percentage of scalp hair follicles remaining in anagen in organ 
culture under control conditions 
The proportion of hair follicles remaining in anagen throughout nine days of 
culture was calculated and any follicles which developed catagen-like changes in 
their bulb morphology were not counted as anagen hair follicles.  The number of 
anagen follicles gradually decreased after two days in culture. Values are the mean 
± SEM of 5 individuals; at least 6 follicles were examined per person. 
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Figure 22  Total amount of hair produced in organ culture under control 
conditions 
Anagen follicles were measured while cultured in basic culture medium under 
control conditions. The overall amount of hair produced in vitro was 0.477 ± 0.023 
mm/follicle (mean ± SEM). Values are the mean ± SEM of 5 individuals; at least 6 
follicles were examined per person for each condition.  
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3.1.1.2  PGF2α stimulated human hair follicle growth in vitro in a dose 
responsive manner  
To investigate the biological effects of PGF2α on human scalp hair follicles in vitro, 
isolated human scalp hair follicles were cultured in the presence of either the 
vehicle control or three concentrations of PGF2α (10, 100 and 1000 nM).  Scalp hair 
follicles grew well in normal control and PGF2α-supplemented culture media 
showing synthesis of new hair fibre, inner and outer root sheaths, but not the 
connective tissue sheath (Figure 23).  
All 3 concentrations of PGF2α stimulated human scalp hair follicles to grow faster in 
vitro (Figure 24); 10 nM increased growth significantly by approximately 16% (P < 
0.01**) while 100 & 1000 nM had a similar and greater effect of approximately 
25% (P<0.001***) (mean ± SEM of 5 individuals; at least 6 follicles were examined 
per person per condition) (Figure 24).   
The effect of PGF2α on the proportion of follicles exhibiting changes in morphology 
during culture was also examined.  All 3 different concentrations of PGF2α slightly 
raised the number of follicles remaining in anagen, with 10 nM increasing % 
anagen by day 9 by about 6% (P < 0.05*) and 100 & 1000 nM by about 10% (P < 
0.01**) (Figure 25).  
The overall amount of hair actually produced by all the follicles in the organ 
culture was calculated by recording the final length of each follicle on the last day 
of the experiment, day 9, or the last day the follicle maintained a normal anagen 
morphology. PGF2α at all 3 concentrations increased the overall amount of hair 
follicle synthesised in organ culture (Figure 26), from 0.477 ± 0.023 mm/follicle 
(mean ± SEM) by about 20% to 0.567 ± 0.023 mm/follicle with 10 nM PGF2α 
(P<0.05*), by about 32% to 0.626 ± 0.025 mm/follicle with 100 nM PGF2α 
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(P<0.01**) and by about 30% to 0.616 ± 0.024 mm/follicle with 1000 nM PGF2α 
(P<0.01**) (Figure 26a, b).   
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Figure 23  Sequential photomicrographs of a human hair follicle growing in 
vitro in media with 100 nM PGF2α 
Light micrographs taken under an inverted microscope every 24 hours for 9 days 
of typical scalp hair follicles growing in organ culture with 100 nM PGF2α showing 
growth of hair fibre and the inner and outer root sheaths, but not the connective 
tissue sheath (CTS). Hair follicles synthesised new hair fibre increasing in length 
(at a faster rate compared to the vehicle) over 9 days, and most maintained the 
follicle bulb anagen morphology.  Scale bars = 0.5 mm. 
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Figure 24  PGF2α stimulated human hair follicle growth in organ culture 
Anagen follicles were assessed daily for changes in morphology and measured 
while cultured in basic culture medium under different conditions: vehicle alone 
(control) and PGF2α (10, 100 & 1000 nM) using an inverted microscope fitted with 
an eyepiece graticule. PGF2α increased scalp follicle growth rate in vitro, 10 nM (P < 
0.01**) and 100 & 1000 nM (P < 0.001***). Values are the mean ± SEM of 5 
individuals; at least 6 follicles were examined per person for each condition. 
Statistical analysis was performed using a two-factor within-subjects ANOVA using 
SPSS, after confirming normal distribution, using the Kolmogorov-Smirnov test 
(KS-test).   
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Figure 25  PGF2α prolongs anagen in scalp hair follicles in organ culture  
The proportion of hair follicles remaining in anagen throughout nine days of 
culture was calculated excluding any follicles which developed catagen-like 
changes. The number of anagen follicles gradually decreased after one day in 
culture. PGF2α prolonged anagen on day 9 by about 6% with 10 nM (P<0.05*) and 
by about 10% with 100 & 1000 nM (P<0.01**). Values are the mean ± SEM of 5 
individuals for each experiment; at least 6 follicles were examined per person for 
each condition. Statistical analysis was performed using a two-factor within-
subjects ANOVA using SPSS, after confirming normal distribution, using the KS-
test.   
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Figure 26  PGF2α increased total amount of hair produced in organ culture 
Anagen follicles were measured while cultured under different conditions: vehicle 
alone (control) and PGF2α (10, 100 & 1000 nM).  PGF2α at all 3 concentrations 
increased the overall amount of hair produced in vitro. Expressed as mean actual 
values (a) or as a % of their own control follicles (b); by about 20% with 10 nM 
PGF2α (P<0.05*), by about 32% with 100 nM PGF2α (P<0.01**) and by about 30% 
with 1000 nM PGF2α (P<0.01**).  Values are the mean ± SEM of 5 individuals; at 
least 6 follicles were examined per person for each condition. Statistical analysis 
was performed using a two-factor within-subjects ANOVA using SPSS after 
confirming normal distribution, using the KS-test.    
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3.1.1.3  A PGF2α analogue, latanoprost, also stimulated human hair follicle 
growth in vitro in a dose responsive manner  
To investigate the biological effects of latanoprost, a PGF2α analogue, on human 
scalp hair follicles in vitro, isolated human scalp hair follicles were cultured in the 
presence of either the vehicle control or three concentrations of latanoprost (10, 
100 and 1000 nM). Scalp hair follicles grew well in normal control and 
latanoprost-supplemented culture media.  
Latanoprost stimulated human scalp hair follicles to grow faster in vitro (Figure 
27); 10 nM increased growth significantly by approximately 18% (P < 0.01**) 
while 100 & 1000 nM had a similar and greater effect of approximately 26% 
(P<0.001***) (mean ± SEM of 5 individuals; at least 6 follicles were examined per 
person per condition) (Figure 27).  
When the effect of latanoprost on the proportion of follicles experiencing changes 
in morphology during culture was examined, all 3 different concentrations of 
latanoprost slightly raised the number of follicles remaining in anagen, with 10 nM 
increasing % anagen by day 9 by about 6% (P < 0.05*) and 100 & 1000 nM by 
about 10% (P < 0.01**) (Figure 28).  
Latanoprost at all 3 concentrations also increased the overall amount of hair 
follicle synthesised in organ culture (Figure 29), from 0.477 ± 0.022 mm/follicle 
(mean ± SEM) by about 22% to 0.579 ± 0.023 mm/follicle with 10 nM latanoprost 
(P<0.05*), by about 33% to 0.6318 ± 0.026 mm/follicle with 100 nM latanoprost 
(P<0.01**) and by about 31% to 0.6208 ± 0.025 mm/follicle with 1000 nM 
latanoprost (P<0.01**) (Figure 29).  
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Figure 27  Latanoprost stimulated human hair follicle growth in organ 
culture 
Anagen follicles were assessed daily for changes in morphology and measured 
while cultured under different conditions: vehicle alone (control) and latanoprost 
(10, 100 & 1000 nM) using an inverted microscope fitted with an eyepiece 
graticule.  Latanoprost increased scalp follicle growth rate in vitro, 10 nM (P < 
0.01**) and 100 & 1000 nM (P < 0.001***). Values are the mean ± SEM of 5 
individuals; at least 6 follicles were examined per person for each condition. 
Statistical analysis was performed using a two-factor within-subjects ANOVA using 
SPSS, after confirming normal distribution, using the Kolmogorov-Smirnov test 
(KS-test).   
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Figure 28  Latanoprost prolongs anagen in scalp hair follicles in organ 
culture  
The proportion of hair follicles remaining in anagen throughout nine days of 
culture was calculated and any follicles which developed catagen-like changes in 
their bulb morphology were not counted as anagen hair follicles.  The number of 
anagen follicles gradually decreased after two days in culture.  Latanoprost 
prolonged anagen on day 9 by about 6% with 10 nM (P<0.05*) and by about 10% 
with 100 & 1000 nM (P<0.01**).  Values are the mean ± SEM of 5 individuals; at 
least 6 follicles were examined per person for each condition. Statistical analysis 
was performed using a two-factor within-subjects ANOVA using SPSS, after 
confirming normal distribution, using the KS-test.   
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Figure 29  Latanoprost increased total amount of hair produced in organ 
culture 
Latanoprost at all 3 concentrations increased the overall amount of hair produced 
in vitro.  Results are expressed as mean actual values (a) or as a % of their own 
control follicles (b), by about 22% with 10 nM (P<0.05*), by about 33% with 100 
nM (P<0.01**) and by about 31% with 1000 nM (P<0.01**).  Values are the mean ± 
SEM of 5 individuals; at least 6 follicles were examined per person for each 
condition. Statistical analysis was performed using a two-factor within-subjects 
ANOVA using SPSS after confirming normal distribution, using the KS-test.    
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3.1.1.4  Two PGF2α receptor (FP) antagonists AS604872 (AGN222827) and 
AL-8810 blocked PGF2α-stimulation of scalp hair growth in organ culture  
To determine whether the PGF2α stimulation was a receptor-mediated response, 
the effect of two PGF2α receptor antagonists AGN222827 and AL-8810 on PGF2α-
stimulated hair growth was investigated on follicles from 5 further individuals; at 
least 6 follicles were examined per person per condition. The addition of 0.01% 
DMSO to the control media, necessary to solublise the PGF2α receptor antagonists 
(AGN222827 and AL-8810), caused no significant differences in growth rate 
(P=0.107), percentage of follicles remaining in anagen at day 9 (P=0.216) nor the 
overall amount of hair synthesised (P=0.142) compared to the original control 
media (compare Figures 24-26 with 31-33). Similarly, the presence of 0.01% 
DMSO did not significantly alter any of responses to 100nM PGF2α (P=0.086-0.207) 
(compare Figures 24-26 with 31-33).  PGF2α alone (100 nM) again significantly 
increased all parameters compared to the vehicle alone: hair growth rate (P < 
0.001***) (Figure 31), the % of follicles remaining in anagen (P < 0.001**) (Figure 
32) and the overall amount of hair follicle synthesised by about 32% (P<0.01**) 
(Figure 33).  The stimulatory effect of the PGF2α on all parameters was blocked 
when it was combined either with the PGF2α receptor antagonist AGN222827 at 
1µM or AL-8810 at 10µM (P < 0.05*- 0.001***) (Figures 30-33). Both PGF2α 
receptor antagonist, AGN222827 at 1µM and AL-8810 at 10µM alone slightly, but 
not significantly, inhibited all parameters of scalp hair growth compared to those 
in the control conditions (P= 0.076- 0.1) (Figures 30-33).  
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Figure 30  Sequential photomicrographs of a human hair follicle growing in 
culture with 100 nM PGF2α + 1µM PGF2α receptor antagonist, AGN222827  
Photographs of the same human hair follicle were taken under an inverted 
microscope every 24 hours for nine days growing in organ culture in 100 nM PGF2α 
and 1µM PGF2α receptor antagonist (AGN222827), showing growth of hair fibre, 
the inner and outer root sheaths, but not the connective tissue sheath (CTS). Hair 
follicles synthesised new hair fibre regularly increasing in length (similarly to the 
vehicle but at a slower rate compared to 100 nM PGF2α alone) over 9 days, and 
most maintained the follicle bulb anagen morphology. Scale bar = 0.3 mm  
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Figure 31  The PGF2α receptor antagonists, AGN222827 and AL-8810, blocked 
PGF2α-stimulation of scalp hair follicle growth rate  
PGF2α (100 nM) alone significantly increased the hair growth rate (P< 0.001***) in 
organ culture. This growth-stimulating effect of PGF2α (100 nM) was abolished 
when it was combined with the PGF2α receptor antagonists AGN222827 (1µM) (a) 
and AL-8810 (10µM) (b) (P < 0.001***). Results are the mean ± SEM of 5 
individuals; at least 6 follicles were examined per person per condition. Statistical 
analysis was performed using a two-factor within-subjects ANOVA using SPSS after 
confirming normal distribution, using KS-test.   
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Figure 32  PGF2α receptor antagonists, AGN222827 and AL-8810, blocked the 
PGF2α-promoted increase in % of scalp hair follicles in anagen  
PGF2α (100 nM) alone significantly increased the the percentage of follicles in 
anagen (P< 0.01**), but this effect was abolished when it was combined with the 
FP antagonists AGN222827 (1µM) (a) and AL-8810 (10µM) (b) (P< 0.01**).  Values 
are the mean ± SEM of 5 individuals; at least 6 follicles were examined per person 
for each condition. Statistical analysis was performed using a two-factor within-
subjects ANOVA using SPSS after confirming normal distribution, using KS-test. 
(a)           AGN222827 
50
55
60
65
70
75
80
85
90
95
100
0 2 4 6 8 10
Control
PGF2α 
PGF2α + AGN222827
AGN222827
 
(b)           AL-8810 
50
55
60
65
70
75
80
85
90
95
100
0 2 4 6 8 10  Time (Days) 
Fo
lli
cl
es
 r
em
ai
ni
ng
 in
 a
na
ge
n 
(%
) 
** 
Fo
lli
cl
es
 r
em
ai
ni
ng
 in
 a
na
ge
n 
(%
) 
Time (Days) 
** 
 
Control 
PGF2α 
PGF2α+ AL-8810 
AL-8810 
 
 
 
145 
 
Figure 33  The PGF2α receptor antagonists AGN222827 and AL-8810 blocked 
PGF2α-stimulated increased total amount of hair production  
PGF2α (100 nM) increased the overall amount of hair synthesised in organ culture 
by about 32% (P < 0.01**), but the FP antagonists AGN222827 at 1µM (a, b) and 
AL-8810 at 10µM (c, d) both abolished this response (P< 0.01**). Results are 
expressed as mean actual values (a, c) or as a % of their own control follicles (b, d). 
Values are the mean ± SEM of 5 individuals; at least 6 follicles were examined per 
person for each condition. Statistical analysis was performed using a two-factor 
within-subjects ANOVA using SPSS after confirming normal distribution, using KS-
test. 
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3.2  Histological investigation of deer and human skin  
To become familiar with the structure of the skin and hair follicle, Sacpic staining 
was carried out on horizontal and vertical frozen skin sections from deer and 
human skin (as described in section 2.1.4).  Deer skin was used first to learn the 
techniques of cryosectioning and histology because the skin is readily available 
without ethical difficulties and contains large hair follicles which are less difficult 
to orientate to obtain appropriate vertical sections than the smaller human 
follicles.  Sacpic is a histochemical stain in which a number of different dyes are 
involved to differentiate hair follicle components (Nixon, 1993; Nutbrown & 
Randall 1996). The general structure of the anagen follicles showed a thin 
epidermis in both species and the stained hair follicles were prominent within 
obvious blue/green stained dermis (Figure 34 & 35).  In the hair bulb, the dermal 
papilla was surrounded by the hair matrix and the hair fibre was surrounded by 
the inner and outer root sheaths. The connective/dermal sheath encapsulated the 
entire follicle separating it from the dermis. These hair follicle layers were 
differentiated by Sacpic staining, with the inner root sheath staining bright red, the 
outer root sheath blue and the connective tissue sheath dark blue with black/blue 
nuclei. Also, fully keratinised parts of hair and epidermis were stained yellow.   
The histological staining of human scalp hair and red deer neck hair follicles 
indicated that the overall structure of the follicles were similar. However, there 
were a few differences between them; human hair follicles were visibily much 
smaller than the deer hair follicles, but lacked an obvious medulla like that present 
within the deer hair which could be seen in both vertical (Figure 34c) and midway 
cross sections (Figure 34d).  Deer skin also had a thicker dermis while human skin 
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had a thicker fat layer.  Cross-sections of human skin (Figure 35e) also revealed 
additional grouping of follicles in trios.  
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Figure 34 Structure of red deer skin  
(a) Photograph of red deer skin. This side view shows the general skin structure 
with intact anagen follicles penetrating into the dermis. (Scale bar = 500µm) 
(b) Photomicrograph of vertical cryosection of red deer skin 
This shows a thin epidermis (E) with longitudinal hair follicles extending into the 
thick dermal layer (D).  The structure of hair follicle components are highlighted by 
the Sacpic stain including the red inner root sheath (IRS) and the hair fibre (H). 
(Scale bar = 200µm) 
(c) The structure of an anagen hair bulb and lower follicle. This vertical 
cryosection stained with Sacpic shows the dermal papilla (DP), hair matrix (M), 
connective tissue sheath (CTS), which encapsulates the entire follicle separating it 
from the dermis, hair medulla (MD), inner root sheath (IRS) and the outer root 
sheath (ORS). (Scale bar = 100µm) 
(d) A cross section through an anagen hair follicle about half way up the 
follicle. The Sacpic staining shows the hair cortex (C), medulla (M), the red inner 
root sheath (IRS), the outer root sheath (ORS) and the connective tissue sheath 
(CTS). (Scale bar= 100µm). 
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Figure 35 Structure of human scalp skin      
(a) Photograph of intact human scalp skin. This shows the general skin 
structure with longitudinal hair follicles (HF) which extend into subcutaneous fat 
layer (SF), a thin epidermis (E), and a thick dermis (D) composed of collagen. 
(Scale bar = 350µm)  
Right is a higher magnification of an isolated hair follicle displaying the connective 
tissue sheath (CTS), pigmented matrix (M) in the hair bulb and the dark pigmented 
hair fibre (HF). (Scale bar = 150µm) 
(b) Sacpic stained cryosection of human scalp skin. Histology highlights a 
longitudinal hair follicle which extends into the subcutaneous fat layer (SF) with its 
attachment to the sebaceous gland (SG);  a thin epidermis (E), a thick dermis below 
with bright blue stained collagen (C) and also some of the components of the hair 
follicle including the outer root sheath (ORS), inner root sheath (IRS), connective 
tissue sheath (CTS) and the hair fibre (H).  (Scale bar = 200µm).  
(c) The structure of an anagen hair bulb. The dermal papilla (DP) is connected 
to the connective tissue sheath (CTS) at its base and surrounded by the matrix (M). 
The hair bulb is deep within the skin located in the subcutaneous fat (SF). (Scale 
bar = 150µm) 
(d) Higher magnification photomicrograph of an anagen mid follicle. The 
Sacpic staining clearly highlights the structures of the yellow keratinised hair fibre 
(KHF), the dark hair medulla (MD), the red inner root sheath (IRS), the green outer 
root sheath (ORS) and the sebaceous glands (SG). (Scale bar = 150µm) 
(e) Horizontal section of mid human scalp skin stained with Sacpic. 
Bundles of hair follicles can be seen in cross-sections of the follicles demonstrate 
the dermis, yellow keratinised hair fibre surrounded by the red stained inner layer 
of the inner root sheath (IRS), blue outer root sheath (ORS) and darker blue 
connective tissue sheath (CTS). (Scale bar = 150µM) 
(f) Higher magnification of a follicle horizontal section located in the mid 
part of the hair follicle.  
This shows a fully keratinised yellow hair fibre, the hair shaft medulla and cortex, 
hair shaft cuticle, inner root sheath (IRS) cuticle, Huxley’s and Henle’s layers of the 
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inner root sheath, the outer root sheath (ORS) and connective tissue sheath (CTS) 
which surrounded the follicle and separated it from the dermis. (Scale bar = 
100µM)  
(g) Compilation of longitudinal human hair follicles with the relevant cross 
sections at different levels.  
The upper part of the follicles just below the sebaceous gland duct showed the 
connective tissue sheath (CTS), the outer root sheath (ORS), the inner root sheath 
(IRS) and the keratinised hair fibre (KHF). The hair bulb region showed the dermal 
papilla (DP) which was located in the centre surrounded by the epithelial matrix 
(M) cells; both are encapsulated by the connective tissue sheath (CTS). The 
connective tissue sheath was present in all cross and longitudinal sections, 
separating the hair follicle components from the dermis and the subcutaneous fat. 
(Scale bar = 200µM)   
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3.3  Location of cytokeratins 5 & 6 in human scalp hair follicles 
Immunohistochemical analysis of human scalp hair follicle cryosections were used 
to investigate the location of cytokeratins 5 & 6. An antibody for these highly 
expressed antigens was used to master the immunohistochemistry techniques.  A 
goat polyclonal anti-cytokeratins 5 & 6 antibody was optimised for use at a 1:50 
dilution.  As described in section 2.1.5.1, three negative controls were carried out.  
The first two were to determine whether either the primary antibody alone or the 
AEC colour system caused colour development, but neither showed any non-
specific staining.  There was also no non-specific staining in the third negative 
control (Figure 36a, c) in which 1.5% NMS/PBS was used instead of the primary 
antibody to determine whether the secondary antibody was causing non-specific 
binding. 
Cytokeratin 5/6 was strongly expressed in the outer root sheath of the hair follicle 
(Figure 36b, d). 
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Figure 36  Location of cytokeratins 5 & 6 in human scalp hair follicle 
Expression of cytokeratin 5/6 was detected by immunohistochemistry using a goat 
polyclonal anti-cytokeratins 5 & 6 antibody diluted 1:50. Before application of the 
antibody, the tissue’s non specific binding sites were first blocked with 5% (v/v) 
normal mouse serum in PBS.  Sections were counterstained with Harris’s 
haematoxylin and blued in Scott’s tap water.  
(a) Absence of staining in the negative control where 1.5% normal mouse 
serum/PBS replaced the primary antibody. (Scale bar = 150µm) 
(b) Cytokeratin 5/6 expression in human scalp skin.  Positive red staining present 
only in the outer root sheath (ORS) of the hair follicle.  (Scale bar = 150µm) 
(c)  Negative control. (Scale bar = 100µm) 
(d) Horizontal section of mid human scalp hair follicle shows location of 
cytokeratin 5 & 6 in outer root sheath (ORS). CTS: connective tissue sheath, HF: 
hair fibre (Scale bar = 150µm).      
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3.4  Expression of NKI-beteb in human scalp hair follicles 
To determine the location of hair follicle melanocytes, as these are potential 
targets for prostaglandin regulation, the expression of NKI-beteb was investigated 
in human scalp skin by immunohistochemistry using a mouse monoclonal primary 
antibody to human melanoma associated antigen, NKI-beteb at 1:10 dilution, after 
extensive optimisation.  Prior to antibody application the sections were blocked 
with 1% normal goat serum in PBS.   
Three negative controls were carried out as described in section 2.1.5.1.  There 
was some non-specific staining when 1% normal goat serum/PBS replaced the 
primary antibody, therefore the concentration of the blocking serum was 
increased to 10% to reduce background staining. 
NKI-beteb was expressed in melanocytes in the hair bulb matrix above and around 
the upper portion of the dermal papilla (Figure 37b).  No staining was observed in 
other parts of the skin. There was also no non-specific staining in the negative 
control (Figure 37a) when the primary antibody was replaced with 1% normal 
goat serum/PBS. ……………………………………………………………………………………………. 
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Figure 37  Location of NKI-beteb expression in scalp hair follicles  
Immunohistochemistry was performed using a mouse monoclonal primary 
antibody to human melanoma associated antigen; NKI-beteb (1:10 dilution).  
(a) Absence of staining in the negative control in the hair bulb when the primary 
antibody was replaced with 1% normal goat serum. (Scale bar = 150µm) 
(b) Red stain indicating expression of NKI-beteb in the hair bulb, staining was 
predominantly seen in the matrix above, and around, the upper portion of the 
dermal papilla as indicated by the arrows. 
D: dermis, DP: dermal papilla and HM: hair matrix.  (Scale bar = 150µm)  
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3.5  Immunohistochemical localisation of prostaglandin F2α receptor (FP) in 
anagen scalp hair follicles 
The expression of the protein for FP was investigated in lower human hair follicles 
by immunohistochemistry using two polyclonal antibodies (goat polyclonal anti-
human PGF2αR (N-18 & T-15) antibodies). Both of these antibodies had to be 
optimised since they had not previously been used for this technique. A range of 
dilutions between 1:10 to 1:100 was investigated and 1:75 in 1.5% normal mouse 
serum was considered optimal for both antibodies.   
Immunostaining was detected in the cells of the dermal papilla and in the 
connective tissue sheath surrounding the hair bulb and lower follicle, but not in the 
epithelial cells or melanocytes of the hair bulb matrix in cryosections of scalp skin 
from 5 individuals with both antibodies (Figure 38b, c, e, f); no similar staining was 
seen when the primary antibodies were excluded (Figure 38a, d). 
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Figure 38  Immunolocalisation of FP in the human scalp hair follicle bulb 
Immunohistochemical analysis of normal scalp cryosections localised FP protein in 
the hair bulb in the cells of the dermal papilla and connective tissue sheath (b, c, e, 
f) using two goat polyclonal anti-human FP antibodies diluted 1:75 in normal 
mouse serum.  Sections were counter stained with Harris’s haematoxylin and 
blued in Scott’s tap water. Normal dark pigment (melanin) is visible in the hair 
bulb. Bulb components are labeled as follows: DP, dermal papilla; CTS, connective 
tissue sheath; HM, hair matrix. Red: positive staining; blue: haematoxylin 
counterstain.  
No staining occurred in the hair bulb in the negative control when the primary 
antibodies were omitted (a, d).  FP protein was localised in the hair bulb in the 
cells of the dermal papilla (DP) and connective tissue sheath (CTS) with PGF2αR (N-
18) antibody (b, e) and with PGF2αR (T-15) antibody (c, f). 
Scale bars a, b, c = 150 µm; d, e, f = 100 µm 
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3.6  Investigations to determine whether FP gene is expressed in the human 
scalp hair follicle using molecular biological methods  
RT-PCR was used to investigate the expression of FP genes in occipital scalp 
anagen hair follicles from 5 different adult male individuals.  Non balding scalp hair 
follicles were isolated, poly(A+)RNA extracted and cDNA was prepared separately 
from each individual’s sample. Each cDNA was prepared from 65 lower hair 
follicles per donor and each individual’s hair follicles were investigated separately 
(Table 3).  Anagen hair follicle microdissection as detailed in section 2.2.1.2, 
proved to be extremely difficult and time consuming, especially when the skin 
sample had been stored in RNAlater as the tissue becomes hard.  Generally about 
ten clean, undamaged follicles were obtained in an hour, thus appoximately a day 
had to be dedicated for each sample. 
The quality of each RNA sample was checked by gel electrophoresis on a 1.5% 
agarose gel. The total RNA from each sample had sharp 28S and 18S rRNA bands 
and the 28S rRNA band was approximately twice as intense as the 18S rRNA band 
(Figure 39).  This indicated that the RNA samples were of good quality as intact 
RNA has sharp bands and can be detected by this 2:1 ratio (28S:18S), while 
degraded RNA will not exhibit a 2:1 ratio, and a completely degraded RNA will 
appear as a very low molecular weight smear (Skrypina et al., 2003). 
The concentration and purity of each total RNA sample was also checked 
spectrophotometrically (Table 3) before further purification was carried out to 
isolate poly(A+)RNA. To remove any contaminating genomic DNA the poly(A+)RNA 
samples were treated with DNase I and cDNAs were synthesised immediately 
using the avian myeloblastosis virus (AMV) reverse transcription system.  
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Table 3  Human scalp skin samples used to prepare lower follicle RNA 
 
 
Human sample  
number  
 
 
Gender 
 
Age 
(Years)
 
Total RNA 
purity 
(A260/ A280)  
 
Total RNA 
concentration 
(µg/ml) 
H1 Male 41 1.35 165  
H2 Male 38 1.7 102  
H3 Male 46 1.8 136  
H4 Male 45 1.5 149  
 H5 Male 37 1.85 122  
 
 
 
Figure 39  Gel electrophoresis of RNA from human scalp follicles 
The success of the extractions were checked by gel electrophoresis of RNA, loading 
10µl from each total RNA sample into a 1.5% agarose gel; 18S and 28S ribosomal 
RNA bands were obvious in the total RNA samples, exhibiting a 2:1 ratio.   
 
 
 
 
 
        H1                    H2                    H3                    H4                     H5 
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3.6.1 RT-PCR results for β-actin gene expression from human lower hair 
follicles 
Amplification of a positive control gene, β-actin, was carried out to investigate the 
cDNA quality of all the samples prior to investigating the expression of the FP gene. 
Human β-actin is a highly expressed housekeeping gene with 3432 bp length and 
11 exons on chromosome 22 (www.Ensemble.org). Established β-actin primers 
that amplified 838 bp DNA molecules of exon 11 were used (Shorter et al., 2008). 
Successful β-actin gene expression would indicate that the isolated RNA was of 
sufficient quality and the cDNA suitable for further analysis.  
Agarose gel electrophoresis of the PCR products (30 µl) of hair follicle cDNAs 
prepared from isolated scalp hair follicles from each of 5 different individuals 
showed appropriately sized bands corresponding to β-actin (838 bp) (Figure 40). 
No bands were observed in the negative control in which the template cDNA was 
omitted from the PCR reaction mix.  This indicated that the product bands resulted 
from the direct amplification of cDNA synthesised from the mRNA samples, and 
also showed that the reagents used in the PCR reaction mix were free from any 
DNA contamination.  
To confirm the identity of the β-actin PCR products, sequence analysis of the PCR 
product was carried out. The β-actin PCR products showed 98% homology with 
the known human sequence (Figure 41). Using the chromatogram programme, 
each base is represented by a colour and the colour of the highest peak at each 
interval determines the base in the sequence.  When two or more peaks happen at 
once and neither is significantly higher than the other, then the result is recorded 
as ‘n’ in the sequencing data. Therefore ‘n’ does not necessarily mean that an 
incorrect base is present. 
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Figure 40  Gel electrophoresis of β-actin RT-PCR products from human scalp 
lower hair follicles  
β-actin gene expression in cDNA from 5 human scalp lower hair follicle samples 
were investigated by RT-PCR using specific primers for β-actin, and 5µl of cDNA 
from each sample. The resulting PCR products were separated by agarose gel 
(1.5% w/v) electrophoresis and visualised with ethidium bromide staining. 10µl of 
molecular weight markers (100bp DNA ladder; 11 fragments ranging from 100–
1,500bp) (lane 1) and 30 μl of each person’s PCR product (lanes 2-6) were loaded 
on to the gel. A negative control where cDNA was excluded from the PCR reaction 
mix was loaded on to lane 7. All PCR products showed appropriately sized bands 
(838 bp) corresponding to β-actin gene.   
 
 
 
    
 
 
 
                        Scalp hair follicles 
1           H1        H2        H3         H4       H5       -ve      
500 bp 
β-actin
838 bp
1000 bp 
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Figure 41 Sequencing results for β-actin RT-PCR product amplified from 
human hair follicle mRNA     
The PCR products of β-actin gene amplification using human hair follicle cDNA 
were separated by gel electrophoresis and a band of the expected amplification 
size (838 bp) was cut out from the gel; the DNA was purified and sent for 
sequencing to check its identity.  The NCBI BLAST program was then used to align 
the sequenced product (query: red) against the known human β-actin sequence 
(subject: black).  The matching bases between the two sequences are indicated by 
a bar.  The homology of the sequenced PCR product to the known human β-actin 
sequence is 98%. 
 
 
Query: 2   tgtggcccccgaggagcaccccgtgctgctgaccgaggcccccctgaaccccaaggccaa 61 
           |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 33  tgtggctcccgaggagcaccccgtgctgctgaccgaggcccccctgaaccccaaggccaa 92 
 
                                                                        
Query: 62  ccgagagaagatgacncagattatgtttgagaccttcaacaccccagccatgtacgtngc 121 
           ||| ||||||||||| ||||| ||||||||||||||||||||||||||||||||||| || 
Sbjct: 93  ccgcgagaagatgacccagatcatgtttgagaccttcaacaccccagccatgtacgttgc 152 
 
                                                                        
Query: 122 tatccaggctgtgctatccctgtacgcctctggccgtaccactggcattgtgatggactc 181 
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct: 153 tatccaggctgtgctatccctgtacgcctctggccgtaccactggcatcgtgatggactc 212 
 
                                                                        
Query: 182 nggtgacggggtcacccacactgtgcccatctacgaggggtatgccctcccccatgccat 241 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 213 cggtgacggggtcacccacactgtgcccatctacgaggggtatgccctcccccatgccat 272 
 
                                                                        
Query: 242 cctgcgtctggacctggctggccgggacctgactgactacctcatgaagatcctcaccga 301 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 273 cctgcgtctggacctggctggccgggacctgactgactacctcatgaagatcctcaccga 332 
 
                                                                        
Query: 302 gcgcggctacagcttcaccaccacggccgagcgggaaatcgtgcgtgacattaaggagaa 361 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 333 gcgcggctacagcttcaccaccacggccgagcgggaaatcgtgcgtgacattaaggagaa 392 
 
                                                                        
Query: 362 gctgtgctacgtcgccctggacttcgagcaagagatggccacngctgcttccngctcttc 421 
           |||||||||||||||||||||||||||||||||||||||||| ||||||||| |||| || 
Sbjct: 393 gctgtgctacgtcgccctggacttcgagcaagagatggccacggctgcttccagctcctc 452 
 
                          
Query: 422 tctggagaagagct 435 
            ||||||||||||| 
Sbjct: 453 cctggagaagagct 466 
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3.6.2  Validation of the RT-PCR for FP gene expression using rat liver tissue 
A new specific set of forward and reverse primers for FP genes were designed as 
described in section (2.2.1.6).  The designed primers to detect the FP gene were 
first checked on rat liver tissue cDNA which is known to express the FP gene 
(Arend et al., 2005; Koukoui et al., 2006).  Rat liver was used first as a positive 
control tissue as it was available and easy to prepare compared to human hair 
follicle cDNA. An amplified band of the expected size for FP gene (1100bp in rat) 
was obtained after agarose gel electrophoresis (Figure 42). No bands were 
observed in the negative control in which the template cDNA was excluded from 
the PCR reaction mix. 
3.6.3  Expression of the genes for FP in human hair follicles using RT-PCR 
Following successful detection of gene expression in rat liver, FP gene expression 
was investigated in human scalp hair follicles. Extensive optimisation of the RT-
PCR experimental conditions were carried out which are described in section 
2.2.1.5 and the resulting PCR products were separated by 1.5% agarose gel 
electrophoresis.  All 5 human scalp lower hair follicle cDNA samples produced PCR 
products which corresponded to the expected amplification size (1080 bp) in 
human tissue (Figure 43). There were no bands in the negative control in which 
the cDNA was replaced with nuclease-free water. 
The identities of the FP gene PCR products were checked by sequence analysis.  
The comparison with the known expected human FP gene sequence using NCBI 
BLAST program showed that the human hair follicle FP gene PCR product had 99% 
homology to the known human FP gene sequence after adjusting the similar peaks 
with the chromatogram programme as described in 3.7.1 (Figure 44). 
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Figure 42  Gel electrophoresis of FP gene RT-PCR product from rat liver cDNA 
FP gene expression in mRNA from rat liver tissue sample was investigated using 
RT-PCR. Specific primers for the FP gene were used with 5 µl cDNA. The PCR 
products were analysed using 1.5% agarose gel electrophoresis and visualised 
with ethidium bromide staining. Lane 1 – 100-1500 bp molecular weight marker 
(10 µl), lane 2 – blank, lane 3 – rat liver tissue FP gene PCR product (30 µl). Lane 
4 – negative control (30 µl) in which cDNA was excluded from the PCR reaction 
mix.  The expected amplicon size is 1100 bp.   
    
 
 
   
 
 
      1             2       Rat liver      -ve      
1100 bp 
1500 bp 
1000 bp 
500 bp 
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Figure 43 Human anagen hair follicles expressed the gene for FP 
FP gene expression in mRNA from 5 human anagen lower hair follicle samples was 
investigated using RT-PCR.  Specific primers for FP gene were used with 10 µl 
cDNA.  The PCR products were analysed using 1.5% agarose gel electrophoresis. 
10 µl of DNA ladder 100-1500 bp (lanes 1 & 8) and 30 µl of each person’s PCR 
product (lanes 2-6) were loaded on to the gel. A negative control where cDNA was 
excluded from the PCR reaction mix was loaded on to lane 7. All PCR products 
showed appropriately sized bands (1080 bp) corresponding to FP gene. 
 
 
 
     
FP 
1080 bp 
1500 bp 
1000 bp 
500 bp 
1           2            3              4             5           6           7            8 
                    Lane 
               Scalp hair follicles                       -ve 
H1          H2         H3         H4        H5     control 
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Figure 44  Sequencing results for FP RT-PCR product amplified from human 
hair follicle cDNA, compared to known human sequence   
To confirm the identity of the PCR products, the products were separated by 
agarose gel electrophoresis and the band of expected amplicon size (1080 bp) was 
excised from the gel, DNA extracted and purified and sent for sequence analysis for 
identification. The NCBI BLAST programme was used to align the sequenced 
product (query: red) against the known human FP gene sequence (subject: black).  
The bases that match in the two sequences are shown by a vertical line. The FP 
PCR product of the human hair follicle exhibited 99% homology to the known 
human FP gene sequence.  
 
Query  1    GCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTA  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  43   GCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTA  102 
 
Query  61   ATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  103  ATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCA  162 
 
Query  121  TATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTA  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  163  TATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTA  222 
 
Query  181  ATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  223  ATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCT  282 
 
Query  241  GATAAAGAATGGATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  283  GATAAAGAATGGATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGC  342 
 
Query  301  ATGGTGTTTTCTGGTCTGTGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  343  ATGGTGTTTTCTGGTCTGTGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGT  402 
 
Query  361  ATTGGAGTCACAAAACCAATATTTCATTCTACNAAAATTACATCCAAACA  410 
            |||||||||||||||||||||||||||||||| ||||||||||||||||| 
Sbjct  403  ATTGGAGTCACAAAACCAATATTTCATTCTACGAAAATTACATCCAAACA  452 
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3.7  Experiments to determine which hair follicle components express the 
gene for FP   
3.7.1  Preliminary investigation of scalp hair follicle proportions  
Initially a small experiment was carried out to measure some areas of isolated 
anagen scalp hair follicle to ensure that the whole of the potential bulge region was 
collected (detailed in section 2.2.1.3.1). When 10 follicles from a fresh occipital 
scalp skin sample from a 37 year old male were measured using a dissecting 
microscope. The mean distance of the upper level of the sebaceous gland from the 
skin surface was 0.92 ± 0.1 mm, the lower level of the sebaceous gland from the 
bottom of the hair follicle was 1.99 ± 0.1 mm and the mean length of the follicles 
was 3.445 ± 0.1 mm (Table 4).  These data from the fresh skin sample were used to 
guide the “bulge region” in microdissection of the follicle area below the sebaceous 
gland from the skin samples which were kept in RNAlater as the sebaceous gland 
could not be seen easily in tissues which had been kept in this preservative 
solution. 
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Table 4  Measurements of the distance of the sebaceous gland from both the 
skin surface and the hair follicle bulb in human scalp skin 
 
Follicle  
number 
 
Distance of the top of 
sebaceous gland 
from the skin surface 
(mm) 
The distance of the bottom 
of sebaceous gland from the 
bottom of the hair follicle 
(mm) 
 
Length of 
follicle surface 
to bottom of 
bulb(mm) 
1 0.71 1.84 3.15
2 1.09 2.07 3.6
3 0.98 2.10 3.55
4 0.93 1.96 3.4
5 0.87 1.90 3.3
6 1.03 2.0 3.6
7 0.90 2.02 3.5
8 0.84 2.15 3.55
9 1.0 2.03 3.5
10 0.85 1.92 3.3
Mean ± 
SD 
0.92 ±0.1 1.99 ±0.1 3.445 ±0.1
 
 
3.7.2 RT-PCR for the FP gene using isolated scalp hair follicle components 
To detect the location of FP gene expression in human hair follicles, RT-PCR was 
performed on isolated follicular components from 125 follicles from each of three 
different human scalp skin samples (Table 5) and each individual’s hair follicles 
components were investigated separately. Anagen hair follicles were carefully 
microdissected to isolate the dermal papilla, connective tissue sheath, matrix, 
follicle “bulge area” and the follicle area between the bulge and the bulb as detailed 
in section 2.2.1.3.2. This further microdissection was very difficult and time 
consuming and approximately three days were required to get individual 
components from 125 follicles. Each microdissected hair follicle component from 
the follicles from each individual were pooled immediately after microdissection 
and measured as described previously (2.2.1.4). The quantity and quality of the 
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total RNA samples were checked; when the total RNA from each hair follicle 
component was tested by gel electrophoresis, that from matrix and lower follicle 
area between the bulge and the bulb showed sharp 28S and 18S rRNA bands and 
the 28S rRNA bands were approximately twice as intense as the 18S rRNA bands 
(Figure 45), indicating good quality.  The total RNA from other three hair follicle 
components (dermal papilla, connective tissue sheath and the follicle in bulge 
region) had only weak 28S and 18S rRNA bands which did not show a 2:1 ratio 
indicating that these RNA samples were of poor quality. 
 Spectrophotometric analysis of the concentration and purity of the total RNA from 
the three hair follicle components samples shows very low concentrations, 
especially for dermal papilla (DP), connective tissue sheath (CTS) and the follicle in 
the “bulge region”.  The hair matrix (HM) and lower follicle (LF) below the bulge 
had more concentrated RNA (Table 6).    
Table 5 Human skin samples used to prepare isolated hair follicle 
components 
Follicles used to prepare components, including dermal papilla, connective tissue 
sheath, matrix, follicle “bulge region” and the lower follicle area between the bulge 
and the bulb 
 
 
Sample number Gender Age (Years) 
 
Source 
H6 Male 39 Occipital scalp 
H7 Female 48 Facelift 
H8 Male 42 Occipital scalp 
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Table 6 Spectrophotometric analysis of human scalp hair follicle components 
RNA   
DP: dermal papilla, CTS: connective tissue sheath around the bulb, HM: hair matrix 
and LF: lower follicle area below the bulge region. 
 
Total RNA sample Purity (A260/ A280) Concentration (ng/ml) 
 
 
H6 
DP 1.15 33 
CTS 1.08 29 
HM 1.7 72 
Bulge 1.2 40 
LF 1.55 78 
 
 
H7 
DP 1.1 25 
CTS 1 22 
HM 1.55 65 
Bulge 1.18 39 
LF 1.45 74 
 
 
H8 
DP 1.4 41 
CTS 1.25 34 
HM 1.8 81 
Bulge 1.3 47 
LF 1.7 86 
 
 
 
 
 
 
 
 
 
 
 
 
178 
 
Figure 45 Agarose gel electrophoresis of total RNA extracted from hair 
follicle components from three samples 
The agarose gel electrophoresis of the total RNA from hair follicle components 
from 3 individuals. 10µl from each sample was loaded on to a 1.5% agarose gel. 
Lane 1 - dermal papilla (DP), lane 2 - connective tissue sheath (CTS), lane 3 – 
matrix (M), lane 4 - follicle in bulge region (B) and lane 5 – lower follicle region 
between the bulge and the bulb (LF). The 18S and 28S ribosomal RNA bands were 
strong in the bulb matrix and the lower follicle but weak in the other three.  
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3.7.3  RT-PCR results for β-actin gene expression from human hair follicle 
components 
cDNAs prepared from each of the components from three individuals were 
checked for their quality by RT-PCR using primers for the positive control gene β-
actin. When the PCR products were separated by agarose gel electrophoresis, all 3 
samples amplified bands for each individual component, corresponding to the 
expected amplicon size for β-actin (838 bp) (Figure 46). The PCR products from 
matrix, the follicle in the “bulge region” and the lower follicle region below the 
“bulge” showed stronger bands which indicated that those cDNA quantities were 
sufficient to be used for FP gene amplification, but PCR products from dermal 
papilla and the connective tissue sheath showed weak bands indicating that the 
cDNA was of poor quantity and more cDNA must be used for FP gene amplification. 
No bands were observed in the negative control in which the template cDNA was 
omitted from the PCR reaction mix. 
The identities of the PCR products were checked by sequence analysis. The 
homology of the sequenced PCR product to the known human β-actin gene 
sequence for the dermal papilla was 93%, the connective tissue sheath was 91%, 
the matrix was 94%, the follicle in bulge region was 90% and the lower follicle 
between the bulge and the bulb was 96% (Data not shown). 
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Figure 46  Gel electrophoresis of β-actin PCR products from human hair 
follicle components 
A typical agarose gel electrophoresis (1.5% w/v) after RT-PCR of human hair 
follicle components using primers for β-actin and 10µl of cDNA. Lane 1–10µl 
molecular weight markers (DNA ladder; eleven fragments ranging from 100–
1,500bp), lane 2-6 – human hair follicle components β-actin PCR products (30 μl): 
lane 2, dermal papilla (DP); lane 3: connective tissue sheath (CTS), lane 4: matrix 
(M), lane 5: follicle in bulge region (B) and lane 6: lower follicle between the bulge 
and the bulb (LF), lane 7 – negative control in which cDNA was omitted from the 
PCR reaction mix (30 μl).  The expected amplicon size for β-actin is 838 bp.   
 
 
 
 
 
β-actin 
 838bp 
         1        DP     CTS     M        B        LF        7 
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3.7.4 Expression of FP gene in cDNA extracted from human hair follicle 
components using RT-PCR 
When FP gene expression was investigated in the human hair follicle components 
cDNA samples (15µl) from the dermal papilla, connective tissue sheath, matrix, 
follicle from the “bulge area” and the area between the bulge and the bulb, none of 
the cDNA samples from any of the 3 different individuals produced detectable PCR 
products (Figure 47). However, the expression of FP gene in whole lower hair 
follicles (Figure 47 lane 8) and the detection of good β-actin expression in the 
matrix, follicle from the “bulge” area and the lower follicle between the “bulge” and 
the bulb (Figure 46) suggested that this was not due to problems with the FP PCR 
or the amount of cDNA available for the three mainly epithelial components.         
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Figure 47  PCR detection of FP gene in human hair follicle components  
Expression of FP gene in human hair follicle components was investigated by RT-
PCR using 15µl of cDNA.  Lane 1 –10µl molecular weight markers (100bp DNA 
ladder), lane 2-6 – FP gene PCR products from human hair follicle components 
(30μl loaded). DP: dermal papilla, CTS: connective tissue sheath, M: matrix, B: 
follicle from bulge area and LF: lower follicle area between the bulge and the bulb, 
lane 7 – negative control (-ve) in which cDNA was excluded (30μl).  Lane 8 – 
(30μl) positive control, FP gene expression from human hair follicle cDNA (H1, 
10μl).  The expected amplicon size for FP gene is 1080 bp.  The PCR products 
(lanes 2-6) did not show any bands indicating that the cDNA from hair follicle 
components were not of sufficient quantity to yield FP gene amplification. There 
was a band of expected amplicon size (1080 bp) for the positive control in lane 8. 
 
 
 
 
 
   1          DP       CTS        M          B          LF       -ve        FP  
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3.7.5  The expression of FP gene in amplified RNA from human hair follicle 
components cells using RT-PCR  
To determine whether the lack of detection of FP gene expression (Figure 47) was 
simply due to insufficient cDNA, the experiment described in 3.7.2 was repeated 
using a further three human male scalp skin samples (Table 7), but the RNA from 
each hair follicle component was amplified before cDNA synthesis as described in 
section 2.2.1.4.5. 
Table 7 Human scalp hair follicle samples used to prepare hair follicle 
components for amplified RNA studies, their RNA concentrations and 
purities after amplification.   
Human 
sample 
Age (year) Component 
parts 
Purity (A260/ 
A280) 
Concentration 
(µg/ml) 
 
 
H9 
 
 
30 
DP 1.8 22.3 
CTS 1.75 18.5 
HM 1.95 26.2 
Bulge 1.7 20.8 
LF 1.85 28.4 
 
 
H10 
 
 
45 
DP 2 16.6 
CTS 1.75 13.7 
HM 1.8 19.5 
Bulge 1.9 14.7 
LF 1.85 17.9 
 
 
H11 
 
 
41 
DP 1.85 18.2 
CTS 1.8 14.8 
HM 1.9 20.4 
Bulge 1.8 16.2 
LF 1.85 21.1 
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The quality of each extracted RNA sample was checked before amplification by gel 
electrophoresis on a 1.5% agarose gel (Figure 48). The total RNA from each sample 
showed sharp 28S and 18S rRNA bands and the 28S rRNA bands were 
approximately twice as intense as the 18S rRNA bands (Figure 48), indicating that 
the RNA samples were of appropriate quality. The RNA samples were amplified 
using the SMARTTM mRNA Amplification Kit; the concentration and purity were 
checked spectrophotometrically (Table 7). All three samples after amplification 
showed much higher concentrations for all the hair follicle components compared 
to the earlier non-amplified RNAs (see Table 6 & 7). The amplified RNA samples 
were treated with DNase I and cDNAs were synthesised immediately.  
3.7.6 PCR detection of β-actin in amplified hair follicle components 
The cDNAs prepared from all three samples were checked for their quality by RT-
PCR using primers for the positive control gene, β-actin.  All amplified hair follicle 
components from each individual produced bands corresponding to the expected 
amplicon size for β-actin (838 bp) when separated by agarose gel electrophoresis 
(Figure 49). No bands were observed in the negative control when the template 
cDNA was omitted. 
The identities of the PCR products were checked by sequence analysis. The 
sequenced dermal papilla, connective tissue sheath, hair matrix, the follicle in the 
“bulge” region and lower follicle PCR products were aligned with the known 
human β-actin sequence using NCBI BLAST program and showed 97%, 92%, 94%, 
90% & 95% respectively (Figure 50). 
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Figure 48 Agarose gel electrophoresis of total RNA from hair follicle 
components prior to amplification 
Agarose gel electrophoresis showed obvious 28S and 18S ribosomal RNA bands 
exhibiting 2:1 ratio in all components RNA when 10µl from each sample was 
loaded into a 1.5% agarose gel. DP: dermal papilla, CTS: connective tissue sheath, 
M: hair matrix, the follicle in bulge region and LF: lower follicle below the bulge 
region.  
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Figure 49 Agarose gel electrophoresis of β-actin PCR products from amplified 
RNA from human hair follicle components 
A typical agarose gel electrophoresis (1.5% w/v) after RT-PCR of amplified RNA 
from human hair follicle components using primers for β-actin and 10µl of cDNA. 
Lanes 1 & 8 –10µl molecular weight markers (DNA ladder 100-1500 bp), lane 2-6 
– hair follicle components β-actin PCR products (30 μl): lane 2: dermal papilla 
(DP); lane 3: connective tissue sheath (CTS), lane 4: matrix (M), lane 5: follicle in 
bulge region (B); lane 6: lower follicle between the bulge and the bulb (LF) and 
lane 7 – negative control in which cDNA was omitted from the PCR reaction mix 
(30 μl). The expected amplicon size for β-actin is 838 bp.  All hair follicle 
components showed a strong band indicating that those cDNA were of good 
quality and they were suitable to be used for FP gene amplification.  
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Figure 50  Sequencing results for β-actin RT-PCR product from amplified RNA 
from hair follicle components    
The identity of a β-actin PCR product was checked by sequence analysis using the 
NCBI BLAST program to align the homology of the sequenced product (query: red) 
against the known human β-actin gene sequence (subject: black).  The matching 
bases between the two sequences are indicated by a bar.  The homology of the 
sequenced PCR product to the known human β-actin sequence for the dermal 
papilla was 97% (a), connective tissue sheath was 92% (b), matrix was 94% (c), 
the follicle in bulge region was 90% (d) and lower follicle between the bulge and 
the bulb was 95% (e).  
(a)        Dermal papilla 
Query: 2   tgtggcccccgaggagcaccccgtgctgctgaccgaggcccccctgaaccccaaggccaa 61 
           |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 33  tgtggctcccgaggagcaccccgtgctgctgaccgaggcccccctgaaccccaaggccaa 92 
 
                                                                        
Query: 62  ccgagagaagatgacncagatcatgtttgagaccttcaacaccccagccatgtacgtngc 121 
           ||| ||||||||||| ||||||||||||||||||||||||||||||||||||||||| || 
Sbjct: 93  ccgcgagaagatgacccagatcatgtttgagaccttcaacaccccagccatgtacgttgc 152 
 
                                                                        
Query: 122 tatccaggctgtgctatccctgtacgcctctggncgnaccactggcattgtgatggactc 181 
           ||||||||||||||||||||||||||||||||| || ||||||||||| ||||||||||| 
Sbjct: 153 tatccaggctgtgctatccctgtacgcctctggccgtaccactggcatcgtgatggactc 212 
 
                                                                        
Query: 182 nggtgacggggtcacccacactgtgcccatctacgaggggtatgccctcccccatgccat 241 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 213 cggtgacggggtcacccacactgtgcccatctacgaggggtatgccctcccccatgccat 272 
 
                                                                        
Query: 242 cctgcgtctggacctggctggccgggacctgactgactacctcatgaagatcctcacnga 301 
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct: 273 cctgcgtctggacctggctggccgggacctgactgactacctcatgaagatcctcaccga 332 
 
                                                                        
Query: 302 gcgcggctacagcttcaccaccacggccgagcgggaaatcgtgcgtgacattaaggagaa 361 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 333 gcgcggctacagcttcaccaccacggccgagcgggaaatcgtgcgtgacattaaggagaa 392 
 
                                                                        
Query: 362 gctgtgctacgtcgccctggacttcgagcaagagatggccacngctgcttccnnctcttc 421 
           |||||||||||||||||||||||||||||||||||||||||| |||||||||  ||| || 
Sbjct: 393 gctgtgctacgtcgccctggacttcgagcaagagatggccacggctgcttccagctcctc 452 
 
                          
Query: 422 tctggnnaanagct 435 
            ||||  || |||| 
Sbjct: 453 cctggagaagagct 466 
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3.7.7 Expression of FP gene in amplified RNA from hair follicle components 
using RT-PCR 
The expression of the FP gene was investigated in the human scalp hair follicle 
components using 10 µl of amplified cDNA. Dermal papilla and connective tissue 
sheath cDNA samples from three different individuals all showed appropriate 
bands corresponding to the FP gene (1080 bp) (Figure 51); none of the other three 
components, the matrix, the follicle from the “bulge” area and the area between the 
“bulge” and the bulb, showed any detectable bands.  
The identities of the dermal papilla (DP) and connective tissue sheath (CTS) PCR 
products were confirmed by sequence analysis. When the DP and CTS PCR 
products sequences were aligned with the known human FP gene sequence using 
the NCBI BLAST program, they showed 98% & 95% homology respectively (Figure 
52). 
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Figure 51 PCR detection of FP gene from amplified RNA from human hair 
follicle components 
The FP gene expression using amplified RNA from hair follicle components was 
investigated by RT-PCR.  Lane 1 & 8 –10µl molecular weight markers (100-1500 
bp DNA ladder), lane 2-6 – FP gene PCR products from human hair follicle 
components (30μl loaded); DP: dermal papilla, CTS: connective tissue sheath, M: 
matrix, B: follicle from bulge area and LF: lower follicle area between the bulge and 
the bulb; lane 7 – negative control (-ve) in which cDNA was omitted (30μl).  The 
expected amplicon size for FP gene is 1080 bp.  Only the dermal papilla (DP) and 
the connective tissue sheath (CTS) (lane 2, 3) showed bands indicating FP gene 
amplification but none of the other components, M, bulge and LF (lane 4-6)  
showed any bands.  
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Figure 52 Sequencing results for FP gene PCR product, following 
amplification from human hair follicle dermal papilla and connective tissue 
sheath cells  
To ascertain the identity of the dermal papilla and connective tissue sheath PCR 
products of FP gene expression from amplified RNA from human hair follicle 
components,  sequence analysis was carried out.  The NCBI BLAST programme was 
used to align the sequenced products (red; query) against the known human FP 
gene sequence (black; subject).  The FP gene PCR product sequence of the human 
hair follicle dermal papillae (a) and connective tissue sheath (b) exhibited 98% & 
95% homology respectively to the known human FP gene sequence.  
(a) Dermal papilla 
Query  1    GCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTA  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  43   GCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTA  102 
 
Query  61   ATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  103  ATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCA  162 
 
Query  121  TATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTA  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  163  TATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTA  222 
 
Query  181  ATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  223  ATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCT  282 
 
Query  241  GATAAAGAATGGATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  283  GATAAAGAATGGATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGC  342 
 
Query  301  ATGGTGTTTTCTGGTCTGTGNCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGT  360 
            |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  343  ATGGTGTTTTCTGGTCTGTGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGT  402 
 
Query  361  ATTGGAGTCACAAAACCNATATTTCATTCTACNAAAATTACATCCAAACA  410 
            ||||||||||||||||| |||||||||||||| ||||||||||||||||| 
Sbjct  403  ATTGGAGTCACAAAACCAATATTTCATTCTACGAAAATTACATCCAAACA  452 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
193 
 
(b) Connective tissue sheath 
Query  1    GCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTA  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  43   GCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTA  102 
 
Query  61   ATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  103  ATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCA  162 
 
Query  121  TATCAGAGATTTAGACAGAAGTCCAAGNCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTA  180 
            ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  163  TATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTA  222 
 
Query  181  ATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  223  ATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCT  282 
 
Query  241  GATAAAGAATGGATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  283  GATAAAGAATGGATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGC  342 
 
Query  301  ATGGTGTCTTCTGGTCTGTGNCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGT  360 
            ||||||| |||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  343  ATGGTGTTTTCTGGTCTGTGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGT  402 
 
Query  361  ATTGGAGTCACAAAACCNATATTTCATTCTACNAAAATTACATCCAAACA  410 
            ||||||||||||||||| |||||||||||||| ||||||||||||||||| 
Sbjct  403  ATTGGAGTCACAAAACCAATATTTCATTCTACGAAAATTACATCCAAACA  452 
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3.8  Determination of which prostaglandins are present in scalp hair follicles 
by lipidomic analysis 
To determine which prostaglandins occur naturally in human scalp hair follicles in 
anagen, the types of prostanoid, dihydroprostaglandin and isoprostane lipid 
mediators were investigated in isolated anagen scalp hair follicles using 
electrospray tandem mass spectrometry coupled to liquid chromatography 
(LC/ESI-MS/MS), a method adapted from Masoodi and Nicolaou (2006). 
Prostanoid profiles are tissue-dependent and quantitative methodologies need a 
high sensitivity and selectivity because of the short half-lives, low concentrations 
and structural similarities of these compounds. The LC/ESI-MS/MS is a sensitive 
and quick assay appropriate to lipidomic analyses. Electrospray ionisation (ESI) 
was used in this analysis as prostanoids have free carboxylic acid groups and ESI 
results in a copious [M-H] carboxylate ion that allows for relatively low 
concentrations to be detected.  
The LC/ESI-MS/MS analysis identified 7 prostanoids, 1 isoprostane and 1 
dihydroprostaglandin in scalp hair follicle samples from 3 individuals using a 
range of multiple reaction monitoring (MRM) transitions and optimum collision 
energy for each compound (Table 8) to generate the most abundant product ions 
(Kempen et al., 2001; Yang et al., 2002; Masoodi and Nicolaou, 2006; Taylor et al., 
2006). The limits of detection were in the range of 0.1-10 pg/µl and the limits of 
quantification were in the range of 0.5-20 pg/µl depending on the compounds.  The 
ESI-MS/MS product ion spectra revealed 7 prostanoids: PGF2α (Figure 53), PGE1, 
PGD1, PGE2, PGD2, TXB2 and 6-keto PGF1α; a dihydroprostaglandin: 13,14 dihydro-
15-keto PGE2; an isoprostane: 8-iso-PGE2. The LC/ESI-MS/MS chromatographic 
separation of the compounds on a C18 column using a gradient of two acetonitrile- 
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Table 8 Optimal collision energies and multiple reaction monitoring 
transitions used for the LC/ESI-MS/MS assay of prostanoids, isoprostane and 
dihydroprostaglandins (Masoodi and Nicolaou, 2006). 
Multiple reaction monitoring (MRM) transitions and optimum collision energy to 
generate the most abundant product ions for each compound. PGB2-d4: internal 
standard. 
 
 
Compound 
 
 
MRM (m/z) 
 
Collision energy (eV) 
PGD1 
PGE2 
PGB2-d4  
PGE1 
PGF2α 
TXB2 
6-keto PGF1  
13,14-dihydro PGF2  
13,14-dihydro-15-keto PGF1  
13,14-dihydro-15-keto PGE1 
13,14-dihydro-15-keto PGE2 
8-iso-PGE2 
PGD2 
353>317 
351>271 
337>179 
353>317 
353>193 
369>169 
369>163 
355>311 
355>193 
353>335 
351>333 
351>315 
351>271 
15 
17 
20 
15 
25 
17 
23 
30 
32 
12 
12 
15 
17 
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Figure 53  An example ESI-MS/MS product ion spectrum of PGF2α 
ESI-MS/MS analysis identified PGF2α, PGE1, PGD1, PGE2, PGD2,  TXB2, 6-keto PGF1α, 
13,14 dihydro-15-keto PGE2 and 8-iso-PGE2 in scalp hair follicles from 3 
individuals. The spectra were recorded at the optimum collision energy for each 
compound (Table 8). This typical graph shows the ESI-MS/MS spectrum of PGF2α 
detected. The molecular ion [M-H]- is m/z 353, using a collision energy of 25 eV. 
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based solvents identified  prostaglandins PGF2α, PGE1, PGD1, PGE2, PGD2, TXB2, 6-
keto PGF1α, 13,14 dihydro-15-keto PGE2 and 8-iso-PGE2 (Figure 54). The isobaric 
compounds PGE2 and PGD2 were detected through the same MRM transition, but 
were separated chromatographically (m/z 351 271; retention times: 3.25 and 
4.11 min, respectively) (Figure 54a). Similarly PGE1 and PGD1 were separated 
chromatographically (m/z 353 317; retention times were 2.38 and 4.43 min, 
respectively) (Figure 54b).  Calibration lines for the various prostaglandins were 
produced by analysing an 6 point standard curve from 1-100 pg/µl for each 
compound (appendix 6.4). 
The quantities of the identified prostanoids were worked out as concentration per 
mg of protein in the sample as the mean ± SEM from three different experiments 
each analysed in duplicate. The most predominant prostanoid lipid mediators 
identified were PGE2 (17.1920±2.2 pg/mg protein) and PGF2α (13.39±1.8 pg/mg of 
follicle protein) (Figure 55). The concentration of the other prostanoids identified 
were: PGD2: 8.5843±3.5, PGE1: 5.2710±0.2, PGD1: 3.8817±5.7, 15-k-PGE2: 
3.5317±8.9, 8-iso-PGE2: 4.3589±3.6, TXB2: 4.0145±1.1, 6-keto PGF1α: 3.2861±4.5 
pg/mg of follicle protein (Figure 55).  
 
 
 
198 
 
Figure 54  Representative LC/ESI-MS/MS chromatograms of the prostanoids, 
dihydroprostaglandins and isoprostanes produced by human scalp hair 
follicles 
The compounds were chromatographically determined on a C18 column using a 
gradient of two acetonitrile-based solvents. This demonstrated the chromatograms 
of these lipid mediators: PGF2α, PGE1, PGD1, PGE2, PGD2, TXB2, 6-keto PGF1α, 13,14 
dihydro-15-keto PGE2 and 8-iso-PGE2 (a-g). The run time of the assay was 30 min 
including a 10 min wash cycle programmed to run before the next injection.  
(a) Chromatogram showing LC/ESI-MS/MS analysis of PGE2 & PGD2 
 
 
 
         
 
 
       
  
 
(b) Chromatogram showing LC/ESI-MS/MS analysis of PGE1 & PGD1 
 
 
      
 
 
 
(c) Chromatogram showing LC/ESI-MS/MS analysis of PGF2α 
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(d) Chromatogram showing LC/ESI-MS/MS analysis of TXB2 
      
 
(e) Chromatogram showing LC/ESI-MS/MS analysis of 6-keto PGF1 
           
 
(f) Chromatogram showing LC/ESI-MS/MS analysis of 13,14-dihydro-15-keto PGE2 
      
 
(g) Chromatogram showing LC/ESI-MS/MS analysis of 8-iso-15-PGE2 
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Figure 55  Profile of the prostanoids naturally present in human scalp 
anagen hair follicles using LC/ESI-MS/MS 
Values are the mean ± SEM of 3 samples of human scalp hair follicles from adult 
men; each sample was analysed in duplicate. 
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3.9  Immunohistochemical localisation of PGE2 receptor (EP2) in the human 
scalp hair follicle bulb  
Following the identification of large amount of PGE2 in the human scalp anagen 
hair follicles using LC/ESI-MS/MS (Figure 54a, 55), the expression of PGE2 
receptor (EP2) protein was investigated in the human scalp hair follicle from 5 men 
(26-48 years) by immunohistochemistry using a goat polyclonal anti-human EP2 
antibody. This antibody had to be optimised, a range of antibody dilutions between 
1:50 to 1:200 was investigated and 1:100 in 1.5% normal mouse serum was 
considered optimal.   
No non-specific staining occurred in the negative controls when the primary 
antibody was absent (Figure 56a, c).  EP2 was expressed in the cells of the human 
hair follicle dermal papilla and connective tissue sheath surrounding the hair bulb 
and lower follicle (Figure 56b, d).  
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Figure 56  Immunolocalisation of EP2 in the human hair follicle bulb 
Immunohistochemistry was performed using a goat polyclonal antibody to EP2 
(1:100 dilution). DP: dermal papilla, CTS: connective tissue sheath; HM: hair 
matrix. Red: positive staining; blue: hematoxylin counterstain.  
Absence of staining in the negative control where the primary antibody was 
replaced with 1.5% normal mouse serum (a, c). EP2 protein was localised in the 
cells of the dermal papilla (DP) and connective tissue sheath (CTS) surrounding the 
hair bulb and lower follicle but not in the epithelial cells or melanocytes of the hair 
bulb matrix (b, d). 
Scale bars a,b = 150µm; c,d = 100µm 
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3.10  The effects of a prostamide F2α analogue, bimatoprost, on human scalp 
hair growth in organ culture  
3.10.1  Bimatoprost stimulated human hair follicle growth in organ culture in 
a concentration-dependent manner  
Bimatoprost, a treatment for glaucoma (ocular hypertension) has been shown to 
have potent ocular hypotensive activity and stimulate eyelash growth as a side 
effect. To investigate the effects of different concentrations of bimatoprost on scalp 
hair follicle growth in the absence of any blood supply in vitro, hair follicle organ 
culture was carried out.  Carefully microdissected hair follicles were maintained in 
serum-free culture medium for 9 days (Figure 57) with daily observation of their 
morphology, measurement and photography.  
Since bimatoprost needed to be solubilised in DMSO, 0.01% DMSO was added to all 
control conditions used for these experiments using scalp hair follicle samples 
from a further 5 individuals. Most of the hair follicles (>70%) increased in length 
regularly during the nine day culture period in all conditions (Figures 57, 58, 59). 
Follicles which showed no increase in length over 3 days were assumed to be 
damaged and removed from the experiment. Sequential photographs taken every 
24 hours showed that this hair follicle elongation was due to the production of a 
new hair fibre alongside with associated inner and outer root sheath, but the 
connective tissue sheath did not grow and remained at the initial length 
throughout the culture period (Figure 57). Daily observation of the hair follicle 
bulb morphology was carried out to monitor each follicle’s anagen status (Figure 
59).  Some hair follicles developed catagen-like changes in their bulb morphology 
with pigmentation ceasing and the base of the hair fibre retracting up the follicle, 
leaving behind a rounded up ball of dermal papilla cells (see Figure 19c,d).  After 2 
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days there was a gradual increase in the number of follicles showing catagen-like 
changes in the hair bulb region (Figure 59). The overall amount of hair actually 
produced by all the follicles in the organ culture was also calculated from the final 
increase in length of each follicle on the final day, day 9, or the last day the follicle 
maintained a normal anagen morphology (Figure 60). All 3 concentrations of 
bimatoprost stimulated human scalp hair follicle growth rate in organ culture, 10 
nM promoted growth significantly by about 16% (P<0.01**), while 100 & 1000 nM 
had a greater effect of about 27% (P<0.001***; mean ± SEM) (Figure 58).  
Bimatoprost also prolonged anagen increasing the number of hairs remaining in 
anagen on day 9 by about 7% with 10 nM (P<0.05*) and about 11% with 100 & 
1000 nM (P<0.01**) (Figure 59). Bimatoprost also stimulated the overall amount 
of hair synthesised in organ culture, expressed as actual values (Figure 60a) and as 
a % of their control follicles (Figure 60b). These were from 0.482 ± 0.021 
mm/follicle (mean ± SEM) by about 20% to 0.575 ± 0.024 mm/follicle with 10 nM 
(P<0.05*), by about 35% to 0.648 ± 0.024 mm/follicle with 100 nM (P<0.01**) and 
by about 33% to 0.639 ± 0.024 mm/follicle with 1000 nM (P<0.01**). 
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Figure 57  Sequential photomicrographs of a human scalp hair follicle 
growing in vitro in media with 100 nM bimatoprost 
(a) Sequential photomicrographs of typical scalp hair follicles were taken every 24 
hours for 9 days in organ culture with 100 nM bimatoprost, demonstrating growth 
of new hair fibre and the root sheaths but not the connective tissue sheath (CTS). 
Scale bar = 500µm. 
(b) Enlarged photomicrographs of the hair follicle bulb (pictured in a), showing 
anagen morphology during 9 days in culture. Scale bar = 200µm. 
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Figure 58  Bimatoprost stimulated human scalp hair follicle growth in organ 
culture 
Anagen follicles were measured while cultured in basic culture medium either 
vehicle alone (control), or bimatoprost (10, 100 & 1000 nM) using an inverted 
microscope fitted with an eyepiece graticule. Hair follicles increased in length 
regularly and bimatoprost increased scalp hair follicle growth rate: with 10 nM (P 
< 0.01**) and with 100 & 1000 nM (P < 0.001***). Values are the mean ± SEM of 5 
individuals for each experiment; at least 6 follicles were examined per person for 
each condition. Statistical analysis was performed using a two-factor within-
subjects ANOVA using SPSS, after confirming normal distribution, using KS-test.   
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Figure 59  Bimatoprost prolongs anagen in scalp hair follicles in organ 
culture  
Anagen follicles were assessed daily for changes in morphology while cultured in 
basic culture medium containing either the vehicle alone (control), or bimatoprost 
(10, 100 & 1000 nM). The proportion of hair follicles remaining in anagen 
throughout the culture was calculated and any follicles which developed catagen-
like changes in their bulb morphology were not counted as anagen. The proportion 
of anagen follicles gradually decreased after one day in culture. Bimatoprost 
prolonged anagen on day 9 by about 7% with 10 nM (P<0.05*) and by about 11% 
with 100 & 1000 nM (P<0.01**). Values are the mean ± SEM of 5 individuals; at 
least 6 follicles were examined per person for each condition. Statistical analysis 
was performed using a two-factor within-subjects ANOVA using SPSS, after 
confirming normal distribution, using the KS-test.   
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Figure 60  Bimatoprost increased the total amount of hair produced in organ 
culture 
Anagen follicles were measured while cultured in basic culture medium either 
vehicle or bimatoprost (10, 100 & 1000 nM). Bimatoprost stimulated the overall 
amount of hair synthesised in organ culture, results are expressed as mean actual 
values (a) or as a % of their own control follicles (b), by about 20% with 10 nM 
(P<0.05*), by about 35% with 100 nM (P<0.01**) and by about 33% with 1000 nM 
(P<0.01**). Values are the mean ± SEM of 5 individuals; at least 6 follicles were 
examined per person for each condition. Statistical analysis was performed using a 
two-factor within-subjects ANOVA using SPSS, after confirming normal 
distribution, using KS-test.   
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3.10.2 An FP antagonist, AS604872 (AGN22827), and a prostamide F2α 
receptor antagonist, AGN211336, blocked bimatoprost-stimulation of scalp 
hair growth in organ culture 
To determine whether the bimatoprost stimulation was through FP and/or 
prostamide F2α receptor, the effect of an FP antagonist, AS604872, and a 
prostamide F2α receptor antagonist, AGN211336, on bimatoprost-stimulated hair 
growth was investigated on follicles from 5 further individuals; at least 6 follicles 
were examined per person per condition. Bimatoprost (100 nM) alone significantly 
increased the hair growth rate by about 27% (P < 0.001***) (Figure 62), the % of 
follicles remaining in anagen by about 11% (P < 0.01**) (Figure 63) and the total 
increase in follicle length by about 35% (P < 0.01**) (Figure 64). This stimulatory 
action of bimatoprost on all parameters was abolished when it was combined 
either with AS604872 or AGN211336 at 1µM (P < 0.05*- 0.001***) (Figures 61-64). 
The combination of bimatoprost and either of the antagonists were not 
significantly different from the control for all the parameters: growth rate 
(P=0.098), percentage of follicles remaining in anagen at day 9 (P=0.104) nor the 
overall amount of hair follicle synthesised (P=0.086) (mean ± SEM) (Figures 62-
64).  
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Figure 61 Sequential photomicrographs of a human scalp hair follicle 
growing in culture with 100 nM bimatoprost + 1µM prostamide F2α receptor 
antagonist, AGN211336  
(a) Photographs of the same human hair follicle were taken every 24 hours for 
nine days growing in culture under combination of the 100nM bimatoprost and 
1µM AGN211336 condition. Hair follicles synthesised new hair fibre regularly, 
increasing in length (similar to the vehicle but at much slower rate compared to 
100nM bimatoprost alone). Scale bar = 0.5mm  
(b) Enlarged photomicrographs of the hair follicle bulb (pictured in a), showing 
that the follicle maintained the anagen bulb morphology during the 9 days in 
culture. Scale bar = 0.2mm 
(a) 
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Figure 62  AS604872 and AGN211336 blocked bimatoprost-stimulation of 
scalp hair follicle growth rate 
Bimatoprost (100nM) alone significantly increased the hair growth rate by about 
27% (P< 0.001***) in organ culture. This growth-stimulating effect was abolished 
when it was combined with the FP antagonist, AS604872, (1µM) (a) and the 
prostamide F2α receptor antagonist, AGN211336, (1µM) (b) (P < 0.001***).  Results 
are the mean ± SEM of 5 individuals; at least 6 follicles were examined per person 
per condition. Statistical analysis was performed using a two-factor within-
subjects ANOVA using SPSS after confirming normal distribution, using KS-test. 
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Figure 63  AS604872 and AGN211336 blocked the bimatoprost-promoted 
increase in % of scalp hair follicles in anagen  
Bimatoprost (100 nM) alone significantly increased the percentage of follicles in 
anagen by about 11% (P< 0.01**) but this effect was blocked when it was 
combined with the FP antagonist AS604872 (1µM) (a) and the prostamide F2α 
receptor antagonist AGN211336 (1µM) (b) (P< 0.01**).  Values are the mean ± 
SEM of 5 individuals; at least 6 follicles were examined per person for each 
condition. Statistical analysis was performed using a two-factor within-subjects 
ANOVA using SPSS after confirming normal distribution, using the KS-test.   
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Figure 64  AS604872 and AGN211336 blocked bimatoprost-stimulated 
increase in total amount of hair production  
The overall amount of hair produced by all the follicles in organ culture was 
calculated by recording the final length of each follicle on the last day the follicle 
maintained a normal anagen morphology. Bimatoprost alone (100 nM) increased 
the overall amount of hair synthesised expressed as mean actual values (a, c) or as 
a % of their own control follicles (b, d) by about 35% (P < 0.01**), but the FP 
antagonist AS604872 (1µM) (a, b) and the prostamide F2α receptor antagonist 
AGN211336 (1µM) (c, d) both abolished this response (P< 0.01**).  Values are the 
mean ± SEM of 5 individuals; at least 6 follicles were examined per person for each 
condition. Statistical analysis was performed using a two-factor within-subjects 
ANOVA using SPSS after confirming normal distribution, using the KS-test.   
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Figure 65  Photomicrographs of scalp hair follicles after growing in different 
conditions in organ culture for 9 days 
Photomicrographs of typical scalp hair follicles after 9 days in organ culture in 
various conditions. From left: control medium, 100 nM PGF2α. The remaining 
follicles were cultured in the presence of 0.01% DMSO to increase drug solubility; 
these included: control medium containing the vehicle, 100nM PGF2α, 100nM PGF2α 
with FP antagonist AS-604872 (1μM); control medium containing the vehicle, 
100nM bimatoprost, or 100nM bimatoprost with FP antagonist AS-604872 (1μM). 
Scale bar = 0.5 mm 
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3.11  Identification of genes for prostamide F2α receptors  in human scalp 
hair follicles using molecular biological methods 
Since bimatoprost interacts with spliced variants of the FP (prostamide receptors) 
(Liang et al., 2008), RT-PCR was used to investigate the expression of FP variant 
genes in occipital scalp anagen hair follicles from 5 different adult male individuals. 
Non balding scalp hair follicles were isolated, poly(A+)RNA extracted and cDNA 
was prepared separately from each individual’s sample. Each cDNA was prepared 
from 65 lower hair follicles per donor and each individual’s hair follicles were 
investigated separately (Table 9). The quality of each RNA sample was checked by 
gel electrophoresis on a 1.5% agarose gel. The total RNA from each sample had 
sharp 28S and 18S rRNA bands and the 28S rRNA band was approximately twice 
as intense as the 18S rRNA band (Figure 66), indicating that the RNA samples were 
of good quality. The concentration & purity of each total RNA sample was also 
checked spectrophotometrically (Table 9), followed by further purification to 
isolate poly(A+)RNA. The poly(A+)RNA samples were treated with DNase I to 
remove any contaminating genomic DNA and cDNAs were synthesised 
immediately.  
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Table 9  The concentration and purity of RNA from lower follicles from 
human scalp skin samples used for prostamide receptor detection  
  
 
Human 
sample  
number  
 
 
Gender 
 
Age 
(years) 
 
Total RNA 
purity 
(A260/ A280) 
 
Total RNA 
concentration 
(µg/ml) 
 
H12 Male 33 1.65 162 
H13 Male 40 1.8 147 
H14 Male 46 1.75 125 
H15 Male 38 1.9 132 
H16 Male 35 2.0 170 
 
Figure 66  Gel electrophoresis of RNA from human scalp follicles  
Electrophoresis on a 1.5% agarose gel confirmed successful extraction of RNAs; 
10µl from each total RNA sample was loaded. Two bands of 18S and 28S ribosomal 
RNA are obvious in the total RNA samples, exhibiting 2:1 ratio.   
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3.11.1  RT-PCR for β-actin gene expression from anagen lower hair follicles 
The cDNA qualities from all five lower hair follicle samples were initially checked 
using the positive control gene, β-actin, prior to investigating the expression of FP 
variant genes. RT-PCR was carried out using specific primers and 5µl of cDNA from 
each sample. Agarose gel electrophoresis (1.5% w/v) of the PCR products (30µl) 
from each of 5 individuals showed appropriately sized bands corresponding to β-
actin (838 bp) (Figure 67). No bands were observed in the negative control in 
which the template cDNA was omitted from the PCR reaction mix. This indicated 
that the product bands resulted from the direct amplification of cDNA synthesised 
from the mRNA samples, and the reagents used in the PCR reaction mix were free 
from any DNA contamination.  
The identity of β-actin PCR products were confirmed by sequence analysis of the 
PCR products. When the sequenced products were aligned with the known human 
β-actin gene sequences using the NCBI BLAST program (http://www.ncbi. 
nlm.nih.gov/blast/ bl2seq/wblast2.cgi), β-actin PCR products showed 96% 
homology (data not shown).  
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Figure 67  β-actin gel electrophoresis  
β-actin gene expression in cDNA from five human scalp anagen lower hair follicles 
was investigated by RT-PCR using 5µl of cDNA.  The resulting PCR products were 
separated by agarose gel (1.5% w/v) electrophoresis and visualised with ethidium 
bromide staining. 10µl DNA ladder 100-1500 bp (lane 1) and 30μl of each person’s  
PCR products (lanes 2-6) were loaded on to the gel. A negative control in which 
cDNA was omitted from the PCR reaction mix was loaded on lane 7. All PCR 
products showed appropriately sized bands (838 bp) corresponding to β-actin.  
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3.11.2 Expression of the genes for the prostamide F2α receptors (FP splice 
variants) in human hair follicles using RT-PCR  
When the expression of FP gene splice variants were examined in human scalp hair 
follicles using primers which detects all the known FP splice variants (altFPs) three 
bands were seen (Figure 68a). Their sizes suggested the wild-type FP, prostamide 
receptor variant 4 (altFP4) or 3 and small amounts of another prostamide receptor 
possibly variant 1 (altFP1) or 2. Further RT-PCR reactions using relevant specific 
primers (Table 2) were carried out to determine which splice variants of variant 5 
(altFP5), variant 4 (altFP4), variant 3 (altFP3), variant 2 (altFP2) and variant 1 
(altFP1) were expressed in hair follicles. These primers only identified altFP4 and 
altFP1 genes in cDNA from scalp hair follicles from 5 individuals (Figure 68b, c).  
The altFP5, altFP3 and altFP2 were not detected (data not shown). There were no 
bands in the negative controls when the cDNA was replaced with nuclease-free 
water.  
The identities of the PCR products for the splice variants altFP4 and altFP1 were 
checked by sequence analysis and their identities verified when compared against 
the relevant human FP gene sequence in GenBank.  The altFP4 and altFP1 gene 
PCR products had 95 & 98 % homology respectively (Figure 69a, b). 
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Figure 68  Human scalp anagen hair follicles expressed genes for 2 
prostamide F2α receptors  
Agarose gel electrophoresis of PCR products (30 µl loaded) of lower hair follicle 
cDNAs from 5 different individuals showed appropriately sized product bands for 
FP variant receptors with primers for all FP splice variants (a), altFP4 (b) and 
altFP1 (c). There were no bands in the negative controls when cDNAs were 
omitted. 
(a) Lanes 1 and 8, DNA ladder (100-1500 bp), lanes 2–6, altFPs PCR products 
showing bands corresponding to wild-type FP (321 bp) at the bottom, altFP1 at the 
middle and altFP4 at the top; lane 7, negative control. 
(b) Lanes 1 and 8, DNA ladder (100-1500 bp), lanes 2–6, altFP4 PCR products 
(141bp); lane 7, negative control. 
(c) Lanes 1 and 8, DNA ladder (100-1500 bp), lanes 2–6, altFP1 PCR products 
(392bp); lane 7, negative control. 
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Figure 69  Sequencing results for FP splice variants RT-PCR products 
amplified from human scalp hair follicle cDNA, compared to known human 
sequence   
To confirm the identity of the PCR products, they were separated by agarose gel 
electrophoresis and bands of expected amplicon size corresponding to altFP4 and 
altFP1 were excised from the gel and sequenced. The NCBI BLAST programme was 
used to align the sequenced products (query: red) against the known human FP 
gene sequence (subject: black).  The bases that match in the two sequences are 
shown by a vertical line.   
(a) The altFP4 PCR product of the human hair follicle exhibited 95% homology.  
(b) The altFP1 PCR product of the human hair follicle exhibited 98% homology.  
  
(a)        altFP4 
Query  6      AGGTGTGGATGGAGAGGC-ACATGAAAGTGGATC-AACAACTCAATACATGGGTGCTGGC  63 
              |||||||||||||||||| ||||||||||||||| |||||||  |||||||||||||||| 
Sbjct  47     AGGTGTGGATGGAGAGGCAACATGAAAGTGGATCAAACAACT-TATACATGGGTGCTGGC 105 
 
Query  64     TCAGACGTGACACCTGAGGCTCCAGAAC  91 
              |||||||||||||||||||||||||||| 
Sbjct  106    TCAGACGTGACACCTGAGGCTCCAGAAC  133 
 
(b)  altFP1 
Query  83     TTTCT-GGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTGGAAACCTGTGA  14     
              ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  43002  TTTCTAGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTGGAAACCTGTGA 43061 
 
Query  142    AACAACACTTTTTGCTCTCCGAATGGTTACATGGAATCAAATCTTAGATCATAAAAGTAT  201 
              ||||||||||||||||||||||||||  |||||||||||||||||||||| |    |||| 
Sbjct  43062  AACAACACTTTTTGCTCTCCGAATGGCAACATGGAATCAAATCTTAGATCCTTGG-GTAT  43120 
 
Query  202    ATATTCTTCTACGAAAGGCTGTCCTTAAAAATCTCTATAAAACTTGCCAGTCAATGCTGT  261 
              |||||||||||||||||||||||||||| |||||||||||  |||||||||||||||||| 
Sbjct  43121  ATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAG-CTTGCCAGTCAATGCTGT  43179 
 
Query  262    GGGAGTG  268 
              || |||| 
Sbjct  43180  GG-AGTG  43185 
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3.11.3  Location of gene expression for prostamide F2α receptors in amplified 
RNA from human hair follicle components  
Amplified RNA (see section 3.8.5) from human scalp hair follicle components from 
3 individuals (Table 7) were used to localise the gene expression of the prostamide 
F2α receptors (FP splice variants) in scalp hair follicle. RT-PCR was carried out 
using primers for altFPs, altFP5, altFP4, altFP3, altFP2 and altFP1 (see Table 2). 
When the PCR products were separated using agarose gel electrophoresis, dermal 
papilla and connective tissue sheath cDNA samples from each of 3 different 
individuals exhibited 3 bands using primers for altFPs (Figure 70a) which were 
similar to those of the prostamide F2α receptor gene expression in lower hair 
follicles (Figure 68). None of the other components, the matrix, the follicle from 
bulge area and the follicle area between the bulge and the bulb, showed any 
detectable bands (Figure 70, 72).  Further RT-PCRs with primers for altFP4 (Figure 
70b, 72) and altFP1 (Figure 70c, 72) also paralleled the FP distribution in the DP 
and CTS, but none of other components expressed either gene splicing variants.  
None of the hair follicle components cDNA showed detectable PCR products with 
the other primers for altFP5, altFP3 and altFP2 (data not shown). The negative 
controls were clear from any bands when cDNAs were omitted.  
The identity of altFP4 and altFP1 PCR products from dermal papilla and connective 
tissue sheath were checked by sequence analysis; when they were aligned with the 
known human FP gene sequence using NCBI BLAST program, dermal papilla PCR 
products showed 94 & 91 % and connective tissue sheath PCR products showed 91 
& 90 % homology respectively (Figure 71a, b, c, d). 
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Figure 70  Dermal papilla and connective tissue sheath cells of human scalp 
hair follicles expressed genes for 2 prostamide F2α receptors  
Typical agarose gel electrophoresis of PCR products from scalp hair follicle 
components, shows that only dermal papilla (DP) and connective tissue sheath 
(CTS) cDNA developed appropriately sized product bands for prostamide F2α 
receptor (FP splice variants) with primers for altFPs (a), altFP4 (b) and (altFP1) 
(c).  No detectable bands were produced with cDNA from other components: the 
hair matrix (HM), the follicle from bulge area and the lower follicle area between 
the bulge and the bulb (LF).  
(a) Lanes 1 and 8, DNA ladder (100-1500 bp), lanes 2–6, altFPs PCR products from 
hair follicle components, shows bands for DP and CTS cDNA only corresponded to 
wild-type FP (321 bp) at the bottom, altFP1 at the middle and altFP4 at the top; 
lane 7, negative control without cDNA (-ve). 
(b) Lanes 1 and 8, DNA ladder (100-1500 bp), lanes 2–6, altFP4 PCR products from 
hair follicle components, show expected size bands (141 bp) with DP and CTS 
cDNA; lane 7, negative control (-ve). 
(c) Lanes 1 and 8, DNA ladder (100-1500 bp), lanes 2–6, altFP1 PCR products from 
hair follicle components, show expected size bands (392 bp) with DP and CTS 
cDNA only; lane 7, negative control (-ve). 
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Figure 71  Sequence analyses for FP splice variants RT-PCR products 
amplified from scalp hair follicle components cDNA, DP and CTS 
The identities of altFP4 and altFP1 PCR products from DP and CTS were confirmed 
by sequencing. The sequenced products (query: red) were aligned against the 
known human FP gene sequence (subject: black) using NCBI BLAST programme.  
The bases that match in the two sequences are shown by a vertical line.   
(a) The altFP4 PCR product of the human hair follicle DP cells exhibited 94% 
homology.  
(b) The altFP4 PCR product of the human hair follicle CTS cells exhibited 91% 
homology. 
(c) The altFP1 PCR product of the human hair follicle DP cells exhibited 91% 
homology.  
(d) The altFP1 PCR product of the human hair follicle CTS cells exhibited 90% 
homology.  
 
(a) altFP4 for DP 
Query  2      AGTTGTTTGATCCACTTTCATGTTGCCTCTCCATCCACACCTTAGTTCTTTCTGTCATAT  61 
              ||||||||||||||||||||||||||||||||||||||||||| ||| |||||||||| | 
Sbjct  41247  AGTTGTTTGATCCACTTTCATGTTGCCTCTCCATCCACACCTT-GTT-TTTCTGTCAT-T  41191 
 
Query  62     TCTCGATTGAAGTGTCTTATCGC  84 
              ||||| |||| |||||||||||| 
Sbjct  41190  TCTCG-TTGA-GTGTCTTATCGC  41170 
 
 
(b) altFP4 for CTS  
Query  2      AGTTGTTTGATCCACTTTCATNTTGCCTCTCCATCCACACCTTAGAACTTTCTGTCATAT  61 
              ||||||||||||||||||||| ||||||||||||||||||||| |   |||||||||| | 
Sbjct  41247  AGTTGTTTGATCCACTTTCATGTTGCCTCTCCATCCACACCTT-GTT-TTTCTGTCAT-T  41191 
 
Query  62     TCTCGATTGAAGTGTCTTATCGC  84 
              ||||| |||| |||||||||||| 
Sbjct  41190  TCTCG-TTGA-GTGTCTTATCGC  4117 
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(c)        altFP1 for DP 
Query  83     TTTCT-GGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTGGAAACCTGTGA  14     
              ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  43002  TTTCTAGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTGGAAACCTGTGA  43061 
 
Query  142    AACAACACTTTTTGCTCTCCGAATGGTTACATGGAATCAAATCTTAGATCATAAAAGTAT  201 
              |||||||||||||||||||||||||||||||||||||||||||||||||| |    |||| 
Sbjct  43062  AACAACACTTTTTGCTCTCCGAATGGTTACATGGAATCAAATCTTAGATCCTTGG-GTAT  43120 
 
Query  202    ATATTCTTCTACGAAAGGCTGTCCTTAAAAATCTCTATAAAACTTGCCAGTCAATGCTGT  261 
              |||||||||||||||||||||||||||| |||||||||||  |||||||||||||||||| 
Sbjct  43121  ATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAG-CTTGCCAGTCAATGCTGT  43179 
 
Query  262    GGGAGTG  268 
              || |||| 
Sbjct  43180  GG-AGTG  43185 
 
(d) altFP1 for CTS 
Query  83     TTTCT-GGTTACAATGGCCAACATTGCAATAAATGGAAATCATTCTCTGGAAACCTGTGA  14     
              ||||| |||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  43002  TTTCTAGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTGGAAACCTGTGA  43061 
 
Query  142    AACAACACTTTAGGCTCTCCGAATGGTTACATGGAATCAAATCTTAGATCATAAAAGTAT  201 
              |||||||||||  ||||||||||||||||||||||||||||||||||||| |    |||| 
Sbjct  43062  AACAACACTTTTTGCTCTCCGAATGGTTACATGGAATCAAATCTTAGATCCTTGG-GTAT  43120 
 
Query  202    ATATTCTTCTACGTNAGGCTGTCCTTAAAAATCTCTATAAAACTTGCCAGTCAATGCTGT  261 
              |||||||||||||  ||||||||||||| |||||||||||  |||||||||||||||||| 
Sbjct  43121  ATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAG-CTTGCCAGTCAATGCTGT  43179 
 
Query  262    GGGAGTG  268 
              || |||| 
Sbjct  43180  GG-AGTG  43185 
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Figure 72  Summery of the localisation of the gene expression of prostaglandin 
and prostamide F2α receptors in scalp hair follicle dermal papilla and 
connective tissue sheath but not in other follicular components  
(a) Photomicrographs of an isolated scalp hair follicle and its microdissected 
components. The hair bulb (outlined in red) was microdissected into the 
mesenchyme-derived dermal papilla (DP; outlined in red), the hair matrix (HM), 
containing dividing and differentiating keratinocytes and actively pigmenting 
melanocytes, and the surrounding connective tissue sheath (CTS); also outlined in 
red. The sheath is seen dissected flat.  Follicles were collected above the bulb up to 
the top of the sebaceous gland and then separated into the ‘bulge’ area, containing 
epithelial and melanocyte stem cells (B) and the remaining lower follicle (LF). 
(b) Table of results of RT-PCR using specific primers for all splice variants of FP, FP 
and each of 5 splice variants of FP (see Figure 70) in hair follicle components. 
Prostamide receptor FP variants 1 & 4 and the prostanoid receptor FP were detected 
only in the dermal papilla and connective tissue sheath (CTS) components from each 
of 3 individual’s scalp follicles; no expression was seen in the other components 
examined. CTS: connective tissue sheath; √ = gene expression in one person’s 
follicles, x = no expression.  
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4 Discussion 
 
Hair loss disorders, such as androgenetic alopecia (Hamilton, 1951) or alopecia 
areata (Randall, 2001b), cause significant psychological distress (Girman et al., 1998; 
Gulec et al., 2004) and negative effects on the quality of life even in men who have 
never sought treatment (Girman et al., 1998). Unfortunately, hair loss disorders are 
currently poorly controlled; available therapies are either limited in their 
effectiveness or have unwanted side effects (Rogers and Avram, 2008; Garg and 
Messenger, 2009).  Interestingly, two of the main therapies for androgenetic alopecia 
were developed for other conditions.  Minoxidil (Regaine), which opens ATP-sensitive 
potassium channels (Shorter et al., 2008), was originally an oral antihypertensive 
drug, but this application was discontinued as it stimulated unacceptable hair growth 
in many areas (Messenger and Rundegren, 2004). Finasteride (Propecia), which 
reduces androgen effects by blocking testosterone metabolism to the more active 5α-
dihydrotestosterone, was initially designed for prostate disorders (Kaufman et al., 
1998; Whiting et al., 2003).  The most recent drugs reported to stimulate hair growth 
as an unexpected side-effect are analogues of PGF2α and prostamide F2α, such as 
latanoprost and bimatoprost, used as eyedrops to reduce intraocular pressure in 
glaucoma. These drugs frequently stimulate eyelashes to lengthen, thicken and 
darken (Curran, 2009).  However, human hair follicles exhibit different behaviour 
depending on their body site.  For example hair greying with age occurs first above 
the ears before gradually spreading over the scalp (Keogh and Walsh, 1965).  There 
are also extreme differences in response to androgens which stimulate hair growth in 
many areas, such as the beard, have no effect on eyelashes and, in contrast, inhibit 
scalp follicles causing balding (Randall, 2007, 2008a).  Therefore, it is important to 
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determine whether PGF2α and prostamide F2α analogues can also stimulate scalp 
follicle growth.    
Why eyelash stimulation occurs with this glaucoma therapy is unknown; possibilities 
include stimulating blood flow to the eyelashes or direct effects on the eyelash 
follicles.  Latanoprost has been reported to relax rabbit ciliary arteries (Ishikawa et 
al., 2002).  Although eyelashes are rather specialised hairs which protect the eyes 
from foreign objects, they are produced by hair follicles and are regularly replaced via 
the hair cycle (Thibaut et al., 2009).  In this way they resemble all other hair follicles, 
including those on the scalp (Kligman, 1959; Higgins et al., 2009a).   
The initial aim of this study was to determine if scalp hair follicles could also respond 
to PGF2α related compounds and therefore could be useful for treating hair loss 
disorders. Working on the hypotheses that eyelash follicles resemble other hair 
follicles and that PGF2α is acting directly on the eyelash follicles themselves, 
experiments were carried out to see whether PGF2α could stimulate growth in 
isolated human scalp hair follicles in organ culture.  Isolated human scalp anagen hair 
follicles have an exciting and fascinating ability to grow in organ culture for several 
days, maintaining the epithelial & mesenchymal interactions (Reynolds et al., 1999; 
Rendl et al., 2005) and cell division necessary for the ordered synthesis of new 
pigmented hair as seen in vivo (Shorter et al., 2008) (See Figure 19); any stimulation 
of growth under these conditions cannot be due to effects on the vasculature.  
The difference between producing a long or short human hair is primarily due to 
alterations in the length of anagen, the growing part of the hair growth cycle, rather 
than the rate of hair growth which is relatively constant in vivo.  Anagen varies from 
several years in a large terminal scalp follicle, forming a long hair to only a few weeks 
for the short hairs on the finger (Saitoh and Sakamoto, 1970). During balding in 
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androgenetic alopecia, the length of scalp follicle anagen is substantially reduced and 
the resting phase, telogen, is increased (Whiting, 1993). When hypertrichosis of 
eyelashes was reported after unilateral topical latanoprost treatment of 89 glaucoma 
patients; changes to eyelashes including increased number, thickness, length and 
pigmentation had occurred in 5 of the patients in less than 3 weeks, similar to those 
patients who had received long term treatment (Johnstone, 1998), suggesting effects 
on follicles already in anagen.  The organ culture method used here is based on that 
established by Philpott et al (Philpott et al., 1990), but was extended to include daily 
observation of follicle morphology, to monitor if the follicle remained in anagen, and 
length measurement. These modifications reveal much more detail.  They allow 
assessment of any effects on the length of anagen and provide a more precise rate of 
growth, since the final length can be related to the number of days the follicle was 
actually growing.  They also enable a more accurate measurement of the increase in 
hair length, as apparent increases due to the upward movement of the hair when 
follicles enter the catagen-like stage are avoided. The overall increase in hair length 
over the experimental period incorporates both the effect on anagen and any 
alteration in growth rate.  
In line with the established method (Philpott et al., 1990), insulin was added to all 
culture conditions. Insulin advances the movement of ions across the plasma 
membrane (Irwin and Rippe, 2008) and acts as a stimulant of glucose uptake into 
cells and storage (Cushman and Wardzala, 1980; Suzuki and Kono, 1980; Leney and 
Tavare, 2009).  It is not used to supplement the medium in experiments involving 
minoxidil as it interfers with minoxidil’s effects (Shorter et al., 2008). 
Follicles grew well in control conditions regularly increasing in length throughout the 
culture period.  Observation of cultured follicles indicated that this increase in hair 
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follicle length was due to the production of a hair fibre and associated inner and outer 
root sheathes, but the connective tissue sheath did not increase in length and 
remained at the same level as in day 0; growth was not due to a loss of follicle 
morphology during culture (Figure 19).  Follicles which showed no increase in length 
over 3 days were assumed to be damaged and removed from the experiment. 
In control conditions human scalp hair follicles grew at a rate of about 0.1 mm per 
day (Figure 20) and some hair follicles developed catagen-like changes in their bulb 
morphology, but most follicles (about 70%) maintained their anagen bulb 
morphology during the nine days of culture (Figure 21). Those follicles which were 
designated as undergoing catagen-like changes in their hair bulb morphology showed 
that pigmentation had ceased and the base of the hair fibre moved upward, losing 
contact with the regulatory mesenchyme-derived dermal papilla, which became 
rounded up into a ball of cells (Figure 19c, d).  After 2 days there was a gradual 
increase in the number of follicles showing catagen-like changes in the hair bulb 
region.  The overall amount of hair follicle synthesised in organ culture was calculated 
from the increased length of each follicle on the last day of the experiment, day 9, or 
the last day that follicle maintained a normal anagen morphology; in control 
condition about 40% hair fibre was synthesised (Figure 22).   
PGF2α stimulated individual isolated scalp hair follicles from 10 different people to 
grow significantly faster and stay in anagen longer in organ culture, resulting in about 
a third more new hair being synthesised over 9 days especially with 100 & 1000 nM 
(Figures 23-26).  This was a dose-responsive effect, though increasing over 100 nm 
caused no further enlargement; this would concur with the saturation of a receptor-
mediated effect via the PGF2α receptor, FP, as reported in other tissues (Sharif et al., 
1999; Liang et al., 2003; Woodward et al., 2003).  
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All 3 concentrations of PGF2α stimulated human scalp hair follicles to grow faster in 
vitro; increased growth rate significantly by about 16% with 10 nM (P < 0.01**) while 
100 & 1000 nM had a similar and greater effect, about 25% (P < 0.001***) (Figure 
24).  PGF2α slightly raised the number of follicles remaining in anagen by about 6% 
with 10 nM (P < 0.05*) and by about 10% with 100 & 1000 nM (P < 0.01**) (Figure 
25).  PGF2α also stimulated the overall amount of hair follicle synthesised in organ 
culture by about 20% with 10 nM (P < 0.05*), by about 32% with 100 nM (P < 0.01**) 
and by about 30% with 1000 nM (P < 0.01**) (Figure 26).   
To confirm that the PGF2α effects was through prostanoid FP receptor in the hair 
follicles themselves, the ability of the FP antagonists, AS604872 and AL-8810, to 
block PGF2α-stimulated hair growth in organ culture was assessed.  Both AS604872 
and AL-8810 have been reported to be potent FP antagonists in human and feline 
ocular tissue (Sharif et al., 1999; Woodward et al., 2007; Woodward and al., in press) 
with pA2 of about 7.33 against the human FP receptor (Cirillo et al., 2007).  DMSO 
(0.01%) was added to the control media as this was necessary to solubilise the FP 
antagonists, however, it caused no significant differences in growth rate, percentage 
of follicles remaining in anagen at day 9 nor the overall amount of hair follicle 
synthesised compared to the original control media (see Figures 20-22; 31-33).  
Similarly, the presence of 0.01% DMSO did not alter any of responses to 100 nM 
PGF2α (see Figures 24-26; 31-33). PGF2α alone again significantly increased all 
parameters compared to the control (hair growth rate (P < 0.001***; Figure 31), the 
% of follicles remaining in anagen (P < 0.01**; Figure 32) and the total amount of hair 
produced (P < 0.01**; Figure 33)), but those stimulatory effects were blocked when 
combined with either the FP antagonist, AS604872, at 1µM or AL-8810 at 10µM (P < 
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0.01**- 0.001***; Figures 30-33). Neither FP antagonist alone significantly inhibited 
any parameters of scalp hair growth compared to the control conditions.  
The saturation of the effect at receptor relevant concentrations and the ability of the 
potent FP antagonists, AS-604872 and AL-8810, to block the stimulatory effects of 
PGF2α at all hair growth parameters in this dynamic bioassay indicate a receptor-
mediated response.  
Latanoprost, the PGF2α analogue, has also been reported to increase eyelash growth 
in human beings (Johnstone, 1997).  To determine whether latanoprost can stimulate 
scalp hair growth in vitro, the pharmacological responses of different concentrations 
of latanoprost on human scalp hair follicles was also investigated in organ culture.  
Latanoprost had similar effects to the natural ligand, PGF2α, stimulating individual 
isolated scalp hair follicles from 10 different people to grow significantly faster by 
about 18% with 10 nM (P < 0.01**) while 100 & 1000 nM had a similar and greater 
effect, about 26% (P<0.001***) (Figure 27).  Latanoprost also slightly raised the 
number of follicles remaining in anagen by about 6% with 10 nM (P < 0.05*) and by 
about 10% with 100 & 1000 nM (P < 0.01**) (Figure 28) and increased the overall 
amount of hair follicle synthesised in organ culture by about 22% with 10 nM 
(P<0.05*), by about 33% with 100 nM (P<0.01**) and by about 31% with 1000 nM 
(P<0.01**) (Figure 29).   
This stimulation of the growth of human scalp hair follicles mirrors that seen in vivo 
in monkeys. Uno et al., (2002) also reported that different concentrations of 
latanoprost had variable responses in scalp hair growth in stump-tailed macaques; 
the lower concentration (115 nM) caused minimal hair growth, whilst the higher 
concentration (1.15 µM) caused significant hair growth.  Using a murine model, the 
stimulatory effects of latanoprost on the hair follicles and the follicular melanocytes 
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in both the telogen and anagen stages were observed following treatment with PGF2α 
and several analogues including latanoprost; they also stimulated conversion from 
the telogen to the anagen phase (Sasaki et al., 2005), also indicating a non-eyelash 
follicle response.  
The scalp hair follicle response to latanoprost in organ culture, like that to PGF2α, was 
also a dose-responsive effect, though increasing over 100 nM caused no further 
stimulation; suggesting the saturation of a receptor-mediated effect.  
Importantly, these results indicate that PGF2α and latanoprost can stimulate growth in 
human scalp hair follicles as well as eyelashes. The strong similarities in the 
responses to a natural ligand, PGF2α, and the synthetic analogue, latanoprost, could 
suggest that both are working through the same receptors in the hair follicles.  
Alternatively, this could reflect the maximum increase in growth that can be acheved 
in organ culture under these conditions; recent experiments have highlighted that the 
conditions employed can affect follicular responses (Shorter et al., 2008).  Since this is 
occurring in isolated follicle organ culture without any possibility of involving 
alterations in blood supply, interactions with other skin tissues or circulating cells, 
direct effects via receptors in hair follicle cells seem likely. The PGF2α and latanoprost 
receptor-mediated stimulation of hair growth possibly occur via altering paracrine 
transcription factors mediated by dermal papilla cells.  Interaction of PGF2α and 
latanoprost with their receptor, FP, trigger Gq protein-coupled activating Ca2+ 
signalling pathways, which lead to initiating second messenger production of inositol 
1,4,5-triphosphate and activation of protein kinase C. This can cause activation and 
increase in the cytoplasmic β-catenin protein level. The activated β-catenin protein is 
then translocates to the nucleus and forms a complex with members of Lef1/Tcf 
family of transcription factors and subsequently regulates the expression of Wnt-
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target genes.  The β-catenin is at the core of the Wnt signalling pathway and Wnt/β-
catenin signalling pathway has a crucial role in the hair follicle development and 
cycling (Van Genderen et al.,  1994); several studies have suggested that multiple 
steps in hair follicle development and cycling are dependent upon a change in the 
transcriptional status of genes that are regulated by Wnt/β-catenin signalling 
pathway (Reddy et al., 2001; Merril et al., 2001; DasGupta and Fuchs, 1999). In mice, 
it was demonstrated that high level of β-catenin cause rapid proliferation of matrix 
cells (Gat et al., 1998; Chan et al., 1999).  Selective ablation of Lef1 gene in the 
epidermis inhibits hair follicle development (Van Genderen et al.,1994). In contrast, 
transgenic mice over-expressing Lef1 resulted in de novo hair follicle formation in the 
skin and forced activation of Wnt/β-catenin signalling in the epidermis induced extra 
hairs (Gat et al., 1998; Millar S 2002; Alonso and Fuchs, 2003). It was demonstrated 
that increase in the levels of nuclear β-catenin in dermal papilla cells induced stem 
cell differentiation (Hino et al., 2005) and chronic activation of β-catenin results in 
proliferation of the outer root sheath and other epithelial components of the hair 
follicle (Seidensticker and Behrens, 2000).  Many studies in mouse models have 
revealed that Wnt/β-catenin signalling plays a crucial role in hair follicle 
morphogenesis (DasGupta and Fuchs, 1999;  Huelsken et al., 2001).  Dkk4 is a direct 
target gene of Wnt/β-catenin signalling and is predominantly expressed in the hair 
follicle placode (Sick et al., 2006; Bazzi et al., 2007).  Ablation of β-catenin blocks HF 
formation all together (Huelsken et al., 2001) and introducing stabilised β-catenin 
induced resting hair follicles into anagen and promoted growth of existing follicle in 
mice (Celso et al., 2004).  
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Another possible mechanism of PGF2α and latanoprost receptor-mediated action is 
via Ca2+ signalling pathway (Figure 73). Interaction of PGF2α and its analogues with 
FP trigger Gq protein-coupled activating Ca2+ signalling pathways which helps 
releasing of other paracrine regulatory transcription factors by nucleus which may 
act on the proliferation and differentiation of matrix keratinocytes and melanocytes 
independent of β-catenin. It has been proposed that intracellular Ca2+ is involved in 
the differentiation, proliferation, and gene regulation of precursor cells fated to 
become hair cells (Correia et al., 2001);  Ca2+ is critical for mechanosensory 
adaptation and modulation in hair cells.  It was demonstrated by a study that a mobile 
Ca2+ is highly concentrated in hair cells (Lenzi and Roberts, 1994). Most processes of 
terminal keratinocyte epidermal differentiation are controlled by the intracellular 
calcium concentration (Brown et al., 1995).  Few Wnt-mediated pathways have been 
proposed to function independent of β-catenin. One pathway involves activation of 
calcium/calmodulin-dependent kinase II (CamKII) and protein kinase C (PKC); Ca2+ 
has been implicated as an important second messenger in all of these pathways 
(Kohn and Moon, 2005) supporting the Ca2+ signalling pathway action independent of 
β-catenin.  Activation of specific prostanoid FP receptor initiate second messenger 
production (inositol 1,4,5-trisphosphate) which can initiate signalling via 
extracellular signal-regulated kinase (ERK1/2) pathway to initiate target gene 
transcription.  It has been suggested that target gene transcription can occur via 
prostanoid-receptor-mediated trans activation of receptor tyrosine kinases (RTKs) 
such as the epidermal growth factor receptor (EGFR) (Jabbour., 2006). The activation 
of target genes such as COX-2 can promote prostanoid-receptor signalling and can 
also in turn elevates the expression of pro-angiogenic genes such as VEGF, bFGF, Ang-
1 and Ang-2 (Tsujii et al., 1998; Sales et al., 2002; Jabbour., 2006).  The VEGF is one of 
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the possible paracrine factors which may alter hair growth, therefore, this could also 
be one of the possible routes for hair growth stimulation via FP.  Several studies are 
supporting the involvement of VEGF in hair growth.  Cultured dermal papilla cells had 
been shown to express VEGF (Hibberts, 1996; Lachgar et al., 1996b; Merrick, 1999) 
and catagen and telogen phase human scalp hair follicle dermal papilla cells were 
found to express decreased levels of VEGF mRNA (Lachgar et al., 1996).  Minoxidil, a 
treatment for androgenetic alopecia, has been shown to stimulates VEGF mRNA 
expression in cultured human dermal papilla cells (Lachgar et al., 1998).   
To investigate whether human scalp hair follicles contained PGF2α receptor, FP, 
protein immunohistochemistry was carried out.  
Initially, in order to learn the structure of the skin and hair follicle, histological 
staining of red deer (Cervus elaphus) and human skin sections was performed using 
Sacpic stain.  It was more difficult to obtain good vertical sections of human scalp skin 
than deer skin due to the smaller size of human follicles as well as the small sample 
sizes and limited availability.  Longitudinal and horizontal cross cryosections were 
stained using the histological stain, Sacpic, which provides a good differentiation of 
the skin and hair follicle structure (Nixon, 1993; Nutbrown and Randall, 1996).  
Sacpic staining technique is better than other histochemical staining methods such as 
haematoxylin and eosin staining because it employes a number of different dyes 
which successfully highlight the different layers of hair follicles in both longitudinal 
and cross sections at the level of light microscope.  It coloured the dermis an obvious 
blue/green in both deer and human skin and the hair follicle layers were easily 
differentiated into the inner root sheath which stained bright red, the outer root 
sheath (blue) and the connective tissue sheath a darker blue colour with black/blue 
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nuclei.  Fully keratinised parts of the hair fibre and the epidermis were stained yellow 
(Figure 34).  The histological staining of human scalp skin showed a thin epidermis, a 
collagenous dermis beneath it and the underlying subcutaneous fat layer in which the 
hair follicle bulb extends down into it (Figure 35).  Similar Sacpic staining results in 
the skin and hair follicles were observed in human skin by Nutbrown and Randall 
(1996) in deer by Croft (2002) and in sheep by Nixon (1993).   
Immunohistochemistry was initially performed using a polyclonal antibody against 
cytokeratins 5 & 6 to learn the technique as this is a highly expressed cytoskeletal 
protein in the hair follicle outer root sheath (Hans-Jürgen et al., 1987).  The other 
proteins of interest are much less highly expressed, since FP and EP2 are cell surface 
receptors (Srinivasan et al., 2002) while NKI-beteb recognises 7 and 100-Kd cell 
surface melanosomal antigens on melanocytes (Hayashibe et al., 1986; Randall et al., 
2008).  Negative controls were carried out on parallel sections to the antibody stained 
sections for all the immunohistochemistry experiments to detect whether any non-
specific staining occurred and to ensure any positive staining was due to the binding 
of the antibody to the specific antigen (Polak, 2003).  Three controls were performed; 
initially the primary antibody was replaced with 1.5% normal mouse serum or 1% 
normal goat serum, checking that the secondary antibody or any of the later reagents 
were not binding non-specifically to the tissue without the presence of the primary 
antibody.  In the second one, the secondary antibody was excluded and replaced with 
PBS, this checked that the AEC colour system is not binding to the primary antibody 
without the presence of the secondary antibody.  In the third control both primary 
and secondary antibodies were replaced, this checked that the blocking procedure 
had been efficient and the AEC colour detection system was not activated alone.   
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The most important factors which affect the staining result are antibody 
concentration, the antibody incubation time, the blocking serum types and the 
blocking serum concentration (Polak, 2003).  Although higher primary antibody 
concentration can give stronger staining results, the antibody concentrations were 
optimised to balance between gaining the best staining results and reducing the 
chance of getting non-specific staining.  Increasing serum blocking concentration, 
incubation time and using additional blocking serum can reduce non-specific staining, 
but too extensive blocking techniques can also reduce the intensity of the positive 
staining.  
When cytokeratins 5 & 6 expression was investigated in human skin and hair follicles 
using immunohistochemistry, positive staining was detected in the outer root sheath 
of the hair follicles (Figure 36b, d).  The negative controls showed no staining (Figure 
36a, c), indicating that the staining seen was due to specific binding of the primary 
antibody with the target antigen.  These results correlate to previous studies using 
human hair follicles (Stark et al., 1987).  Similar results obtained by previous studies 
in the deer follicle (Croft, 2002) and sheep wool (Bond et al., 1996), in which positive 
staining for cytokeratin 5/6 occurred in the outer root sheath and hair medulla. 
The expression of melanoma associated antigen, a melanocyte marker, was also 
investigated in human hair follicles using a monoclonal primary antibody to human 
melanoma associated antigen, NKI-beteb to confirm the location of melanocytes as 
these are possibly targets of PGF2α related drugs as they cause darkening of eyelashes 
(Reynolds et al., 1998).  Staining occurred in the hair follicle bulb matrix above and 
around the upper part of the dermal papilla (Figure 37b).  The negative controls 
showed no staining (Figure 37a) indicating that the positive staining was due to 
specific binding of the antibody to melanoma associated antigen.  Similar results have 
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been reported (Horikawa et al., 1996; Commo and Bernard, 2000; Randall et al., 
2008) in which positive staining using NKI-beteb antibody occurred in the human 
hair follicle bulb above and around the upper part of the dermal papilla.  The hair 
bulb melanocytes, around and above the upper outer edges of the dermal papilla are 
the active hair follicles melanocytes which are necessary for hair pigmentation 
(Staricco, 1960, 1963); i.e. they would be the direct, or indirect, target of PGF2α 
analogues in eyelash darkening. Melanoma associated antigen was detected in other 
areas of the hair follicle in the outer layer of the outer root sheath below the level of 
the sebaceous gland but these cells were not actively pigmenting keratinocytes.  NKI-
beteb antibody recognises mature and immature melanosomes (premelanosomes) 
which may be present on very immature melanocytes before starting pigment 
synthesis (Vennegoor et al., 1988); this area is believed to be the site of melanocyte 
stem cells (Commo and Bernard, 2000; Nishimura et al., 2002; Nishimura et al., 
2005). 
To confirm the presence of FP in human scalp hair follicles, the location of FP protein 
was also investigated by immunohistochemistry using two polyclonal antibodies to 
FP (goat polyclonal anti-human PGF2αR (N-18 & T-15) antibodies).  These antibodies 
were the only types commercially available and required extensive optimisation.  FP 
was detected in the connective tissue sheath and the dermal papilla of human scalp 
hair follicle (Figures 38b, c, e, f).  There was no sign of staining in areas containing 
melanocytes. These results suggest that FP protein is located in the mesenchyme-
derived components of human hair follicle, but not in the epithelial or melanocyte 
cells. Since this work was done, a paper was published reporting FP protein 
expression in the dermal papilla, the connective tissue sheath and the outer root 
sheath companion layer of human scalp hair follicle by immunohistochemistry using 
 
 
245 
 
different polyclonal primary antibodies raised in rabbit; at 1/200 dilution (Colombe 
et al., 2008).  
To confirm the presence and localisation of FP in human scalp hair follicles, the 
expression of the FP gene was examined in microdissected whole lower anagen scalp 
hair follicles using RT-PCR.    
When cDNA was synthesised from each sample, it was first investigated using the 
positive control primers specific to cytoskeletal protein, β-actin.  RT-PCR results of 
this positive control highly expressed cytoskeletal protein gene for all cDNAs showed 
bands of expected product size, 838 bp, indicating that the isolated RNA samples 
were of sufficient quality for RT-PCR to be performed effectively using different 
primers (Davies, 2001; Croft, 2002) (Figure 40).  A negative control, in which the 
template cDNA was excluded from the reaction mixture, was used in parallel to all 
RT-PCR investigations.  None of the negative controls generated any PCR product 
(Figure 40) showing that the β-actin RT-PCR products resulted from the amplification 
of the cDNA samples and there was no DNA contamination in the reaction mixtures.  
All the β-actin PCR products from whole hair follicle samples appeared as sharp 
bands of expected amplification size with no other bands present indicating that 
primers are binding specifically to the cDNA template and there is no contamination 
in the positive reaction mixtures, and the cDNA from each sample was of appropriate 
quality for analysis of the FP gene. 
Due to limited work on this gene, a literature search for a specific primer pair to 
detect FP gene expression from human tissues was unsuccessful.  Therefore, specific 
primers were designed to detect the FP gene from human tissues.  There are a 
number of characteristics that increase the specificity of a primer sequence which 
were considered while designing the primers.  The length of the primer sequences 
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were 20 as they should be between 17 to 25 nucleotides long; the primers need to be 
long enough to reduce the chance of mismatching which results from the sequence 
being found at non-target sites, while too long sequences will decrease the efficiency 
of the PCR as they take longer to hybridise to the template strand (Dieffenbach et al., 
1995).  The proportion of guanine (G) and cytosine (C) bases in the primer sequence 
should be not more than 60%, as high GC ratio affects the melting and denaturing 
temperature due to the strong three hydrogen bond connections between G and C.  
Therefore, the primers designed were well matched for GC content and melting 
temperature to give an annealing temperature which is a few degrees below the 
lowest melting temperature of the primer pair.  The chances of non-specific binding 
will increase with primers with higher melting temperature (Dieffenbach et al., 
1995).  The primers were designed avoiding a rich GC composition at the 3' end, as 
high GC 3' end increases the stability of the two complementary sequences and 
therefore decreases the ease of releasing them during the denaturation cycle.  Also 
during primer design, repeating any of the bases, or sequence of bases, was avoided 
as base repetition will increase the primer chance to mismatch (Kwok et al., 1990).  
The expected size of the base pair PCR product also had to be considered; a very small 
base pair PCR product e.g. 100 bp would have been difficult to detect as it can be lost 
easily on the gel.  The primer pair were not complementary to each other, especially 
at the 3' end, as this leads to the formation of primer-dimers (Dieffenbach et al., 
1995), meaning that the primers would be in competition with the template DNA for 
amplification resulting in an inefficient PCR.   
The designed new primers to detect the FP gene were tested on GenBank to check 
theye were specific for FP and then first checked on rat liver tissue cDNA which is 
known to express the FP gene (Arend et al., 2005; Koukoui et al., 2006).  Rat liver was 
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used first as a positive control tissue as it was available and easy to prepare 
compared to the valuable human hair follicle cDNA.  Human hair follicle cDNA 
samples are also more difficult to prepare due to ethical considerations, the limited 
sample availability and the long time needed to isolate and prepare the hair follicles 
before cDNA synthesis.  An amplified band of the expected size for FP gene (1100bp 
in rat) was obtained after agarose gel electrophoresis (Figure 42).   
 When the methods were optimised successfully they were applied to the human 
samples.  All five human scalp whole hair follicle cDNA samples showed expected size 
bands (Figure 43).  The negative controls, in which the template cDNA was excluded 
from the reaction mix, were clear of any bands.   
The FP RT-PCR products were shown as distinct bands of expected amplification size 
of 1080 bp on the agarose gel and sequence analysis confirmed the identity of the FP 
PCR products formed. Human hair follicle FP PCR products demonstrated 99% 
homology to the known human FP gene sequence (Figure 44).  
To localise the expression of the FP gene in scalp hair follicles, gene expression was 
investigated in hair follicle components: the dermal papilla, the connective tissue 
sheath surrounding the bulb, the hair bulb matrix, the follicle at the level of the 
“bulge” area and the lower follicle between the bulb and the “bulge” area.  The 
components were microdissected from isolated hair follicles from three human scalp 
hair follicle samples using measurements from an experiment done on a fresh scalp 
hair follicle sample as sebaceous gland is hard to detect from samples treated with 
RNAlaterTM.  The cDNAs were prepared separately from the micro-dissected hair 
follicle components from each individual and RT-PCR performed first for the positive 
control gene, β-actin.  All hair follicle components expressed the β-actin gene (Figure 
46), but the strength of the expression was generally lower than that of the whole 
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lower hair follicles (Figure 40).  The only component with similar levels of expression 
was the area of the follicle between the “bulge” and the hair bulb.  The expression 
varied between the components with the lower follicle, the hair bulb matrix and the 
“bulge”, i.e. epithelial cell containing areas, were relatively high while the 
mesenchyme-derived areas, the dermal papilla and the bulbar connective tissue 
sheath were much lower (Figure 46).  This indicates that the cDNA preparation was 
successful in general, but the quantities of cDNA were small for the dermal papilla, 
the connective tissue sheath and the “bulge” area.  This related to their composition 
as all three contain smaller amounts of cells compared to the epithelial hair matrix 
and lower follicle. 
None of PCR of the hair follicle components cDNA using primers for FP showed bands 
(Figure 47).  This would not be expected if sufficient cDNA was available since the 
whole hair follicle samples all expressed the receptor gene.  Since the dermal papilla 
is the main regulatory part of the hair follicle (Oliver, 1970; Oliver and Jahoda, 1989a; 
Jahoda, 1992; Jahoda et al., 2001; Yang and Cotsarelis, 2010) and the polyclonal 
antibody to the FP stained this area, it seemed likely that gene expression of the 
receptor would have been detected in the dermal papilla samples at least.  Similarly, 
the connective tissue sheath around the bulb could have been expected to exhibit 
gene expression since it has many similarities to the dermal papilla, including the 
ability to induce new hair growth (Jahoda and Reynolds, 2001) and some receptor 
immunostaining was also detected here.   
 The low cDNA quantity indicated in the β-actin PCR results (Figure 46) seemed a 
reasonable explanation for these negative results.  This is particularly unsurprising 
for the mesenchyme-derived tissues as hair follicle dermal papilla and connective 
tissue sheath contain small number of cells and most of their bulk is made of 
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extracellular proteins.  The difference between β-actin and FP gene expression even 
in the whole follicle samples (compare figures 40 and 43) reflect the much lower 
expression of FP receptor genes which are encoding receptors for paracrine factors, 
compared to those for the highly expressed cytoskeletal fibre, β-actin. 
Therefore, no conclusions could be drawn about whether there was gene expression 
of FP in these areas.  Since there was more cDNA for the epithelial areas, with the 
lower follicle between the “bulge” and hair bulb samples containing about the same 
as the whole follicle extracts, this is less likely to be the explanation for the lack of 
expression seen. An absence of expression would also concur with the 
immunohistochemical results.  These experiments need to be repeated with either 
higher number of hair follicle components microdissected from each individual or the 
RNA samples must be amplified before converting to cDNA.  Due to the limited human 
scalp skin sample sizes and availability, RNA amplification was the only practical 
route. 
Therefore, the experiment was repeated using a further three human scalp skin 
samples, but the RNA from each hair follicle component was amplified before cDNA 
synthesis.  All samples from each of the 3 individuals showed stronger bands for the 
positive control, β-actin, gene expression similar to those of intact anagen follicles 
(Figure 49).  However, after PCR to detect FP gene expression, only cDNA from the 
dermal papilla and the connective tissue sheath around the bulb showed appropriate 
bands corresponding to FP gene (1080 bp) (Figure 51); none of the other three 
components, the matrix, the follicle from bulge area and the lower follicle between 
the bulge and the bulb, showed any detectable bands.  When the identities of the 
dermal papilla and connective tissue sheath PCR products were checked by sequence 
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analysis, they demonstrated 98% & 95% homology respectively with the known 
human FP gene sequence (Figure 52). 
The expression of the FP gene only in dermal papilla and connective tissue sheath of 
scalp hair follicles corresponded to the location of prostanoid FP receptor protein in 
the mesenchyme-derived parts by immunohistochemistry.  Colombe et al (2008) also 
observed the expression of the FP gene by RT-PCR in human hair follicle and cultured 
cells from the dermal papilla and the connective tissue sheath, supporting this 
receptor gene expression in human scalp follicles and the location.  
To investigate the in vivo relevance of these in vitro organ culture experiments the 
presence of prostanoid, dihydroprostaglandins and isoprostane lipid mediators were 
investigated in anagen follicles isolated from human scalp skin from 3 individuals, 
using lipidomic approaches. Liquid chromatography electrospray tandem mass 
spectrometry (LC/ESI-MS/MS) of follicle lipid extracts clearly identified 7 
prostanoids: PGF2α, PGE1, PGE2, PGD1, PGD2, TXB2 and 6-keto PGF1α; a 
dihydroprostaglandin, 13, 14 dihydro-15-keto PGE2 and an isoprostane, 8-iso-PGE2 
(Figure 54).  The highest amount of naturally occurring lipid mediators detected in 
scalp hair follicle were PGE2 (17.192 ± 2.2 pg/mg protein) and PGF2α (13.39 ± 1.8 
pg/mg protein) (Figure 55).  The levels of the PGF2α were lower than those previously 
reported in human myometrium tissue at term gestation before labour onset (Durn et 
al., 2010a) only about 25% of the level, whilst, the levels of the PGE2 were higher than 
those reported in human non labour myometrium tissue by about 90% of the level.  
The eicosanoids are known to have significant physiological roles in the skin 
including repairs of cutaneous integrity and the restoration of skin function following 
injury (Ziboh et al., 2000).  
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The presence of high levels of PGE2 in the isolated scalp hair follicles was interesting. 
The PGE2 has been implicated in causing re-growth of hair in mice (Torii et al., 2002) 
and a prostaglandin E receptor, EP3, was localised to the dermal papilla of mouse 
anagen follicles using in situ hybridization.  During telogen, the EP3 mRNA expression 
disappeared, but was detected again in the dermal papilla of new anagen follicles.  
PGE2 production has also been demonstrated in cultured rat vibrissae dermal papilla 
cells (Lachgar et al., 1996) and human dermal papilla cells (Michelet et al., 1997) by 
high pressure-liquid chromatography/enzymatic immunoassay (HPLC/EIA) analysis. 
Therefore, the location of EP2 receptor protein was also investigated in human scalp 
hair follicles by immunohistochemistry using a polyclonal antibody to EP2 (goat 
polyclonal anti-human PGE2αR antibody).  After optimisation, EP2 was detected in the 
connective tissue sheath and the dermal papilla of human hair follicles (Figures 56b, 
d), suggesting that EP2 protein is also located only in the mesenchyme-derived 
components of human hair follicle.  The expression of EP2 has also been reported in 
the dermal papilla and the outer root sheath of human scalp hair follicle by 
immunohistochemistry using different polyclonal primary antibodies raised in rabbit; 
at 1/200 dilution (Colombe et al., 2008). 
Bimatoprost, a prostamide F2α analogue related to PGF2α, currently the most efficient 
treatment to reduce intraocular pressure in glaucoma, used as eyedrops, also 
frequently stimulate eyelashes to lengthen, thicken and darken (Curran, 2009).  
Bimatoprost was licensed as Latisse for the treatment of hypotrichosis of the 
eyelashes by the FDA in December 2008 (NDA 022369).  Therefore, the last aim of 
this study was to determine whether the prostamide F2α analogue, bimatoprost, can 
act on scalp hair follicles and therefore could be useful for treating hair loss disorders.  
Working again on the hypotheses that eyelash follicles resemble other hair follicles 
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and that bimatoprost is acting directly on the eyelash follicles themselves, we 
investigated whether this compound could stimulate growth in isolated human scalp 
hair follicles in organ culture.  
Since bimatoprost needed to be solubilised in DMSO, 0.01% DMSO was added to all 
control conditions used for these experiments on scalp hair follicle samples from a 
further 10 individuals but this did not cause any difference to control follicles which 
behaved as they had in the earlier experiments.  Most of the hair follicles (>70%) 
increased in length regularly during the nine day culture period in all conditions.   
Bimatoprost caused individual isolated scalp hair follicles from 10 different people to 
grow significantly faster by about 16% with 10 nM (P < 0.01**) while 100 & 1000 nM 
had a similar and greater effect, about 27% (P<0.001***) (Figure 58).  Bimatoprost 
also slightly raised the number of follicles remaining in anagen by about 7% with 10 
nM (P < 0.05*) and by about 11% with 100 & 1000 nM (P < 0.01**) (Figure 59) and 
increased the overall amount of hair follicle synthesised in organ culture by about 
20% with 10 nM (P<0.05*), by about 35% with 100 nM (P<0.01**) and by about 33% 
with 1000 nM (P<0.01**) (Figure 60).   
This was a dose-responsive effect, though increasing the bimatoprost concentration 
over 100 nM caused no further enlargement; this would concur with the saturation of 
a receptor-mediated effect as reported in other tissues (Sharif et al., 1999; Liang et al., 
2003; Woodward et al., 2003).  To confirm whether the bimatoprost effects were 
through prostamide F2α receptors and/or FP in the hair follicles themselves, the 
effects of the potent prostamide F2α receptor antagonist, AGN211336, with a pA2 of 
7.6 against the human prostamide receptor (Woodward and al., in press) and the FP 
antagonist, AS604872, on bimatoprost-stimulated hair growth in organ culture was 
also studied.  Bimatoprost (100 nM) alone again significantly increased all hair 
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growth parameters compared to the control (hair growth rate (P < 0.001***), the % of 
follicles remaining in anagen (P < 0.01**) and the total amount of hair produced (P < 
0.01**)) (Figures 62-65) but these stimulatory effects were blocked when combined 
with either AGN211336 or AS604872 at (1µM) (P < 0.01**- 0.001***) (Figures 61-
65).  Since the prostamide F2α receptor antagonist, AGN211336, and the FP 
antagonist, AS604872, both similarly blocked the stimulatory effects of bimatoprost 
on scalp hair growth, suggesting the requirement of both receptors for significant 
bimatoprost action.  
Importantly, these results indicate that bimatoprost can stimulate human scalp hair 
follicles growth as well as that of eyelashes.  The saturation of the effect at receptor 
relevant concentrations and the ability of the potent receptor antagonists, 
AGN211336 and AS604872, to block the stimulatory effects of bimatoprost on all hair 
growth parameters in this dynamic bioassay also indicate a receptor-mediated 
response involving prostamide F2α and FP receptors. Thus, bimatoprost also act on 
receptors located within the hair follicle itself to generate paracrine transcription 
factors to regulate the expression of target genes as mentioned earlier for PGF2α and 
latanoprost.  
To prove the presence of prostamide F2α receptors in human scalp hair follicles, the 
expression of prostamide F2α receptor genes in isolated scalp hair follicles from 
another 5 individuals was investigated using molecular biological methods.  The 
prostamide F2α receptor genes are alternative splicing variants of FP such as FP 
variant 4, which appears to heterodimerize with FP to create a bimatoprost-sensitive 
receptor (Liang et al., 2008).  Specific primers (Liang et al., 2008) were used first to 
detect all the 5 splicing variants of FP, altFPs, and this detected three bands from 
scalp hair follicles cDNA corresponded to wild-type FP and two larger splice variants 
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of between 321 bp and 462 bp size (Figure 68a).  To verify the expression of the FP 
variants, specific primers were used to detect the expression of the 5 previously 
reported splice variants, altFP5, altFP4, altFP3, altFP2, altFP1 (Liang et al., 2008).  
Primers for variants altFP5, altFP3 and altFP2 were taken from (Liang et al., 2008); 
those for variants altFP4 and altFP1 were designed new as described previously.  All 
scalp hair follicle samples expressed genes for altFP4 and altFP1 only (Figure 68b, c) 
and sequence analysis of the PCR products confirmed their identities (Figure 69a, b).  
To localise the expression of prostamide F2α receptor genes in scalp hair follicles, gene 
expression was investigated in hair follicle components as described previously for 
FP.  These included: the dermal papilla, the connective tissue sheath surrounding the 
bulb, the hair bulb matrix, the follicle at the level of the “bulge” area and the lower 
follicle between the bulb and the “bulge”.  The components were microdissected from 
isolated hair follicles from three individuals and the RNA extracts were each 
amplified before cDNA synthesis.  All cDNA samples gave good bands when RT-PCR 
was carried out β-actin (Figure 49).  However, when the primer set for altFPs were 
used only the DP and CTS exhibited three bands from all 3 samples (Figure 70a) like 
those seen in the intact follicle (Figure 68a).  When the primers to detect individual 
FP splice variants: altFP5, altFP4, altFP3, altFP2, altFP1 were used, only the dermal 
papilla and connective tissue sheath around the bulb expressed genes for altFP4 and 
altFP1 (Figure 70b, c); the identities of the PCR products were also confirmed by 
sequence analysis (Figure 71a, b).  None of the other scalp hair follicle components, 
the hair bulb matrix, the follicle at the level of the “bulge” area and the lower follicle 
between the bulb and the “bulge”, developed any bands (Figure 70).  This parallels 
the location of the FP gene discussed earlier. The alternative splicing variants of the 
FP gene such as FP variant 4 which appears to heterodimerize with FP to create a 
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bimatoprost-sensitive receptor, altFP4, (Liang et al., 2008); genes for prostamide F2α 
receptor such as altFP4 have been identified in the human ocular tissue (Liang et al., 
2008).  
The identification of appropriate prostamide F2α receptor gene expression, FP 
variants 4 and, to a lesser extent, 1, and native FP genes in scalp hair follicles and in 
the dermal papilla and connective tissue sheath around the bulb strongly support the 
hypothesis that PGF2α and prostamide F2α analogues act directly on hair follicles via 
receptors within them. The location of FP protein (Figure 38) and the gene 
expression of FP and splice variants altFP4 & 1 (Figures 51, 70) only in the 
mesenchyme-derived dermal papilla and connective tissue sheath of scalp hair 
follicles is particularly interesting.  The dermal papilla determines the type of hair 
formed by a follicle by producing paracrine signals to control other follicular 
functions (Jahoda et al., 1984; Jahoda, 1992) and the connective tissue sheath around 
the bulb can replace this function (Reynolds et al., 1999).  Reports of prostaglandin 
metabolising enzymes and FP in cultured dermal papilla cells from human scalp hair 
follicles (Colombe et al., 2007; Colombe et al., 2008) support this localisation in the 
dermal papilla.  The absence of any relevant prostanoid receptors from the bulb 
keratinocytes which form the hair or the melanocytes which produce the pigment and 
from the “bulge” region, the site of epithelial (Sotiropoulou et al.) and melanocyte 
stem cells (Nishimura et al., 2005), strongly suggests that the dermal papilla is 
coordinating follicular responses of increased growth.  This is presumably by altering 
its production of paracrine factors which influence the activity of the bulb 
keratinocytes and melanocytes. These results suggest that the glaucoma drugs e.g. 
PGF2α, latanoprost and bimatoprost which darken eyelashes as well as increasing 
their length (Curran, 2009; Law, 2010) by actions on the keratinocytes which make 
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the hair and melanocytes which produce the colour pigments act via the dermal 
papilla acting as a single regulatory component which interprets the signals to other 
follicular cell types.  
Overall, these experiments demonstrated that the PGF2α, its analogue, latanoprost, 
and the prostamide F2α analogue, bimatoprost, can stimulate human scalp hair growth 
in organ culture i.e. mirroring the stimulation of eyelashes known to occur in vivo. 
These strong similarities in responses by eyelash and scalp follicles contrast with 
their differing biological responses to androgens (Randall, 2007). From the 
pharmacological perspective, it was not a certainty that bimatoprost effects on 
eyelashes would transition into scalp hair growth.  There are many instances where 
the effects of PGF2α and its analogues acting via FP expressed in tissues and cells are 
not reproduced by bimatoprost and its prostamide congeners (Liang et al., 2003; 
Woodward et al., 2003; Rendl et al., 2005; Woodward and al., in press).  The effects of 
latanoprost, a FP agonist prodrug, and bimatoprost have also been differentiated with 
respect to ocular hypotension (Jahoda et al., 1984; Sharif et al., 1999; Liang et al., 
2008; Woodward and al., in press).  Since the development of new treatments for 
distressing hair growth disorders, such as alopecia and hirsutism, is hampered by our 
lack of understanding of hair follicle biology, the specific effects of PGF2α, prostamide 
F2α and their analogues on hair follicles require further analysis.  Interestingly, the 
current main treatment for alopecia, minoxidil, has been reported to increase 
prostaglandin synthesis in cultured dermal papilla cells (Michelet et al., 1997).  
Overall, these results indicate that PGF2α and prostamide F2α-related glaucoma drugs 
do appear to offer a new approach for treating alopecia and merit further 
investigation. 
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General Discussion & Conclusions 
Overall, the experiments in this thesis have demonstrated that PGF2α, its analogue, 
latanoprost, and the prostamide F2α analogue, bimatoprost, can all stimulate human 
scalp hair follicle growth in organ culture i.e. they have an effect in vitro which 
mirrors the stimulation of eyelashes known to occur in vivo. These strong similarities 
in responses by eyelash and scalp follicles contrast with their differing biological 
responses to androgens (Randall, 2007). From the pharmacological perspective, it 
was also not a certainty that bimatoprost effects on eyelashes would transition into 
promoting scalp hair growth.  There are many instances where the effects of PGF2α 
and its analogues acting via FP expressed in tissues and cells are not reproduced by 
bimatoprost and its prostamide congeners (Liang et al., 2003; Woodward et al., 2003; 
Woodward and al., in press).  The effects of latanoprost, a FP agonist prodrug, and 
bimatoprost have also been differentiated with respect to ocular hypotension (Liang 
et al., 2008; Woodward and al., in press). 
The identification of appropriate receptor gene expression, including native FP, FP 
variant 4 and, to a lesser extent FP variant 1, in scalp hair follicles also strongly 
support the hypothesis that PGF2α and prostamide F2α analogues act directly on hair 
follicles via receptors within them.  
The location of FP protein (Figure 38) and the gene expression of FP and splice 
variants altFP4 & 1 (Figures 51, 70) only in the mesenchyme-derived dermal papilla 
and connective tissue sheath of scalp hair follicles is particularly interesting. Reports 
of prostaglandin metabolising enzymes and FP in cultured dermal papilla cells from 
human scalp hair follicles (Colombe et al., 2007; Colombe et al., 2008) support this 
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localisation in the dermal papilla. The dermal papilla determines the type of hair 
formed by a follicle by producing paracrine signals to control other follicular 
functions (Jahoda et al., 1984; Jahoda, 1992) and the connective tissue sheath around 
the bulb can replace this function (Reynolds et al., 1999).  The absence of any relevant 
prostanoid receptors from the bulb keratinocytes which form the hair or the 
melanocytes which produce the pigment and from the “bulge” region, the site of 
epithelial (Sotiropoulou et al.) and melanocyte stem cells (Nishimura et al., 2005), 
strongly suggests that action of these prostaglandin-related drugs is via the dermal 
papilla.  
These observations support a hypothesis that stimulation of FP or FP variants would 
trigger an altered production of paracrine factors in the dermal papilla which cross 
the dermal papilla basement membrane to increase the activity of the bulb 
keratinocytes and melanocytes (Figure 73). This would mean that the dermal papilla 
would coordinate all the follicular responses of increased growth and pigmentation in 
response to these agents; the response of the target keratinocytes and melanocytes 
would be an indirect one. The paracrine factors whose production and release by the 
dermal papilla cells could be altered by PGF2α and its related PGF2α and prostamide 
analogues might well include an increase in IGF-I and/or a decrease in TGF-β. IGF-I 
stimulates follicular keratinocyte growth and androgen increases its production in 
dermal papilla cells from androgen-stimulated hair follicles (reviewed in Randall 
2007). The secretion of the keratinocyte inhibitory factor, TGF-β, is also stimulated by 
androgen in balding dermal papilla cells in line with androgen’s inhibitory effect on 
scalp hair growth (reviewed in Hamada and Randall 2006). However, in contrast it 
would be predicted in this model that TGF-β secretion might be inhibited by PGF2α 
and its related PGF2α and prostamide analogues.  
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Figure 73  Possible mechanisms for the stimulation of hair growth by PGF2α,      
latanoprost and bimatoprost 
Prostaglandin F2α & the related analogues stimulate eyelash hair growth in vivo & 
scalp hair growth in organ culture. This effect is probably by stimulating appropriate 
receptors in the dermal papilla (middle panel). This may stimulate intracellular 
signalling pathways resulting in increased intracellular Ca++ and β-catenin inside the 
dermal papilla cells.  These would trigger the alterations of the gene expression of 
paracrine signals and their extracellular release so that they could in turn stimulate 
the activity of the keratinocytes and melanocytes to result in increased hair growth 
(lower panel).   
            : FP and/or prostamide F2α receptors,           direction of movement of paracrine 
factors. 
. . .  . . 
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Paracrine factors secreted by the dermal papilla have also been implicated in 
regulating melanocyte activity. Stem cell factor (SCF) is believed to be secreted by 
dermal papilla cells and to stimulate pigmentatory activity in melanocytes via their 
cell surface c-kit receptors (Hibberts et al., 1996; Randall et al., 2008). SCF is, 
therefore, also a potential candidate for increased secretion by the dermal papilla 
under PGF2α, latanoprost or bimatoprost.  
If this is a correct model, there will have to be intracellular signalling within the 
dermal papilla cells which ends with the altered synthesis and secretion of paracrine 
factors. Presumably, interaction of latanoprost with the transmembrane protein 
PGF2α receptor, FP, or bimatoprost with the transmembrane protein FP and 
prostamide F2α receptors, altFP4 or altFP1, trigger Gq protein-signal pathways 
(Coleman et al., 1994; Breyer et al., 2001). The observation in the hair growth studies 
that both AS604872, a FP antagonist (Jones et al., 2009) (Figures 62-64), and 
AGN211336, a prostamide F2α receptor antagonist (Woodward et al., 2007) (Figures 
61-64), could block the effect of bimatoprost suggests that these receptors are acting 
as heterodimers with both types of receptors being necessary for signalling at least in 
vitro.  This would parallel reports of heterodimer activity in other tissues e.g. eye 
(Liang et al., 2008). Once activated the Gq protein could possibly stimulate two 
pathways, increasing β-catenin and/or increasing calcium (Ca2+) levels in the 
cytoplasm. The activated β-catenin protein could then translocate into the nucleus 
and form a complex with members of Lef1/Tcf family of transcription factors and 
subsequently up-regulate the expression of target genes producing paracrine factors 
(see suggestions above) which would pass across the dermal papilla membrane into 
the surrounding cells (Figure 73).  β-catenin has already been identified as a core 
signalling molecule in the hair follicle. β-catenin is at the core of the Wnt signalling 
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pathway and the Wnt/β-catenin signalling pathway has a crucial role in hair follicle 
development and cycling (Van Genderen et al., 1994). Several studies have suggested 
that multiple steps in hair follicle development and cycling are dependent upon a 
change in the transcriptional status of genes that are regulated by the Wnt/β-catenin 
signalling pathway (DasGupta and Fuchs, 1999; Merril et al., 2001; Reddy et al., 
2001). In embryonic mice, high levels of β-catenin caused rapid proliferation of 
matrix cells (Gat et al., 1998; Chan et al., 1999) and forced activation of Wnt/β-
catenin signalling in the epidermis induced extra hairs (Gat et al., 1998; Millar S 2002; 
Alonso and Fuchs, 2003). In addition, chronic activation of β-catenin in mice during 
embryonic development resulted in proliferation of the outer root sheath and other 
epithelial components of the hair follicle (Seidensticker and Behrens, 2000).  After 
hair follicles have formed, deleting of β-catenin led to loss of the hair after the first 
hair cycle (Huelsken et al., 2001) and introducing stabilised β-catenin into the 
epidermis of transgenic mice  induced resting hair follicles into anagen and promoted 
the growth of existing follicles (Celso et al., 2004).   
Another possible mechanism is via a Ca2+ signalling pathway. In this model 
interaction of latanoprost or bimatoprost with FP or prostamide receptors could 
trigger Gq protein-coupled initiation of second messenger production of inositol 1, 4, 
5-triphosphate (IP3) which would then activate protein kinase C and increase Ca2+ 
levels. This could stimulate the release of stored paracrine regulatory factors which 
may act on the proliferation and differentiation of matrix keratinocytes and 
melanocytes independent of β-catenin and/or stimulate gene transcription (Figure 
73).  
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These possible mechanisms would allow the fine tuning of the regulatory paracrine 
pathways to enable the observed alterations in hair growth seen in vivo and in vitro 
and in pigmentation reported in vivo.  
The presence of PGF2α and prostamide F2α receptors in the connective tissue sheath 
around the bulb is interesting. However, whether this is actually involved in the 
immediate response or whether they are there in a reserve role in case the dermal 
papilla is damaged is not clear. The actual roles of the connective tissue sheath in an 
anagen follicle is currently one of many aspects of hair follicle biology which are not 
understood. Connective tissue sheath cells are probably acting as a “pool” of papilla 
cells in injury situations, and may interchange with dermal papilla cells during the 
catagen/telogen/early anagen phases of the hair growth cycle (Jahoda and Reynolds, 
2001). They probably enable significant hair cycle-associated plasticity which is likely 
to be involved during clinically important hair follicle transformations, e.g. during 
vellus-to-terminal changes during adult development and/or terminal-to-vellus 
changes during androgenetic alopecia (Tobin et al., 2003). 
Since the development of new treatments for distressing hair growth disorders, such 
as alopecia and hirsutism, is hampered by our lack of understanding of hair follicle 
biology, the specific effects of PGF2α, prostamide F2α and their analogues on hair 
follicles require further analysis.  Interestingly, the current main treatment for 
alopecia, minoxidil, has been reported to increase prostaglandin synthesis in cultured 
dermal papilla cells (Michelet et al., 1997).  
In the future, it will be important to clarify what molecular effects these 
prostaglandin-related drugs have on signalling pathways in the scalp hair follicle. 
This will include both identifying the intra-dermal papilla signalling in response to 
these reagents and any alterations in the paracrine molecules produced by the 
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dermal papilla cells. The easiest way to investigate this would be to use the well 
established cultured dermal papilla system (Randall., 1999) in the presence, and 
absence, of prostaglandin-related drugs using a range of techniques including DNA 
microarray analysis. 
Throughout this thesis there has been an assumption that eyelash hair follicles would 
be similar to scalp hair follicles in their responses to prostaglandin F2α-related drugs 
in organ culture and in their possession of receptors. Parallel experiments on eyelash 
follicles in vitro such as organ culture with those prostaglandin-related drugs and 
investigation of receptor gene expression could have clarified whether our findings in 
scalp hair follicles directly reflect those in eyelashes.  Neither time nor availability of 
eyelash material permitted this, but the conclusion would be much stronger if this 
had been carried out. This should be examined in the future.  
An interesting observation during this research was the detection of PGE2 in scalp 
hair follicles and immunolocation of its receptor, EP2, also in the dermal papilla and 
connective tissue sheath around the bulb. This also merits further investigation to see 
if PGE2 can also stimulate scalp hair follicle growth in organ culture or whether it 
plays another role.   
Overall, the results in this thesis, in combination with the observations of eyelash 
stimulation as a side-effect of glaucoma drugs, indicate that PGF2α and prostamide 
F2α-related glaucoma drugs do appear to be able to stimulate human scalp hair 
growth via a direct effect on PGF2α and prostamide F2α receptors in the follicle 
mesenchyme-derived tissues including the dermal papilla. They also demonstrate the 
actual presence of PGF2α in scalp hair follicles. Thus, all the original aims of this thesis 
have been met.  
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These drugs merit investigation in a small clinical trial as a topical application to the 
scalp of people with early stages of androgenetic alopecia to determine whether these 
organ culture and molecular biological observations can translate to a novel approach 
to treating the common, but psychologically distressing forms of hair loss. 
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6  Appendices 
 
6.1  Sacpic stain 
Preparation of solutions: 
Celestine blue 
A 5% aqueous solution of ferric ammonium sulphate (500 ml) was added to 2.5g 
Celestine blue (C1 51050). After boiling for 3 min, the solution was allowed to cool, 
and filtered (grade 595 paper, Schleicher and Schuell, supplied by SLS, Nottingham, 
UK) before the addition of 70ml glycerol. 
Picric acid/ethanol 
A saturated alcoholic solution of picric acid (5ml) was mixed with 300 ml absolute 
ethanol. 
Picro-indigo carmine 
A saturated aqueous solution of picric acid (300 ml) was mixed thoroughly with 1 g of 
indigo carmine (C1 73015); this solution was filtered before use. 
Safranin 
Safranin (6 g; C150240) was dissolved in 300ml of a 1:1 ethanol:distilled water 
solution. The solution was filtered before use. 
Scott’s tap water 
Sodium hydrogen carbonate (2 g) and magnesium sulphate (20 g) were dissolved in 1 
ml distilled water, filtered and stored at 4°C until use. 
6.2  Preparation of phosphate buffered saline 
NaCl (8g), KCl (0.2g), Na2HPO4 (1.44g) and KH2PO4 (0.24g) were dissolved in 800 ml 
distilled water and the pH controlled at 7.4.      
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6.3  Lowry method for protein content estimation 
Principle:  In biological samples, under alkaline conditions divalent copper ions form 
a complex with peptide bonds to form a monovalent copper ion. The monovalent 
copper ion and the radical groups of tyrosine, tryptophan, and cysteine react with 
Folin reagent to produce an unstable product (chromophore) that becomes reduced 
to molybdenum/tungsten blue, which allows an absorbance to be read at a 
wavelength of 650nm. 
Serial dilutions of bovine serum albumin (BSA; stock concentration 1.5mg/ml) was 
prepared in 0.5M sodium hydroxide (NaOH) to give different concentrations (0.25, 
0.5, 0.75, 1.0 and 1.5 mg/ml).  The reagents were added stepwise according the the 
Lowry method (Lowry et al., 1951) and the absorbances were measured.  This 
enabled a standard calibration line of BSA to be constructed (see appendix 6.4) and 
thus scalp anagen hair follicle protein content to be estimated. 
Three different scalp hair follicle samples HF1, HF2, HF3 (5µl) were added in 
triplicate (Table 10) into a 96 wells plate.  Standard dilutions of BSA were also 
pipetted at the same volume in triplicate into wells as the diagram below shows.  
Solution A and S comprised alkaline copper tartrate solution and surfactant 
respectively. Reagents were subsequently added to the wells as follow: 20µl A mixed 
with 1000µl S to make solution AS, of which 25µl was pipetted into assay wells and 
200µl B (Folin reagent) was added to assay wells as a final step. 
 
 
 
297 
 
Table 10  Representation of a 96 well plate used to estimate protein content  
A 1 3 4 5 6 7 8 9 10 11 12 
B HF1 HF2 HF3    
Hair follicle samples 
(red) 
    
C HF1 HF2 HF3        
D HF1 HF2 HF3        
E            
F 0 0.25 0.5 0.75 1.0 1.5 
BSA standards mg/ml 
    
G 0 0.25 0.5 0.75 1.0 1.5     
H 0 0.25 0.5 0.75 1.0 1.5     
 
The plate was left in the dark for 20 minutes; a blue coloure developed proportionally 
with the amount of protein in the biological samples.  A reading of absorbance at 
650nm wavelength was then taken using spectrophotometer.  The absorbance of 
100% 0.5M NaOH (background) was subtracted from each reading taken to 
normalise data.  Absorbences for the standards were plotted against known 
concentration of BSA, to construct a calibration line (Figure 79).  Using linear 
regression, the concentration of protein in each sample was estimated. 
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6.4  Representative calibration lines for PGF2α, PGD1, PGE1, PGD2, PGE2 and 
13,14-dihydro-15keto PGE2    
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